

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
001 ALAN AMINO ALT/SGPT		CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE	15	%	OR	6.00	{GREATER}					
2026-001	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	16	7.500	1.173	15.63	2.000	14.000				
2026-001	8 OX.OF NADH	220 Medica E.	130 MEDICA	14	10.571	1.450	13.71	5.000	17.000				
2026-001	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	68	11.424	1.835	16.06	5.000	17.000				
2026-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	8.125	0.781	9.61	2.000	14.000				
2026-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	25	7.880	0.431	5.47	2.000	14.000				
2026-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	18	10.667	1.155	10.83	5.000	17.000				
2026-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	47	8.870	0.536	6.04	3.000	15.000				
2026-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	33	11.515	1.258	10.93	6.000	18.000				
2026-001	12 IFCC witho	203 ROCHE	93 ROCHE	22	9.045	0.562	6.22	3.000	15.000				
2026-001	13 ALA &aKETO	165 VITROS	155 ALTV	125	7.080	0.722	10.20	1.000	13.000				
2026-002	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	16	286.750	16.517	5.76	244.000	330.000				
2026-002	8 OX.OF NADH	220 Medica E.	130 MEDICA	14	264.571	8.483	3.21	225.000	304.000				
2026-002	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	68	323.074	11.502	3.56	275.000	372.000				
2026-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	290.625	8.915	3.07	247.000	334.000				
2026-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	25	270.080	10.419	3.86	230.000	311.000				
2026-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	18	342.944	22.057	6.43	292.000	394.000				
2026-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	47	295.745	8.521	2.88	251.000	340.000				
2026-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	33	344.242	7.382	2.14	293.000	396.000				
2026-002	12 IFCC witho	203 ROCHE	93 ROCHE	22	294.318	10.939	3.72	250.000	338.000				
2026-002	13 ALA &aKETO	165 VITROS	155 ALTV	125	277.400	9.054	3.26	236.000	319.000				
2026-003	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	16	62.563	3.482	5.56	53.000	72.000				
2026-003	8 OX.OF NADH	220 Medica E.	130 MEDICA	14	62.000	3.024	4.88	53.000	71.000				
2026-003	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	68	75.574	4.012	5.31	64.000	87.000				
2026-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	66.063	2.015	3.05	56.000	76.000				
2026-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	25	60.560	2.229	3.68	51.000	70.000				
2026-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	18	78.611	5.509	7.01	67.000	90.000				
2026-003	11 MOD. IFCC	203 ROCHE	93 ROCHE	47	66.702	2.617	3.92	57.000	77.000				

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	33	79.242	1.558	1.97	67.000	91.000	
2026-003	12 IFCC witho	203	ROCHE	93	ROCHE	22	67.182	1.992	2.96	57.000	77.000	
2026-003	13 ALA &aKETO	165	VITROS	155	ALTV	125	64.927	2.346	3.61	55.000	75.000	
001	ALAN AMINO ALT/SGPT	CLIA TEST ID #: 255		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}								
2026-004	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	16	379.933	20.121	5.30	323.000	437.000	
2026-004	8 OX.OF NADH	220	Medica E.	130	MEDICA	14	343.429	11.261	3.28	292.000	395.000	
2026-004	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	68	420.632	15.284	3.63	358.000	484.000	
2026-004	11 MOD. IFCC	184	INTEGRA	93	ROCHE	16	374.563	12.067	3.22	318.000	431.000	
2026-004	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	25	350.160	12.022	3.43	298.000	403.000	
2026-004	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	18	443.333	29.208	6.59	377.000	510.000	
2026-004	11 MOD. IFCC	203	ROCHE	93	ROCHE	47	384.652	12.255	3.19	327.000	442.000	
2026-004	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	33	444.697	8.789	1.98	378.000	511.000	
2026-004	12 IFCC witho	203	ROCHE	93	ROCHE	22	380.636	14.024	3.68	324.000	438.000	
2026-004	13 ALA &aKETO	165	VITROS	155	ALTV	125	363.187	10.923	3.01	309.000	418.000	
2026-005	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	16	120.375	5.487	4.56	102.000	138.000	
2026-005	8 OX.OF NADH	220	Medica E.	130	MEDICA	14	116.500	3.541	3.04	99.000	134.000	
2026-005	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	68	141.838	5.590	3.94	121.000	163.000	
2026-005	11 MOD. IFCC	184	INTEGRA	93	ROCHE	16	125.625	2.913	2.32	107.000	144.000	
2026-005	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	25	114.920	4.408	3.84	98.000	132.000	
2026-005	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	18	150.111	8.589	5.72	128.000	173.000	
2026-005	11 MOD. IFCC	203	ROCHE	93	ROCHE	47	126.891	3.985	3.14	108.000	146.000	
2026-005	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	33	149.281	2.695	1.81	127.000	172.000	
2026-005	12 IFCC witho	203	ROCHE	93	ROCHE	22	126.136	5.039	3.99	107.000	145.000	
2026-005	13 ALA &aKETO	165	VITROS	155	ALTV	125	122.339	3.816	3.12	104.000	141.000	
002	ALBUMIN	CLIA TEST ID #: 265		EVALUATION CRITERIA: TARGET VALUE 8 %								
2026-001	3 DYE BI-B.G	165	VITROS	63	KODAK	131	1.536	0.054	3.52	1.400	1.700	
2026-001	3 DYE BI-B.G	184	INTEGRA	93	ROCHE	24	1.726	0.044	2.54	1.600	1.900	
2026-001	3 DYE BI-B.G	184	INTEGRA	93	ROCHE	24	1.767	0.047	2.67	1.600	1.900	
2026-001	3 DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	27	1.556	0.057	3.64	1.400	1.700	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE	SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
	2026-001	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	22	1.648	0.110	6.65	1.500	1.800	
	2026-001	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	17	1.559	0.060	3.85	1.400	1.700	
	2026-001	3 DYE BI-B.G	203 ROCHE	93 ROCHE	69	1.725	0.069	4.02	1.600	1.900	
	2026-001	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	32	1.444	0.050	3.44	1.300	1.600	
	2026-001	3 DYE BI-B.G	220 Medica E.	130 MEDICA	15	1.513	0.088	5.84	1.400	1.600	
	2026-001	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	71	1.399	0.063	4.47	1.300	1.500	
002 ALBUMIN			CLIA TEST ID #: 265	EVALUATION CRITERIA: TARGET VALUE 8 %							
	2026-002	3 DYE BI-B.G	165 VITROS	63 KODAK	131	4.676	0.185	3.95	4.300	5.100	
	2026-002	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	24	4.600	0.000	0.00	4.200	5.000	
	2026-002	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	24	4.535	0.113	2.49	4.200	4.900	
	2026-002	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	27	4.452	0.117	2.62	4.100	4.800	
	2026-002	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	22	4.418	0.164	3.72	4.100	4.800	
	2026-002	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	17	4.469	0.098	2.20	4.100	4.800	
	2026-002	3 DYE BI-B.G	203 ROCHE	93 ROCHE	69	4.581	0.111	2.43	4.200	4.900	
	2026-002	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	32	4.413	0.139	3.14	4.100	4.800	
	2026-002	3 DYE BI-B.G	220 Medica E.	130 MEDICA	15	4.700	0.179	3.81	4.300	5.100	
	2026-002	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	71	4.197	0.116	2.76	3.900	4.500	
	2026-003	3 DYE BI-B.G	165 VITROS	63 KODAK	131	2.132	0.067	3.14	2.000	2.300	
	2026-003	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	24	2.326	0.067	2.90	2.100	2.500	
	2026-003	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	24	2.367	0.047	1.99	2.200	2.600	
	2026-003	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	27	2.144	0.074	3.44	2.000	2.300	
	2026-003	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	22	2.268	0.092	4.07	2.100	2.400	
	2026-003	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	17	2.088	0.083	3.98	1.900	2.300	
	2026-003	3 DYE BI-B.G	203 ROCHE	93 ROCHE	69	2.335	0.076	3.26	2.100	2.500	
	2026-003	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	32	2.050	0.066	3.23	1.900	2.200	
	2026-003	3 DYE BI-B.G	220 Medica E.	130 MEDICA	15	2.167	0.070	3.23	2.000	2.300	
	2026-003	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	71	1.957	0.058	2.95	1.800	2.100	
	2026-004	3 DYE BI-B.G	165 VITROS	63 KODAK	131	5.614	0.181	3.22	5.200	6.100	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-004	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	5.467	0.094	1.72	5.000	5.900
2026-004	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	5.283	0.127	2.41	4.900	5.700
2026-004	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	27	5.285	0.133	2.51	4.900	5.700
2026-004	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	22	5.255	0.195	3.71	4.800	5.700
2026-004	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	17	5.347	0.255	4.76	4.900	5.800
2026-004	3	DYE BI-B.G	203	ROCHE	93	ROCHE	69	5.354	0.125	2.34	4.900	5.800
2026-004	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	32	5.297	0.165	3.11	4.900	5.700
2026-004	3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	5.527	0.191	3.46	5.100	6.000
2026-004	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	71	5.068	0.130	2.56	4.700	5.500
002 ALBUMIN		CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %						
2026-005	3	DYE BI-B.G	165	VITROS	63	KODAK	131	2.776	0.082	2.97	2.600	3.000
2026-005	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	2.948	0.065	2.21	2.700	3.200
2026-005	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	3.000	0.000	0.00	2.800	3.200
2026-005	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	27	2.781	0.082	2.94	2.600	3.000
2026-005	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	22	2.850	0.112	3.92	2.600	3.100
2026-005	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	17	2.681	0.053	1.96	2.500	2.900
2026-005	3	DYE BI-B.G	203	ROCHE	93	ROCHE	69	2.951	0.096	3.26	2.700	3.200
2026-005	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	32	2.678	0.082	3.06	2.500	2.900
2026-005	3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	2.840	0.108	3.81	2.600	3.100
2026-005	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	71	2.564	0.100	3.90	2.400	2.800
003 ALKALINE PHOSPHATE		CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-001	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	28.850	1.388	4.81	23.000	35.000
2026-001	3	COLORIMET.	203	ROCHE	93	ROCHE	43	27.857	1.166	4.19	22.000	33.000
2026-001	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	24.909	1.443	5.79	20.000	30.000
2026-001	6	KINETIC 37	165	VITROS	63	KODAK	131	34.411	2.932	8.52	28.000	41.000
2026-001	6	KINETIC 37	165	VITROS	63	KODAK	131	28.800	2.926	10.16	23.000	35.000
2026-001	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	27	22.885	1.968	8.60	18.000	27.000
2026-001	10	IFCC	203	ROCHE	93	ROCHE	18	27.722	0.731	2.64	22.000	33.000
2026-001	10	IFCC	219	ATELLICA	143	SIEMENS	33	28.182	1.086	3.85	23.000	34.000
2026-001	11	Modified I	38	SIEMENS DI	143	SIEMENS	65	31.469	2.995	9.52	25.000	38.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE														
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2026-001	11 Modified I	191	RX-SERIES	126	RANDOX	16	25.375	3.822	15.06	20.000	30.000			
2026-001	12 P NITRO PH	197	ARCHITECT	1	ABBOTT	11	25.182	2.328	9.25	20.000	30.000			
2026-001	12 P NITRO PH	220	Medica E.	130	MEDICA	14	26.286	1.666	6.34	21.000	32.000			
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275		EVALUATION CRITERIA: TARGET VALUE 20 %										
2026-002	3 COLORIMET.	184	INTEGRA	93	ROCHE	20	272.800	13.140	4.82	218.000	327.000			
2026-002	3 COLORIMET.	203	ROCHE	93	ROCHE	43	263.833	9.365	3.55	211.000	317.000			
2026-002	5 KINETIC 30	197	ARCHITECT	1	ABBOTT	11	241.273	13.725	5.69	193.000	290.000			
2026-002	6 KINETIC 37	165	VITROS	63	KODAK	131	289.800	4.622	1.59	232.000	348.000			
2026-002	6 KINETIC 37	165	VITROS	63	KODAK	131	173.961	9.637	5.54	139.000	209.000			
2026-002	8 BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	27	221.556	21.503	9.71	177.000	266.000			
2026-002	10 IFCC	203	ROCHE	93	ROCHE	18	263.278	5.496	2.09	211.000	316.000			
2026-002	10 IFCC	219	ATELLICA	143	SIEMENS	33	272.667	11.126	4.08	218.000	327.000			
2026-002	11 Modified I	38	SIEMENS DI	143	SIEMENS	65	289.000	8.962	3.10	231.000	347.000			
2026-002	11 Modified I	191	RX-SERIES	126	RANDOX	16	234.938	24.491	10.42	188.000	282.000			
2026-002	12 P NITRO PH	197	ARCHITECT	1	ABBOTT	11	240.364	21.993	9.15	192.000	288.000			
2026-002	12 P NITRO PH	220	Medica E.	130	MEDICA	14	228.000	9.126	4.00	182.000	274.000			
2026-003	3 COLORIMET.	184	INTEGRA	93	ROCHE	20	76.500	3.384	4.42	61.000	92.000			
2026-003	3 COLORIMET.	203	ROCHE	93	ROCHE	43	74.293	2.643	3.56	59.000	89.000			
2026-003	5 KINETIC 30	197	ARCHITECT	1	ABBOTT	11	66.909	4.399	6.58	54.000	80.000			
2026-003	6 KINETIC 37	165	VITROS	63	KODAK	131	72.523	4.261	5.88	58.000	87.000			
2026-003	6 KINETIC 37	165	VITROS	63	KODAK	131	79.800	3.970	4.97	64.000	96.000			
2026-003	8 BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	27	61.741	5.816	9.42	49.000	74.000			
2026-003	10 IFCC	203	ROCHE	93	ROCHE	18	74.667	1.764	2.36	60.000	90.000			
2026-003	10 IFCC	219	ATELLICA	143	SIEMENS	33	76.545	3.066	4.01	61.000	92.000			
2026-003	11 Modified I	38	SIEMENS DI	143	SIEMENS	65	82.031	5.034	6.14	66.000	98.000			
2026-003	11 Modified I	191	RX-SERIES	126	RANDOX	16	69.625	6.224	8.94	56.000	84.000			
2026-003	12 P NITRO PH	197	ARCHITECT	1	ABBOTT	11	67.455	4.943	7.33	54.000	81.000			
2026-003	12 P NITRO PH	220	Medica E.	130	MEDICA	14	65.286	2.657	4.07	52.000	78.000			

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-004	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	347.100	15.287	4.40	278.000	417.000
2026-004	3	COLORIMET.	203	ROCHE	93	ROCHE	43	338.595	10.989	3.25	271.000	406.000
2026-004	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	308.091	20.111	6.53	246.000	370.000
2026-004	6	KINETIC 37	165	VITROS	63	KODAK	131	368.800	15.065	4.08	295.000	443.000
2026-004	6	KINETIC 37	165	VITROS	63	KODAK	131	193.992	12.066	6.22	155.000	233.000
2026-004	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	27	277.778	29.458	10.61	222.000	333.000
2026-004	10	IFCC	203	ROCHE	93	ROCHE	18	339.944	9.064	2.67	272.000	408.000
2026-004	10	IFCC	219	ATELLICA	143	SIEMENS	33	349.879	14.233	4.07	280.000	420.000
2026-004	11	Modified I	38	SIEMENS DI	143	SIEMENS	65	374.508	12.172	3.25	300.000	449.000
2026-004	11	Modified I	191	RX-SERIES	126	RANDOX	16	302.125	31.861	10.55	242.000	363.000
2026-004	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	315.273	37.263	11.82	252.000	378.000
2026-004	12	P NITRO PH	220	Medica E.	130	MEDICA	14	293.786	15.303	5.21	235.000	353.000
2026-005	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	126.600	5.305	4.19	101.000	152.000
2026-005	3	COLORIMET.	203	ROCHE	93	ROCHE	43	122.833	3.612	2.94	98.000	147.000
2026-005	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	111.727	6.703	6.00	89.000	134.000
2026-005	6	KINETIC 37	165	VITROS	63	KODAK	131	107.339	6.055	5.64	86.000	129.000
2026-005	6	KINETIC 37	165	VITROS	63	KODAK	131	132.600	5.314	4.01	106.000	159.000
2026-005	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	27	101.704	8.610	8.47	81.000	122.000
2026-005	10	IFCC	203	ROCHE	93	ROCHE	18	124.167	3.202	2.58	99.000	149.000
2026-005	10	IFCC	219	ATELLICA	143	SIEMENS	33	126.788	5.923	4.67	101.000	152.000
2026-005	11	Modified I	38	SIEMENS DI	143	SIEMENS	65	135.585	5.361	3.95	108.000	163.000
2026-005	11	Modified I	191	RX-SERIES	126	RANDOX	16	112.438	11.869	10.56	90.000	135.000
2026-005	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	111.545	10.175	9.12	89.000	134.000
2026-005	12	P NITRO PH	220	Medica E.	130	MEDICA	14	106.929	5.663	5.30	86.000	128.000
004	AMYLASE	CLIA TEST ID #: 285										
2026-001	3	ENZYM. 37C	165	VITROS	63	KODAK	86	30.035	0.240	0.80	24.000	36.000
2026-001	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	11.176	0.617	5.52	9.000	13.000
2026-001	9	ENZ/COL.37	203	ROCHE	93	ROCHE	32	16.613	0.704	4.24	13.000	20.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-001	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	9.818	0.716	7.29	8.000	12.000
2026-001	11	KINETIC	219	ATELLICA	143	SIEMENS	23	20.000	0.000	0.00	16.000	24.000
004	AMYLASE		CLIA TEST ID #: 285		EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-002	3	ENZYM. 37C	165	VITROS	63	KODAK	86	167.271	7.815	4.67	134.000	201.000
2026-002	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	229.412	4.679	2.04	184.000	275.000
2026-002	9	ENZ/COL.37	203	ROCHE	93	ROCHE	32	244.742	6.319	2.58	196.000	294.000
2026-002	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	184.909	8.949	4.84	148.000	222.000
2026-002	11	KINETIC	219	ATELLICA	143	SIEMENS	23	269.826	7.654	2.84	216.000	324.000
2026-003	3	ENZYM. 37C	165	VITROS	63	KODAK	86	43.651	5.988	13.72	35.000	52.000
2026-003	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	55.118	0.832	1.51	44.000	66.000
2026-003	9	ENZ/COL.37	203	ROCHE	93	ROCHE	32	61.323	1.654	2.70	49.000	74.000
2026-003	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	45.364	2.568	5.66	36.000	54.000
2026-003	11	KINETIC	219	ATELLICA	143	SIEMENS	23	68.696	1.755	2.56	55.000	82.000
2026-004	3	ENZYM. 37C	165	VITROS	63	KODAK	86	211.294	9.377	4.44	169.000	254.000
2026-004	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	298.824	7.180	2.40	239.000	359.000
2026-004	9	ENZ/COL.37	203	ROCHE	93	ROCHE	32	316.438	10.694	3.38	253.000	380.000
2026-004	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	238.636	12.175	5.10	191.000	286.000
2026-004	11	KINETIC	219	ATELLICA	143	SIEMENS	23	350.522	7.638	2.18	280.000	421.000
2026-005	3	ENZYM. 37C	165	VITROS	63	KODAK	86	74.186	6.483	8.74	59.000	89.000
2026-005	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	101.000	2.114	2.09	81.000	121.000
2026-005	9	ENZ/COL.37	203	ROCHE	93	ROCHE	32	107.969	3.477	3.22	86.000	130.000
2026-005	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	81.818	4.648	5.68	65.000	98.000
2026-005	11	KINETIC	219	ATELLICA	143	SIEMENS	23	119.913	2.991	2.49	96.000	144.000
005	ASP. AMINO AST/SGOT		CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}							
2026-001	1	ASPAR&KETO	165	VITROS	63	KODAK	132	15.457	0.872	5.64	9.000	21.000
2026-001	1	ASPAR&KETO	165	VITROS	63	KODAK	132	13.800	0.980	7.10	8.000	20.000
2026-001	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	12.467	1.258	10.09	6.000	18.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-001	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	72	15.125	1.572	10.39	9.000	21.000
2026-001	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	12.111	0.809	6.68	6.000	18.000
2026-001	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	11.240	0.585	5.21	5.000	17.000
2026-001	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	20	14.700	1.646	11.20	9.000	21.000
2026-001	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	12.698	0.630	4.96	7.000	19.000
2026-001	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	15.125	0.992	6.56	9.000	21.000
2026-001	12	IFCC witho	203	ROCHE	93	ROCHE	23	12.739	0.735	5.77	7.000	19.000
2026-001	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	14.714	1.278	8.68	9.000	21.000
005 ASP. AMINO AST/SGOT			CLIA TEST ID #: 295			EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}						
2026-002	1	ASPAR&KETO	165	VITROS	63	KODAK	132	413.200	15.728	3.81	351.000	475.000
2026-002	1	ASPAR&KETO	165	VITROS	63	KODAK	132	480.893	24.022	5.00	409.000	553.000
2026-002	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	313.200	8.542	2.73	266.000	360.000
2026-002	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	72	343.597	12.020	3.50	292.000	395.000
2026-002	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	353.222	12.030	3.41	300.000	406.000
2026-002	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	306.423	16.641	5.43	260.000	352.000
2026-002	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	20	403.200	26.307	6.52	343.000	464.000
2026-002	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	357.455	11.906	3.33	304.000	411.000
2026-002	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	396.061	7.398	1.87	337.000	455.000
2026-002	12	IFCC witho	203	ROCHE	93	ROCHE	23	355.087	10.342	2.91	302.000	408.000
2026-002	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	416.643	16.163	3.88	354.000	479.000
2026-003	1	ASPAR&KETO	165	VITROS	63	KODAK	132	92.092	4.468	4.85	78.000	106.000
2026-003	1	ASPAR&KETO	165	VITROS	63	KODAK	132	93.200	1.600	1.72	79.000	107.000
2026-003	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	74.067	2.568	3.47	63.000	85.000
2026-003	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	72	81.479	2.685	3.29	69.000	94.000
2026-003	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	81.722	2.921	3.57	69.000	94.000
2026-003	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	70.808	3.793	5.36	60.000	81.000
2026-003	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	20	94.368	6.722	7.12	80.000	109.000
2026-003	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	82.535	2.415	2.93	70.000	95.000
2026-003	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	92.969	1.531	1.65	79.000	107.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	12	IFCC witho	203	ROCHE	93	ROCHE	23	82.435	1.930	2.34	70.000	95.000
2026-003	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	95.429	3.678	3.85	81.000	110.000
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}								
2026-004	1	ASPAR&KETO	165	VITROS	63	KODAK	132	537.200	22.498	4.19	457.000	618.000
2026-004	1	ASPAR&KETO	165	VITROS	63	KODAK	132	648.466	33.243	5.13	551.000	746.000
2026-004	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	379.467	27.628	7.28	323.000	436.000
2026-004	5	ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	72	454.732	16.002	3.52	387.000	523.000
2026-004	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	457.389	17.411	3.81	389.000	526.000
2026-004	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	398.538	21.946	5.51	339.000	458.000
2026-004	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	20	521.550	44.529	8.54	443.000	600.000
2026-004	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	465.930	13.788	2.96	396.000	536.000
2026-004	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	514.182	11.826	2.30	437.000	591.000
2026-004	12	IFCC witho	203	ROCHE	93	ROCHE	23	462.870	16.096	3.48	393.000	532.000
2026-004	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	548.714	27.737	5.05	466.000	631.000
2026-005	1	ASPAR&KETO	165	VITROS	63	KODAK	132	182.754	7.938	4.34	155.000	210.000
2026-005	1	ASPAR&KETO	165	VITROS	63	KODAK	132	177.600	6.741	3.80	151.000	204.000
2026-005	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	136.133	3.931	2.89	116.000	157.000
2026-005	5	ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	72	149.639	5.116	3.42	127.000	172.000
2026-005	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	152.889	4.508	2.95	130.000	176.000
2026-005	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	130.560	5.987	4.59	111.000	150.000
2026-005	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	20	177.450	12.576	7.09	151.000	204.000
2026-005	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	154.364	5.139	3.33	131.000	178.000
2026-005	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	172.455	3.385	1.96	147.000	198.000
2026-005	12	IFCC witho	203	ROCHE	93	ROCHE	23	153.348	4.419	2.88	130.000	176.000
2026-005	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	178.143	6.512	3.66	151.000	205.000
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}								
2026-001	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	0.081	0.034	41.64	0	0.480
2026-001	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	0.101	0.048	47.22	0	0.500
2026-001	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	0.094	0.008	8.40	0	0.490

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-001	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	0.101	0.048	47.22	0	0.500
2026-001	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	0.080	0.034	42.57	0	0.480
2026-001	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	0.101	0.048	47.22	0	0.500
2026-001	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	0.103	0.011	10.70	0	0.500
2026-001	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	0.101	0.048	47.22	0	0.500
2026-001	13	AZOBIL.	203	ROCHE	93	ROCHE	48	0.134	0.049	36.35	0	0.530
2026-001	14	VANADATE	219	ATELLICA	143	SIEMENS	33	0.156	0.020	13.10	0	0.560
2026-001	15	DCA 2,4	220	Medica E.	130	MEDICA	13	0.086	0.034	39.57	0	0.490
2026-001	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.150	0.000	0.00	0	0.550
2026-001	18	COLORIMETR	203	ROCHE	93	ROCHE	17	0.150	0.025	16.67	0	0.550
2026-001	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	0.090	0.030	33.33	0	0.490
006	BILIRUBIN, TOTAL		CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}						
2026-002	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	3.391	0.458	13.52	2.710	4.070
2026-002	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	4.403	0.268	6.08	3.520	5.280
2026-002	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	3.391	0.458	13.52	2.710	4.070
2026-002	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	4.083	0.135	3.30	3.270	4.900
2026-002	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	3.391	0.458	13.52	2.710	4.070
2026-002	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	3.879	0.472	12.17	3.100	4.650
2026-002	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	3.391	0.458	13.52	2.710	4.070
2026-002	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	3.733	0.241	6.47	2.990	4.480
2026-002	13	AZOBIL.	203	ROCHE	93	ROCHE	48	3.738	0.156	4.16	2.990	4.490
2026-002	14	VANADATE	219	ATELLICA	143	SIEMENS	33	4.350	0.283	6.50	3.480	5.220
2026-002	15	DCA 2,4	220	Medica E.	130	MEDICA	13	4.848	0.269	5.55	3.880	5.820
2026-002	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	3.750	0.197	5.27	3.000	4.500
2026-002	18	COLORIMETR	203	ROCHE	93	ROCHE	17	3.664	0.114	3.12	2.930	4.400
2026-002	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	4.060	0.133	3.28	3.250	4.870
2026-003	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	0.891	0.079	8.90	0.490	1.290
2026-003	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	0.705	0.088	12.45	0.310	1.110
2026-003	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	0.910	0.025	2.77	0.510	1.310

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	0.705	0.088	12.45	0.310	1.110
2026-003	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	0.783	0.083	10.57	0.380	1.180
2026-003	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	0.705	0.088	12.45	0.310	1.110
2026-003	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	0.832	0.103	12.32	0.430	1.230
2026-003	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	0.705	0.088	12.45	0.310	1.110
2026-003	13	AZOBIL.	203	ROCHE	93	ROCHE	48	0.764	0.045	5.92	0.360	1.160
2026-003	14	VANADATE	219	ATELLICA	143	SIEMENS	33	0.919	0.065	7.07	0.520	1.320
2026-003	15	DCA 2,4	220	Medica E.	130	MEDICA	13	1.017	0.057	5.58	0.620	1.420
2026-003	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.775	0.027	3.47	0.380	1.180
2026-003	18	COLORIMETR	203	ROCHE	93	ROCHE	17	0.756	0.026	3.43	0.360	1.160
2026-003	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	0.825	0.039	4.70	0.430	1.230
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}							
2026-004	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	4.428	0.521	11.78	3.540	5.310
2026-004	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	5.836	0.333	5.70	4.670	7.000
2026-004	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	4.428	0.521	11.78	3.540	5.310
2026-004	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	5.247	0.146	2.78	4.200	6.300
2026-004	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	4.428	0.521	11.78	3.540	5.310
2026-004	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	5.258	0.682	12.97	4.210	6.310
2026-004	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	4.428	0.521	11.78	3.540	5.310
2026-004	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	4.742	0.338	7.13	3.790	5.690
2026-004	13	AZOBIL.	203	ROCHE	93	ROCHE	48	4.898	0.230	4.69	3.920	5.880
2026-004	14	VANADATE	219	ATELLICA	143	SIEMENS	33	5.699	0.330	5.79	4.560	6.840
2026-004	15	DCA 2,4	220	Medica E.	130	MEDICA	13	6.287	0.348	5.54	5.030	7.540
2026-004	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	4.839	0.262	5.42	3.870	5.810
2026-004	18	COLORIMETR	203	ROCHE	93	ROCHE	17	4.804	0.152	3.17	3.840	5.770
2026-004	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	5.331	0.162	3.04	4.260	6.400
2026-005	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	1.813	0.116	6.38	1.410	2.210
2026-005	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	69	1.309	0.127	9.72	0.910	1.710
2026-005	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	1.766	0.044	2.51	1.370	2.170

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	1.309	0.127	9.72	0.910	1.710
2026-005	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	1.597	0.167	10.43	1.200	2.000
2026-005	4	J-G WITH B	191	RX-SERIES	126	RANDOX	16	1.309	0.127	9.72	0.910	1.710
2026-005	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	1.636	0.103	6.28	1.240	2.040
2026-005	7	DIAZO-DYPH	165	VITROS	63	KODAK	128	1.309	0.127	9.72	0.910	1.710
2026-005	13	AZOBIL.	203	ROCHE	93	ROCHE	48	1.537	0.079	5.17	1.140	1.940
2026-005	14	VANADATE	219	ATELLICA	143	SIEMENS	33	1.816	0.102	5.59	1.420	2.220
2026-005	15	DCA 2,4	220	Medica E.	130	MEDICA	13	2.030	0.094	4.65	1.620	2.440
2026-005	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	1.568	0.082	5.20	1.170	1.970
2026-005	18	COLORIMETR	203	ROCHE	93	ROCHE	17	1.509	0.075	5.00	1.110	1.910
2026-005	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	1.676	0.068	4.06	1.280	2.080
010	CALCIUM, TOTAL		CLIA	TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00						
2026-001	3	ARSEN.-III	165	VITROS	63	KODAK	146	5.627	0.153	2.72	4.600	6.600
2026-001	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	5.822	0.157	2.70	4.800	6.800
2026-001	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	6.775	0.238	3.52	5.800	7.800
2026-001	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	25	5.908	0.331	5.60	4.900	6.900
2026-001	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	5.833	0.085	1.46	4.800	6.800
2026-001	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	5.838	0.194	3.33	4.800	6.800
2026-001	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	6.775	0.238	3.52	5.800	7.800
2026-001	3	ARSEN.-III	220	Medica E.	130	MEDICA	17	5.241	0.203	3.87	4.200	6.200
2026-001	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	73	5.814	0.181	3.11	4.800	6.800
2026-001	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	5.808	0.138	2.38	4.800	6.800
2026-001	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	5.840	0.143	2.45	4.800	6.800
2026-001	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	20	5.575	0.236	4.24	4.600	6.600
2026-001	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	5.785	0.110	1.90	4.800	6.800
2026-001	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	58	5.879	0.126	2.14	4.900	6.900
2026-002	3	ARSEN.-III	165	VITROS	63	KODAK	146	10.239	0.262	2.56	9.200	11.200
2026-002	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	11.100	0.387	3.49	10.100	12.100
2026-002	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	10.996	0.390	3.55	10.000	12.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-002	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	25	10.963	0.336	3.07	10.000	12.000
2026-002	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	11.125	0.130	1.17	10.100	12.100
2026-002	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	10.915	0.520	4.77	9.900	11.900
2026-002	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	11.100	0.387	3.49	10.100	12.100
2026-002	3	ARSEN.-III	220	Medica E.	130	MEDICA	17	10.894	0.372	3.41	9.900	11.900
2026-002	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	73	10.332	0.293	2.83	9.300	11.300
2026-002	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	10.738	0.259	2.41	9.700	11.700
2026-002	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	10.740	0.229	2.13	9.700	11.700
2026-002	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	20	10.675	0.349	3.27	9.700	11.700
2026-002	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	10.677	0.289	2.70	9.700	11.700
2026-002	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	58	10.851	0.209	1.92	9.900	11.900
010	CALCIUM, TOTAL	CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00								
2026-003	3	ARSEN.-III	165	VITROS	63	KODAK	146	6.662	0.164	2.46	5.700	7.700
2026-003	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	6.796	0.175	2.58	5.800	7.800
2026-003	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	7.775	0.307	3.95	6.800	8.800
2026-003	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	25	6.916	0.393	5.68	5.900	7.900
2026-003	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	6.717	0.186	2.77	5.700	7.700
2026-003	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	6.846	0.241	3.51	5.800	7.800
2026-003	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	7.775	0.307	3.95	6.800	8.800
2026-003	3	ARSEN.-III	220	Medica E.	130	MEDICA	17	6.271	0.272	4.33	5.300	7.300
2026-003	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	73	6.670	0.184	2.76	5.700	7.700
2026-003	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	6.738	0.144	2.14	5.700	7.700
2026-003	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	6.730	0.210	3.12	5.700	7.700
2026-003	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	20	6.590	0.226	3.42	5.600	7.600
2026-003	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	6.723	0.112	1.67	5.700	7.700
2026-003	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	58	6.821	0.129	1.89	5.800	7.800
2026-004	3	ARSEN.-III	165	VITROS	63	KODAK	146	11.168	0.371	3.32	10.200	12.200
2026-004	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	12.775	0.319	2.50	11.800	13.800
2026-004	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	12.496	0.422	3.38	11.500	13.500

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-004	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	25	12.460	0.505	4.05	11.500	13.500
2026-004	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	13.017	0.172	1.32	12.000	14.000
2026-004	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	12.431	0.478	3.84	11.400	13.400
2026-004	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	12.775	0.319	2.50	11.800	13.800
2026-004	3	ARSEN.-III	220	Medica E.	130	MEDICA	17	12.547	0.552	4.40	11.500	13.500
2026-004	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	73	11.937	0.299	2.51	10.900	12.900
2026-004	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	12.238	0.506	4.14	11.200	13.200
2026-004	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	12.350	0.486	3.94	11.400	13.400
2026-004	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	20	12.260	0.510	4.16	11.300	13.300
2026-004	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	12.154	0.334	2.75	11.200	13.200
2026-004	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	58	12.386	0.359	2.89	11.400	13.400
010	CALCIUM, TOTAL		CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00						
2026-005	3	ARSEN.-III	165	VITROS	63	KODAK	146	7.697	0.196	2.55	6.700	8.700
2026-005	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	7.929	0.239	3.01	6.900	8.900
2026-005	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	8.688	0.237	2.73	7.700	9.700
2026-005	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	25	7.976	0.311	3.91	7.000	9.000
2026-005	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	7.800	0.204	2.62	6.800	8.800
2026-005	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	7.946	0.308	3.87	6.900	8.900
2026-005	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	13	8.688	0.237	2.73	7.700	9.700
2026-005	3	ARSEN.-III	220	Medica E.	130	MEDICA	17	7.441	0.222	2.99	6.400	8.400
2026-005	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	73	7.600	0.221	2.91	6.600	8.600
2026-005	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	7.831	0.143	1.83	6.800	8.800
2026-005	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.880	0.223	2.83	6.900	8.900
2026-005	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	20	7.630	0.312	4.08	6.600	8.600
2026-005	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	7.808	0.213	2.73	6.800	8.800
2026-005	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	58	7.886	0.170	2.16	6.900	8.900
011	CHLORIDE		CLIA TEST ID #: 355			EVALUATION CRITERIA: TARGET VALUE 5 %						
2026-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	89.615	1.332	1.49	85.000	94.000
2026-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	88.000	1.414	1.61	84.000	92.000
2026-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	88.385	1.146	1.30	84.000	93.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	90.385	1.211	1.34	86.000	95.000
2026-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	70	86.638	1.810	2.09	82.000	91.000
2026-001	4	ISE UND-DI	165	VITROS	63	KODAK	47	88.745	1.193	1.34	84.000	93.000
2026-001	4	ISE UND-DI	165	VITROS	156	Kit 32	98	88.510	1.466	1.66	84.000	93.000
2026-001	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	87.538	1.692	1.93	83.000	92.000
2026-001	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	84.500	1.344	1.59	80.000	89.000
2026-001	8	IMT	219	ATELLICA	143	SIEMENS	32	89.781	1.634	1.82	85.000	94.000
2026-001	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	89.070	1.577	1.77	85.000	94.000
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2026-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	109.333	4.497	4.11	104.000	115.000
2026-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	109.259	2.888	2.64	104.000	115.000
2026-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	103.400	2.154	2.08	98.000	109.000
2026-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	107.077	2.556	2.39	102.000	112.000
2026-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	70	104.686	2.333	2.23	99.000	110.000
2026-002	4	ISE UND-DI	165	VITROS	63	KODAK	47	106.809	2.523	2.36	101.000	112.000
2026-002	4	ISE UND-DI	165	VITROS	156	Kit 32	98	106.371	2.290	2.15	101.000	112.000
2026-002	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	107.038	2.835	2.65	102.000	112.000
2026-002	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	107.056	1.779	1.66	102.000	112.000
2026-002	8	IMT	219	ATELLICA	143	SIEMENS	32	106.586	3.168	2.97	101.000	112.000
2026-002	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	109.887	2.159	1.97	104.000	115.000
2026-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	92.296	2.705	2.93	88.000	97.000
2026-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	92.333	3.859	4.18	88.000	97.000
2026-003	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	90.192	1.241	1.38	86.000	95.000
2026-003	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	91.846	2.178	2.37	87.000	96.000
2026-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	70	88.565	1.982	2.24	84.000	93.000
2026-003	4	ISE UND-DI	165	VITROS	63	KODAK	47	91.340	1.325	1.45	87.000	96.000
2026-003	4	ISE UND-DI	165	VITROS	156	Kit 32	98	91.020	1.512	1.66	86.000	96.000
2026-003	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	90.423	1.780	1.97	86.000	95.000
2026-003	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	87.500	1.462	1.67	83.000	92.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	8	IMT	219	ATELLICA	143	SIEMENS	32	91.677	1.614	1.76	87.000	96.000
2026-003	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	91.639	1.619	1.77	87.000	96.000
011	CHLORIDE	CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %						
2026-004	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	118.333	5.185	4.38	112.000	124.000
2026-004	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	116.667	3.333	2.86	111.000	123.000
2026-004	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	108.577	2.133	1.96	103.000	114.000
2026-004	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	112.846	2.143	1.90	107.000	118.000
2026-004	3	ISE DILUTE	203	ROCHE	93	ROCHE	70	111.647	2.375	2.13	106.000	117.000
2026-004	4	ISE UND-DI	165	VITROS	63	KODAK	47	113.304	2.431	2.15	108.000	119.000
2026-004	4	ISE UND-DI	165	VITROS	156	Kit 32	98	112.247	2.010	1.79	107.000	118.000
2026-004	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	113.654	3.782	3.33	108.000	119.000
2026-004	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	115.278	3.228	2.80	110.000	121.000
2026-004	8	IMT	219	ATELLICA	143	SIEMENS	32	97.938	37.131	37.91	93.000	103.000
2026-004	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	117.500	2.708	2.30	112.000	123.000
2026-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	97.407	2.571	2.64	93.000	102.000
2026-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	98.000	3.559	3.63	93.000	103.000
2026-005	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	93.808	1.732	1.85	89.000	98.000
2026-005	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	96.154	1.099	1.14	91.000	101.000
2026-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	70	92.957	2.067	2.22	88.000	98.000
2026-005	4	ISE UND-DI	165	VITROS	63	KODAK	47	95.500	1.598	1.67	91.000	100.000
2026-005	4	ISE UND-DI	165	VITROS	156	Kit 32	98	94.796	1.801	1.90	90.000	100.000
2026-005	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	94.923	2.200	2.32	90.000	100.000
2026-005	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	92.500	1.462	1.58	88.000	97.000
2026-005	8	IMT	219	ATELLICA	143	SIEMENS	32	95.323	2.054	2.15	91.000	100.000
2026-005	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	96.417	2.019	2.09	92.000	101.000
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %						
2026-001	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	69	115.582	3.512	3.04	104.000	127.000
2026-001	1	ENZYMATIC	165	VITROS	63	KODAK	131	109.183	3.854	3.53	98.000	120.000
2026-001	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	112.455	3.313	2.95	101.000	124.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-001	1 ENZYMATI	191 RX-SERIES	126 RANDOX		27	121.074	5.163	4.26	109.000	133.000	
2026-001	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		11	116.091	2.151	1.85	104.000	128.000	
2026-001	1 ENZYMATI	203 ROCHE	93 ROCHE		25	113.560	2.886	2.54	102.000	125.000	
2026-001	1 ENZYMATI	220 Medica E.	130 MEDICA		15	117.467	3.096	2.64	106.000	129.000	
2026-001	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT		10	115.000	2.000	1.74	104.000	127.000	
2026-001	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		25	111.000	2.517	2.27	100.000	122.000	
2026-001	8 ENZYMATI	203 ROCHE	93 ROCHE		20	112.050	1.910	1.70	101.000	123.000	
2026-001	9 ENZYMATI	203 ROCHE	93 ROCHE		18	112.278	1.880	1.67	101.000	124.000	
2026-001	9 ENZYMATI	219 ATELLICA	143 SIEMENS		33	111.030	3.597	3.24	100.000	122.000	
012 CHOLESTEROL, TOTAL		CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %							
2026-002	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		69	194.149	6.232	3.21	175.000	214.000	
2026-002	1 ENZYMATI	165 VITROS	63 KODAK		131	222.420	8.966	4.03	200.000	245.000	
2026-002	1 ENZYMATI	184 INTEGRA	93 ROCHE		11	201.182	5.967	2.97	181.000	221.000	
2026-002	1 ENZYMATI	191 RX-SERIES	126 RANDOX		27	220.185	11.473	5.21	198.000	242.000	
2026-002	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		11	211.000	5.309	2.52	190.000	232.000	
2026-002	1 ENZYMATI	203 ROCHE	93 ROCHE		25	206.240	5.164	2.50	186.000	227.000	
2026-002	1 ENZYMATI	220 Medica E.	130 MEDICA		15	212.533	7.023	3.30	191.000	234.000	
2026-002	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT		10	205.800	4.118	2.00	185.000	226.000	
2026-002	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		25	201.958	5.208	2.58	182.000	222.000	
2026-002	8 ENZYMATI	203 ROCHE	93 ROCHE		20	204.211	4.150	2.03	184.000	225.000	
2026-002	9 ENZYMATI	203 ROCHE	93 ROCHE		18	205.833	4.670	2.27	185.000	226.000	
2026-002	9 ENZYMATI	219 ATELLICA	143 SIEMENS		33	208.545	6.643	3.19	188.000	229.000	
2026-003	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		69	128.149	4.158	3.24	115.000	141.000	
2026-003	1 ENZYMATI	165 VITROS	63 KODAK		131	130.198	4.645	3.57	117.000	143.000	
2026-003	1 ENZYMATI	184 INTEGRA	93 ROCHE		11	128.091	2.644	2.06	115.000	141.000	
2026-003	1 ENZYMATI	191 RX-SERIES	126 RANDOX		27	141.074	7.154	5.07	127.000	155.000	
2026-003	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		11	132.455	3.526	2.66	119.000	146.000	
2026-003	1 ENZYMATI	203 ROCHE	93 ROCHE		25	130.000	2.993	2.30	117.000	143.000	
2026-003	1 ENZYMATI	220 Medica E.	130 MEDICA		15	135.333	4.770	3.52	122.000	149.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2026-003	5	FE-SALTS-N	197 ARCHITECT	1	ABBOTT	10	131.100	1.758	1.34	118.000	144.000	
2026-003	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	25	127.500	3.162	2.48	115.000	140.000	
2026-003	8	ENZYMATIC	203 ROCHE	93	ROCHE	20	128.684	2.974	2.31	116.000	142.000	
2026-003	9	ENZYMATIC	203 ROCHE	93	ROCHE	18	129.444	2.522	1.95	117.000	142.000	
2026-003	9	ENZYMATIC	219 ATELLICA	143	SIEMENS	33	129.485	3.924	3.03	117.000	142.000	
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365	EVALUATION CRITERIA: TARGET VALUE 10 %									
2026-004	1	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	69	220.627	8.645	3.92	199.000	243.000	
2026-004	1	ENZYMATIC	165 VITROS	63	KODAK	131	257.435	9.609	3.73	232.000	283.000	
2026-004	1	ENZYMATIC	184 INTEGRA	93	ROCHE	11	228.273	8.771	3.84	205.000	251.000	
2026-004	1	ENZYMATIC	191 RX-SERIES	126	RANDOX	27	253.000	14.066	5.56	228.000	278.000	
2026-004	1	ENZYMATIC	197 ARCHITECT	1	ABBOTT	11	240.455	5.679	2.36	216.000	265.000	
2026-004	1	ENZYMATIC	203 ROCHE	93	ROCHE	25	237.280	7.723	3.25	214.000	261.000	
2026-004	1	ENZYMATIC	220 Medica E.	130	MEDICA	15	241.067	8.606	3.57	217.000	265.000	
2026-004	5	FE-SALTS-N	197 ARCHITECT	1	ABBOTT	10	237.900	9.823	4.13	214.000	262.000	
2026-004	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	25	230.083	5.830	2.53	207.000	253.000	
2026-004	8	ENZYMATIC	203 ROCHE	93	ROCHE	20	235.421	5.678	2.41	212.000	259.000	
2026-004	9	ENZYMATIC	203 ROCHE	93	ROCHE	18	234.167	5.786	2.47	211.000	258.000	
2026-004	9	ENZYMATIC	219 ATELLICA	143	SIEMENS	33	238.818	8.144	3.41	215.000	263.000	
2026-005	1	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	69	145.179	5.257	3.62	131.000	160.000	
2026-005	1	ENZYMATIC	165 VITROS	63	KODAK	131	153.254	5.335	3.48	138.000	169.000	
2026-005	1	ENZYMATIC	184 INTEGRA	93	ROCHE	11	147.818	3.186	2.16	133.000	163.000	
2026-005	1	ENZYMATIC	191 RX-SERIES	126	RANDOX	27	162.667	9.703	5.96	146.000	179.000	
2026-005	1	ENZYMATIC	197 ARCHITECT	1	ABBOTT	11	152.545	4.812	3.15	137.000	168.000	
2026-005	1	ENZYMATIC	203 ROCHE	93	ROCHE	25	150.600	3.752	2.49	136.000	166.000	
2026-005	1	ENZYMATIC	220 Medica E.	130	MEDICA	15	154.133	4.129	2.68	139.000	170.000	
2026-005	5	FE-SALTS-N	197 ARCHITECT	1	ABBOTT	10	150.900	3.015	2.00	136.000	166.000	
2026-005	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	25	146.833	4.048	2.76	132.000	162.000	
2026-005	8	ENZYMATIC	203 ROCHE	93	ROCHE	20	148.500	3.801	2.56	134.000	163.000	
2026-005	9	ENZYMATIC	203 ROCHE	93	ROCHE	18	149.333	3.958	2.65	134.000	164.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	33	151.000	4.243	2.81	136.000	166.000
013	CHOLESTEROL, (HDL)		CLIA TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}							
2026-001	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	38.800	4.238	10.92	31.000	46.600
2026-001	11	ENC.-COLO.	165	VITROS	63	KODAK	128	53.787	2.478	4.61	43.000	64.500
2026-001	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	60.604	2.295	3.79	48.500	72.700
2026-001	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	39.196	2.533	6.46	31.400	47.000
2026-001	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	27	41.915	8.323	19.86	33.500	50.300
2026-001	11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	59.331	2.511	4.23	47.500	71.200
2026-001	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	42.947	3.396	7.91	34.400	51.500
2026-001	11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	34.333	2.914	8.49	27.500	41.200
2026-001	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	35.750	2.046	5.72	28.600	42.900
2026-001	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	68	61.169	3.229	5.28	48.900	73.400
2026-001	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	68	50.000	4.967	9.93	40.000	60.000
2026-002	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	62.100	3.360	5.41	49.700	74.500
2026-002	11	ENC.-COLO.	165	VITROS	63	KODAK	128	72.187	4.265	5.91	57.700	86.600
2026-002	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	70.509	2.579	3.66	56.400	84.600
2026-002	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	66.046	3.776	5.72	52.800	79.300
2026-002	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	27	64.689	6.852	10.59	51.800	77.600
2026-002	11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	68.866	2.640	3.83	55.100	82.600
2026-002	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	68.988	4.107	5.95	55.200	82.800
2026-002	11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	59.200	3.410	5.76	47.400	71.000
2026-002	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	60.750	2.005	3.30	48.600	72.900
2026-002	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	68	69.000	4.546	6.59	55.200	82.800
2026-002	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	68	50.830	2.344	4.61	40.700	61.000
2026-003	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	43.000	3.899	9.07	34.400	51.600
2026-003	11	ENC.-COLO.	165	VITROS	63	KODAK	128	55.983	3.447	6.16	44.800	67.200
2026-003	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	62.950	2.329	3.70	50.400	75.500
2026-003	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	43.950	2.656	6.04	35.200	52.700

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-003	11 ENC.-COLO.	191 RX-SERIES	126	RANDOX	27	46.404	7.135	15.38	37.100	55.700		
2026-003	11 ENC.-COLO.	203 ROCHE	93	ROCHE	60	60.610	3.657	6.03	48.500	72.700		
2026-003	11 ENC.-COLO.	219 ATELLICA	143	SIEMENS	32	48.244	3.759	7.79	38.600	57.900		
2026-003	11 ENC.-COLO.	220 Medica E.	130	MEDICA	15	39.000	3.011	7.72	31.200	46.800		
2026-003	12 HOM-LQ.S.D	197 ARCHITECT	1	ABBOTT	12	40.750	1.534	3.77	32.600	48.900		
2026-003	13 AMIN.W.E.Q	38 SIEMENS DI	143	SIEMENS	68	58.475	3.070	5.25	46.800	70.200		
2026-003	13 AMIN.W.E.Q	38 SIEMENS DI	143	SIEMENS	68	52.333	4.497	8.59	41.900	62.800		
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375	EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}									
2026-004	5 DEX.SUL/Mg	197 ARCHITECT	1	ABBOTT	10	69.800	5.455	7.82	55.800	83.800		
2026-004	11 ENC.-COLO.	165 VITROS	63	KODAK	128	81.162	5.456	6.72	64.900	97.400		
2026-004	11 ENC.-COLO.	184 INTEGRA	93	ROCHE	24	71.539	3.249	4.54	57.200	85.800		
2026-004	11 ENC.-COLO.	186 BECK. COUL	76	AU-BECKMAN	26	73.369	3.790	5.17	58.700	88.000		
2026-004	11 ENC.-COLO.	191 RX-SERIES	126	RANDOX	27	69.937	7.564	10.82	55.900	83.900		
2026-004	11 ENC.-COLO.	203 ROCHE	93	ROCHE	60	69.910	3.267	4.67	55.900	83.900		
2026-004	11 ENC.-COLO.	219 ATELLICA	143	SIEMENS	32	76.047	4.296	5.65	60.800	91.300		
2026-004	11 ENC.-COLO.	220 Medica E.	130	MEDICA	15	66.867	3.792	5.67	53.500	80.200		
2026-004	12 HOM-LQ.S.D	197 ARCHITECT	1	ABBOTT	12	68.083	3.148	4.62	54.500	81.700		
2026-004	13 AMIN.W.E.Q	38 SIEMENS DI	143	SIEMENS	68	76.333	2.055	2.69	61.100	91.600		
2026-004	13 AMIN.W.E.Q	38 SIEMENS DI	143	SIEMENS	68	47.487	2.611	5.50	38.000	57.000		
2026-005	5 DEX.SUL/Mg	197 ARCHITECT	1	ABBOTT	10	48.700	3.035	6.23	39.000	58.400		
2026-005	11 ENC.-COLO.	165 VITROS	63	KODAK	128	60.217	3.181	5.28	48.200	72.300		
2026-005	11 ENC.-COLO.	184 INTEGRA	93	ROCHE	24	66.200	2.382	3.60	53.000	79.400		
2026-005	11 ENC.-COLO.	186 BECK. COUL	76	AU-BECKMAN	26	49.658	2.824	5.69	39.700	59.600		
2026-005	11 ENC.-COLO.	191 RX-SERIES	126	RANDOX	27	52.715	7.723	14.65	42.200	63.300		
2026-005	11 ENC.-COLO.	203 ROCHE	93	ROCHE	60	64.120	2.719	4.24	51.300	76.900		
2026-005	11 ENC.-COLO.	219 ATELLICA	143	SIEMENS	32	54.000	3.634	6.73	43.200	64.800		
2026-005	11 ENC.-COLO.	220 Medica E.	130	MEDICA	15	44.400	3.158	7.11	35.500	53.300		
2026-005	12 HOM-LQ.S.D	197 ARCHITECT	1	ABBOTT	12	46.333	1.841	3.97	37.100	55.600		
2026-005	13 AMIN.W.E.Q	38 SIEMENS DI	143	SIEMENS	68	57.337	2.684	4.68	45.900	68.800		

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-005	13	AMIN.W.E.Q		38	SIEMENS DI	143	SIEMENS	68	56.667	3.300	5.82	45.300	68.000
014	CREATINE KINASE (CK)			CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-001	3	KINETIC 37		165	VITROS	63	KODAK	68	21.224	3.561	16.78	17.000	25.000
2026-001	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	12	22.667	1.546	6.82	18.000	27.000
2026-001	5	SZASZ-MOD.		219	ATELLICA	143	SIEMENS	22	24.182	3.284	13.58	19.000	29.000
2026-001	8	Hexokinase		203	ROCHE	93	ROCHE	11	24.545	1.827	7.44	20.000	29.000
2026-001	9	SIEMENS		38	SIEMENS DI	143	SIEMENS	19	21.316	2.811	13.19	17.000	26.000
2026-001	10	ENZYMATIC-		203	ROCHE	93	ROCHE	17	24.118	0.963	3.99	19.000	29.000
2026-002	3	KINETIC 37		165	VITROS	63	KODAK	68	294.403	19.042	6.47	236.000	353.000
2026-002	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	12	478.636	28.160	5.88	383.000	574.000
2026-002	5	SZASZ-MOD.		219	ATELLICA	143	SIEMENS	22	489.364	18.673	3.82	391.000	587.000
2026-002	8	Hexokinase		203	ROCHE	93	ROCHE	11	499.091	13.392	2.68	399.000	599.000
2026-002	9	SIEMENS		38	SIEMENS DI	143	SIEMENS	19	478.684	11.868	2.48	383.000	574.000
2026-002	10	ENZYMATIC-		203	ROCHE	93	ROCHE	17	495.529	10.176	2.05	396.000	595.000
2026-003	3	KINETIC 37		165	VITROS	63	KODAK	68	90.194	5.578	6.18	72.000	108.000
2026-003	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	12	118.833	5.289	4.45	95.000	143.000
2026-003	5	SZASZ-MOD.		219	ATELLICA	143	SIEMENS	22	124.273	3.933	3.17	99.000	149.000
2026-003	8	Hexokinase		203	ROCHE	93	ROCHE	11	122.545	4.540	3.70	98.000	147.000
2026-003	9	SIEMENS		38	SIEMENS DI	143	SIEMENS	19	120.211	3.188	2.65	96.000	144.000
2026-003	10	ENZYMATIC-		203	ROCHE	93	ROCHE	17	124.938	2.585	2.07	100.000	150.000
2026-004	3	KINETIC 37		165	VITROS	63	KODAK	68	342.866	23.495	6.85	274.000	411.000
2026-004	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	12	615.167	28.583	4.65	492.000	738.000
2026-004	5	SZASZ-MOD.		219	ATELLICA	143	SIEMENS	22	628.409	20.969	3.34	503.000	754.000
2026-004	8	Hexokinase		203	ROCHE	93	ROCHE	11	639.818	15.908	2.49	512.000	768.000
2026-004	9	SIEMENS		38	SIEMENS DI	143	SIEMENS	19	620.632	17.628	2.84	497.000	745.000
2026-004	10	ENZYMATIC-		203	ROCHE	93	ROCHE	17	635.176	10.348	1.63	508.000	762.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385	EVALUATION CRITERIA: TARGET VALUE 20 %								
2026-005	3 KINETIC 37	165 VITROS	63 KODAK	68	158.866	10.099	6.36	127.000	191.000		
2026-005	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	12	215.667	11.968	5.55	173.000	259.000		
2026-005	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS	22	223.455	7.768	3.48	179.000	268.000		
2026-005	8 Hexokinase	203 ROCHE	93 ROCHE	11	223.364	7.678	3.44	179.000	268.000		
2026-005	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	19	218.053	3.980	1.83	174.000	262.000		
2026-005	10 ENZYMATIC-	203 ROCHE	93 ROCHE	17	225.882	4.323	1.91	181.000	271.000		
016	CREATININE	CLIA TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}								
2026-001	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	17	0.712	0.054	7.52	0.510	0.910		
2026-001	4 ENZYMATIC	203 ROCHE	93 ROCHE	14	0.635	0.049	7.78	0.440	0.840		
2026-001	4 ENZYMATIC	220 Medica E.	130 MEDICA	18	0.716	0.043	6.06	0.520	0.920		
2026-001	6 KIN. ALK P	184 INTEGRA	93 ROCHE	14	0.640	0.047	7.30	0.440	0.840		
2026-001	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	27	0.612	0.040	6.58	0.410	0.810		
2026-001	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	0.657	0.038	5.81	0.460	0.860		
2026-001	6 KIN. ALK P	203 ROCHE	93 ROCHE	28	0.606	0.028	4.65	0.410	0.810		
2026-001	8 IDMS-CREA	165 VITROS	63 KODAK	145	0.621	0.031	5.01	0.420	0.820		
2026-001	9 MODIFIED	219 ATELLICA	143 SIEMENS	32	0.572	0.027	4.66	0.370	0.770		
2026-001	10 JAFFE COMP	203 ROCHE	93 ROCHE	22	0.610	0.026	4.25	0.410	0.810		
2026-001	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	66	0.549	0.086	15.67	0.350	0.750		
2026-002	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	17	4.481	0.282	6.29	4.030	4.930		
2026-002	4 ENZYMATIC	203 ROCHE	93 ROCHE	14	5.035	0.120	2.39	4.530	5.540		
2026-002	4 ENZYMATIC	220 Medica E.	130 MEDICA	18	5.206	0.100	1.92	4.690	5.730		
2026-002	6 KIN. ALK P	184 INTEGRA	93 ROCHE	14	4.811	0.249	5.18	4.330	5.290		
2026-002	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	27	5.110	0.178	3.48	4.600	5.620		
2026-002	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	5.440	0.263	4.84	4.900	5.980		
2026-002	6 KIN. ALK P	203 ROCHE	93 ROCHE	28	4.974	0.161	3.24	4.480	5.470		
2026-002	8 IDMS-CREA	165 VITROS	63 KODAK	145	3.762	0.162	4.30	3.390	4.140		
2026-002	9 MODIFIED	219 ATELLICA	143 SIEMENS	32	5.077	0.154	3.04	4.570	5.580		
2026-002	10 JAFFE COMP	203 ROCHE	93 ROCHE	22	4.967	0.162	3.26	4.470	5.460		

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-002	11 IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	5.332	0.173	3.24	4.800	5.860	
016 CREATININE		CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}						
2026-003	2 AK. PIC. N	191	RX-SERIES	126	RANDOX	17	1.524	0.085	5.59	1.320	1.720	
2026-003	4 ENZYMATIC	203	ROCHE	93	ROCHE	14	1.582	0.046	2.89	1.380	1.780	
2026-003	4 ENZYMATIC	220	Medica E.	130	MEDICA	18	1.582	0.057	3.60	1.380	1.780	
2026-003	6 KIN. ALK P	184	INTEGRA	93	ROCHE	14	1.540	0.074	4.78	1.340	1.740	
2026-003	6 KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	27	1.551	0.048	3.09	1.350	1.750	
2026-003	6 KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	1.592	0.078	4.91	1.390	1.790	
2026-003	6 KIN. ALK P	203	ROCHE	93	ROCHE	28	1.562	0.084	5.36	1.360	1.760	
2026-003	8 IDMS-CREA	165	VITROS	63	KODAK	145	1.365	0.048	3.53	1.160	1.560	
2026-003	9 MODIFIED	219	ATELLICA	143	SIEMENS	32	1.496	0.053	3.56	1.300	1.700	
2026-003	10 JAFFE COMP	203	ROCHE	93	ROCHE	22	1.524	0.083	5.47	1.320	1.720	
2026-003	11 IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	1.608	0.107	6.64	1.410	1.810	
2026-004	2 AK. PIC. N	191	RX-SERIES	126	RANDOX	17	5.545	0.255	4.59	4.990	6.100	
2026-004	4 ENZYMATIC	203	ROCHE	93	ROCHE	14	6.301	0.168	2.67	5.670	6.930	
2026-004	4 ENZYMATIC	220	Medica E.	130	MEDICA	18	6.629	0.183	2.77	5.970	7.290	
2026-004	6 KIN. ALK P	184	INTEGRA	93	ROCHE	14	5.934	0.360	6.06	5.340	6.530	
2026-004	6 KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	27	6.424	0.210	3.27	5.780	7.070	
2026-004	6 KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	6.920	0.300	4.33	6.230	7.610	
2026-004	6 KIN. ALK P	203	ROCHE	93	ROCHE	28	6.189	0.231	3.74	5.570	6.810	
2026-004	8 IDMS-CREA	165	VITROS	63	KODAK	145	4.355	0.194	4.44	3.920	4.790	
2026-004	9 MODIFIED	219	ATELLICA	143	SIEMENS	32	6.462	0.182	2.81	5.820	7.110	
2026-004	10 JAFFE COMP	203	ROCHE	93	ROCHE	22	6.178	0.279	4.51	5.560	6.800	
2026-004	11 IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	6.829	0.232	3.40	6.150	7.510	
2026-005	2 AK. PIC. N	191	RX-SERIES	126	RANDOX	17	2.314	0.117	5.06	2.080	2.550	
2026-005	4 ENZYMATIC	203	ROCHE	93	ROCHE	14	2.509	0.056	2.25	2.260	2.760	
2026-005	4 ENZYMATIC	220	Medica E.	130	MEDICA	18	2.516	0.086	3.43	2.260	2.770	
2026-005	6 KIN. ALK P	184	INTEGRA	93	ROCHE	14	2.448	0.131	5.34	2.200	2.690	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	6 KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	27	2.491	0.069	2.77	2.240	2.740	
2026-005	6 KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	2.594	0.121	4.66	2.330	2.850	
2026-005	6 KIN. ALK P	203	ROCHE	93	ROCHE	28	2.494	0.107	4.29	2.240	2.740	
2026-005	8 IDMS-CREA	165	VITROS	63	KODAK	145	2.121	0.093	4.40	1.910	2.330	
2026-005	9 MODIFIED	219	ATELLICA	143	SIEMENS	32	2.438	0.080	3.27	2.190	2.680	
2026-005	10 JAFFE COMP	203	ROCHE	93	ROCHE	22	2.469	0.094	3.82	2.220	2.720	
2026-005	11 IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	2.578	0.124	4.82	2.320	2.840	
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}						
2026-001	3 GL. OXI. C	165	VITROS	63	KODAK	146	31.566	1.119	3.55	26.000	38.000	
2026-001	3 GL. OXI. C	165	VITROS	63	KODAK	146	35.333	1.247	3.53	29.000	41.000	
2026-001	5 HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	35.778	1.750	4.89	30.000	42.000	
2026-001	5 HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	39.333	0.943	2.40	33.000	45.000	
2026-001	5 HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	33.778	1.165	3.45	28.000	40.000	
2026-001	5 HEXOKINASE	191	RX-SERIES	126	RANDOX	20	38.200	2.088	5.47	32.000	44.000	
2026-001	5 HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	32.900	1.221	3.71	27.000	39.000	
2026-001	5 HEXOKINASE	203	ROCHE	93	ROCHE	47	33.553	0.709	2.11	28.000	40.000	
2026-001	6 HEXOKI. CO	220	Medica E.	130	MEDICA	18	36.778	2.149	5.84	31.000	43.000	
2026-001	12 HEXOKINASE	184	INTEGRA	93	ROCHE	19	34.316	0.862	2.51	28.000	40.000	
2026-001	12 HEXOKINASE	197	ARCHITECT	1	ABBOTT	11	33.000	0.739	2.24	27.000	39.000	
2026-001	12 HEXOKINASE	203	ROCHE	93	ROCHE	22	33.955	0.928	2.73	28.000	40.000	
2026-001	12 HEXOKINASE	219	ATELLICA	143	SIEMENS	32	34.000	1.392	4.09	28.000	40.000	
2026-002	3 GL. OXI. C	165	VITROS	63	KODAK	146	135.667	4.922	3.63	125.000	147.000	
2026-002	3 GL. OXI. C	165	VITROS	63	KODAK	146	137.188	4.192	3.06	126.000	148.000	
2026-002	5 HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	142.333	1.247	0.88	131.000	154.000	
2026-002	5 HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	140.417	4.274	3.04	129.000	152.000	
2026-002	5 HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	131.857	3.204	2.43	121.000	142.000	
2026-002	5 HEXOKINASE	191	RX-SERIES	126	RANDOX	20	137.900	5.476	3.97	127.000	149.000	
2026-002	5 HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	129.700	3.770	2.91	119.000	140.000	
2026-002	5 HEXOKINASE	203	ROCHE	93	ROCHE	47	132.022	2.707	2.05	121.000	143.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-002	6	HEXOKI. CO	220	Medica E.	130	MEDICA	18	139.000	4.359	3.14	128.000	150.000
2026-002	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	133.105	3.865	2.90	122.000	144.000
2026-002	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	11	131.091	2.843	2.17	121.000	142.000
2026-002	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	132.591	3.085	2.33	122.000	143.000
2026-002	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	128.656	3.821	2.97	118.000	139.000
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}						
2026-003	3	GL. OXI. C	165	VITROS	63	KODAK	146	50.128	1.886	3.76	44.000	56.000
2026-003	3	GL. OXI. C	165	VITROS	63	KODAK	146	55.000	1.633	2.97	49.000	61.000
2026-003	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	56.423	1.874	3.32	50.000	62.000
2026-003	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	59.667	1.247	2.09	54.000	66.000
2026-003	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	53.593	2.095	3.91	48.000	60.000
2026-003	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	20	58.350	3.214	5.51	52.000	64.000
2026-003	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	51.700	1.792	3.47	46.000	58.000
2026-003	5	HEXOKINASE	203	ROCHE	93	ROCHE	47	53.217	1.196	2.25	47.000	59.000
2026-003	6	HEXOKI. CO	220	Medica E.	130	MEDICA	18	57.000	2.082	3.65	51.000	63.000
2026-003	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	54.111	1.853	3.42	48.000	60.000
2026-003	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	11	51.545	1.559	3.02	46.000	58.000
2026-003	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	52.500	2.693	5.13	47.000	59.000
2026-003	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	52.781	1.883	3.57	47.000	59.000
2026-004	3	GL. OXI. C	165	VITROS	63	KODAK	146	166.000	4.899	2.95	153.000	179.000
2026-004	3	GL. OXI. C	165	VITROS	63	KODAK	146	171.828	4.877	2.84	158.000	186.000
2026-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	174.000	4.546	2.61	160.000	188.000
2026-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	73	173.425	5.026	2.90	160.000	187.000
2026-004	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	161.786	5.052	3.12	149.000	175.000
2026-004	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	20	166.500	7.884	4.73	153.000	180.000
2026-004	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	161.800	8.146	5.03	149.000	175.000
2026-004	5	HEXOKINASE	203	ROCHE	93	ROCHE	47	163.804	3.651	2.23	151.000	177.000
2026-004	6	HEXOKI. CO	220	Medica E.	130	MEDICA	18	171.556	5.398	3.15	158.000	185.000
2026-004	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	163.579	6.369	3.89	150.000	177.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2026-004	12	HEXOKINASE	197 ARCHITECT	1	ABBOTT	11	162.545	4.356	2.68	150.000	176.000	
2026-004	12	HEXOKINASE	203 ROCHE	93	ROCHE	22	163.182	4.923	3.02	150.000	176.000	
2026-004	12	HEXOKINASE	219 ATELLICA	143	SIEMENS	32	157.844	5.106	3.23	145.000	170.000	
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}								
2026-005	3	GL. OXI. C	165 VITROS	63	KODAK	146	73.786	2.115	2.87	68.000	80.000	
2026-005	3	GL. OXI. C	165 VITROS	63	KODAK	146	75.667	2.867	3.79	70.000	82.000	
2026-005	5	HEXOKINASE	38 SIEMENS DI	143	SIEMENS	73	78.222	2.329	2.98	72.000	84.000	
2026-005	5	HEXOKINASE	38 SIEMENS DI	143	SIEMENS	73	83.333	3.300	3.96	77.000	90.000	
2026-005	5	HEXOKINASE	186 BECK. COUL	76	AU-BECKMAN	28	73.964	2.584	3.49	68.000	80.000	
2026-005	5	HEXOKINASE	191 RX-SERIES	126	RANDOX	20	78.950	3.457	4.38	73.000	85.000	
2026-005	5	HEXOKINASE	197 ARCHITECT	1	ABBOTT	10	71.800	2.088	2.91	66.000	78.000	
2026-005	5	HEXOKINASE	203 ROCHE	93	ROCHE	47	73.745	1.550	2.10	68.000	80.000	
2026-005	6	HEXOKI. CO	220 Medica E.	130	MEDICA	18	78.222	2.323	2.97	72.000	84.000	
2026-005	12	HEXOKINASE	184 INTEGRA	93	ROCHE	19	74.789	2.142	2.86	69.000	81.000	
2026-005	12	HEXOKINASE	197 ARCHITECT	1	ABBOTT	11	72.636	1.367	1.88	67.000	79.000	
2026-005	12	HEXOKINASE	203 ROCHE	93	ROCHE	22	73.909	1.856	2.51	68.000	80.000	
2026-005	12	HEXOKINASE	219 ATELLICA	143	SIEMENS	32	72.625	2.571	3.54	67.000	79.000	
018	IRON, TOTAL	CLIA TEST ID #: 425		EVALUATION CRITERIA: TARGET VALUE 15 %								
2026-001	4	COULOMETR.	165 VITROS	63	KODAK	20	36.550	3.814	10.44	31.000	42.000	
2026-001	6	FERRAC/FER	219 ATELLICA	143	SIEMENS	12	31.167	1.344	4.31	26.000	36.000	
2026-002	4	COULOMETR.	165 VITROS	63	KODAK	20	516.650	21.378	4.14	439.000	594.000	
2026-002	6	FERRAC/FER	219 ATELLICA	143	SIEMENS	12	431.167	10.597	2.46	366.000	496.000	
2026-003	4	COULOMETR.	165 VITROS	63	KODAK	20	121.750	4.795	3.94	103.000	140.000	
2026-003	6	FERRAC/FER	219 ATELLICA	143	SIEMENS	12	111.833	2.115	1.89	95.000	129.000	
2026-004	4	COULOMETR.	165 VITROS	63	KODAK	20	605.947	25.847	4.27	515.000	697.000	
2026-004	6	FERRAC/FER	219 ATELLICA	143	SIEMENS	12	554.833	10.319	1.86	472.000	638.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
018	IRON, TOTAL	CLIA TEST ID #: 425				EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-005	4 COULOMETR.	165	VITROS	63	KODAK	20	212.700	7.274	3.42	181.000	245.000	
2026-005	6 FERRAC/FER	219	ATELLICA	143	SIEMENS	12	195.000	3.464	1.78	166.000	224.000	
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435										
2026-001	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	42.933	3.473	8.09	36.000	49.000	
2026-001	6 NADH	203	ROCHE	93	ROCHE	28	54.852	2.256	4.11	47.000	63.000	
2026-001	6 NADH	219	ATELLICA	143	SIEMENS	21	55.550	1.857	3.34	47.000	64.000	
2026-001	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	26	51.080	6.387	12.50	43.000	59.000	
2026-001	9 LDH1	165	VITROS	63	KODAK	64	80.921	5.576	6.89	69.000	93.000	
2026-002	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	445.867	32.731	7.34	379.000	513.000	
2026-002	6 NADH	203	ROCHE	93	ROCHE	28	545.704	14.550	2.67	464.000	628.000	
2026-002	6 NADH	219	ATELLICA	143	SIEMENS	21	538.286	16.881	3.14	458.000	619.000	
2026-002	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	26	535.615	19.145	3.57	455.000	616.000	
2026-002	9 LDH1	165	VITROS	63	KODAK	64	636.000	28.663	4.51	541.000	731.000	
2026-003	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	121.800	8.886	7.30	104.000	140.000	
2026-003	6 NADH	203	ROCHE	93	ROCHE	28	153.769	4.098	2.66	131.000	177.000	
2026-003	6 NADH	219	ATELLICA	143	SIEMENS	21	157.190	3.911	2.49	134.000	181.000	
2026-003	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	26	144.769	6.880	4.75	123.000	166.000	
2026-003	9 LDH1	165	VITROS	63	KODAK	64	200.688	6.039	3.01	171.000	231.000	
2026-004	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	564.333	36.304	6.43	480.000	649.000	
2026-004	6 NADH	203	ROCHE	93	ROCHE	28	694.407	25.290	3.64	590.000	799.000	
2026-004	6 NADH	219	ATELLICA	143	SIEMENS	21	677.762	17.830	2.63	576.000	779.000	
2026-004	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	26	695.731	23.297	3.35	591.000	800.000	
2026-004	9 LDH1	165	VITROS	63	KODAK	64	786.032	42.721	5.44	668.000	904.000	
2026-005	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	202.800	14.260	7.03	172.000	233.000	
2026-005	6 NADH	203	ROCHE	93	ROCHE	28	255.593	8.211	3.21	217.000	294.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	6	NADH	219	APELLICA	143	SIEMENS	21	258.190	7.195	2.79	219.000	297.000
2026-005	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	26	245.000	12.481	5.09	208.000	282.000
2026-005	9	LDH1	165	VITROS	63	KODAK	64	323.556	10.692	3.30	275.000	372.000
021 MAGNESIUM			CLIA TEST ID #: 455				EVALUATION CRITERIA: TARGET VALUE 15 %					
2026-001	5	COLOR./K E	165	VITROS	63	KODAK	30	1.433	0.125	8.70	1.200	1.600
2026-001	5	COLOR./K E	165	VITROS	63	KODAK	30	1.345	0.062	4.62	1.100	1.500
2026-001	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	1.318	0.039	2.93	1.100	1.500
2026-001	8	XYLIDYL B.	219	APELLICA	143	SIEMENS	13	0.869	0.082	9.45	0.700	1.000
2026-002	5	COLOR./K E	165	VITROS	63	KODAK	30	5.360	0.215	4.02	4.600	6.200
2026-002	5	COLOR./K E	165	VITROS	63	KODAK	30	5.200	0.216	4.15	4.400	6.000
2026-002	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	4.955	0.401	8.09	4.200	5.700
2026-002	8	XYLIDYL B.	219	APELLICA	143	SIEMENS	13	4.485	0.263	5.86	3.800	5.200
2026-003	5	COLOR./K E	165	VITROS	63	KODAK	30	2.267	0.170	7.50	1.900	2.600
2026-003	5	COLOR./K E	165	VITROS	63	KODAK	30	2.145	0.081	3.79	1.800	2.500
2026-003	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	2.009	0.108	5.39	1.700	2.300
2026-003	8	XYLIDYL B.	219	APELLICA	143	SIEMENS	13	1.592	0.121	7.58	1.400	1.800
2026-004	5	COLOR./K E	165	VITROS	63	KODAK	30	6.538	0.233	3.56	5.600	7.500
2026-004	5	COLOR./K E	165	VITROS	63	KODAK	30	6.433	0.205	3.19	5.500	7.400
2026-004	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	6.055	0.380	6.27	5.100	7.000
2026-004	8	XYLIDYL B.	219	APELLICA	143	SIEMENS	13	5.615	0.545	9.70	4.800	6.500
2026-005	5	COLOR./K E	165	VITROS	63	KODAK	30	3.100	0.163	5.27	2.600	3.600
2026-005	5	COLOR./K E	165	VITROS	63	KODAK	30	2.972	0.098	3.29	2.500	3.400
2026-005	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	2.791	0.051	1.84	2.400	3.200
2026-005	8	XYLIDYL B.	219	APELLICA	143	SIEMENS	13	2.338	0.178	7.60	2.000	2.700
022 POTASSIUM			CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30					
2026-001	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	2.035	0.048	2.34	1.700	2.300

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-001	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	2.148	0.050	2.33	1.800	2.400
2026-001	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	2.087	0.034	1.63	1.800	2.400
2026-001	3	ISE DILUT.	203	ROCHE	93	ROCHE	70	2.147	0.063	2.92	1.800	2.400
2026-001	4	ISE UNDIL.	165	VITROS	63	KODAK	48	2.058	0.049	2.40	1.800	2.400
2026-001	4	ISE UNDIL.	165	VITROS	156	Kit 32	97	2.059	0.053	2.59	1.800	2.400
2026-001	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	2.219	0.127	5.73	1.900	2.500
2026-001	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	2.250	0.096	4.26	2.000	2.600
2026-001	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	1.971	0.046	2.31	1.700	2.300
2026-001	5	IMT	219	ATELLICA	143	SIEMENS	32	2.233	0.149	6.67	1.900	2.500
2026-001	5	IMT	219	ATELLICA	143	SIEMENS	32	2.047	0.050	2.44	1.700	2.300
2026-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	71	2.017	0.041	2.05	1.700	2.300
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30						
2026-002	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	5.192	0.096	1.84	4.900	5.500
2026-002	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	5.107	0.133	2.61	4.800	5.400
2026-002	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	5.253	0.081	1.53	5.000	5.600
2026-002	3	ISE DILUT.	203	ROCHE	93	ROCHE	70	5.207	0.087	1.67	4.900	5.500
2026-002	4	ISE UNDIL.	165	VITROS	63	KODAK	48	5.262	0.119	2.27	5.000	5.600
2026-002	4	ISE UNDIL.	165	VITROS	156	Kit 32	97	5.249	0.119	2.27	4.900	5.500
2026-002	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	5.165	0.133	2.57	4.900	5.500
2026-002	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	5.067	0.149	2.94	4.800	5.400
2026-002	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	5.133	0.105	2.05	4.800	5.400
2026-002	5	IMT	219	ATELLICA	143	SIEMENS	32	5.017	0.151	3.01	4.700	5.300
2026-002	5	IMT	219	ATELLICA	143	SIEMENS	32	4.633	0.111	2.39	4.300	4.900
2026-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	71	5.146	0.089	1.72	4.800	5.400
2026-003	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	2.662	0.074	2.77	2.400	3.000
2026-003	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	2.715	0.052	1.93	2.400	3.000
2026-003	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	2.673	0.057	2.15	2.400	3.000
2026-003	3	ISE DILUT.	203	ROCHE	93	ROCHE	70	2.745	0.067	2.44	2.400	3.000
2026-003	4	ISE UNDIL.	165	VITROS	63	KODAK	48	2.681	0.064	2.39	2.400	3.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	4	ISE UNLIL.	165	VITROS	156	Kit 32	97	2.677	0.055	2.05	2.400	3.000
2026-003	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	26	2.765	0.117	4.25	2.500	3.100
2026-003	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	26	2.783	0.107	3.83	2.500	3.100
2026-003	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	2.583	0.083	3.23	2.300	2.900
2026-003	5	IMT	219	ATELLICA	143	SIEMENS	32	2.717	0.121	4.47	2.400	3.000
2026-003	5	IMT	219	ATELLICA	143	SIEMENS	32	2.600	0.102	3.91	2.300	2.900
2026-003	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	71	2.615	0.046	1.77	2.300	2.900
022	POTASSIUM	CLIA TEST ID #: 465		EVALUATION CRITERIA: TARGET VALUE 0.30								
2026-004	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	6.235	0.149	2.39	5.900	6.500
2026-004	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	6.067	0.112	1.85	5.800	6.400
2026-004	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	6.333	0.230	3.63	6.000	6.600
2026-004	3	ISE DILUT.	203	ROCHE	93	ROCHE	70	6.243	0.112	1.79	5.900	6.500
2026-004	4	ISE UNLIL.	165	VITROS	63	KODAK	48	6.340	0.165	2.60	6.000	6.600
2026-004	4	ISE UNLIL.	165	VITROS	156	Kit 32	97	6.288	0.123	1.95	6.000	6.600
2026-004	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	26	6.119	0.218	3.57	5.800	6.400
2026-004	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	26	5.983	0.261	4.36	5.700	6.300
2026-004	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	6.228	0.202	3.25	5.900	6.500
2026-004	5	IMT	219	ATELLICA	143	SIEMENS	32	5.256	1.992	37.90	5.000	5.600
2026-004	5	IMT	219	ATELLICA	143	SIEMENS	32	5.633	0.125	2.21	5.300	5.900
2026-004	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	71	6.180	0.129	2.08	5.900	6.500
2026-005	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	3.315	0.072	2.16	3.000	3.600
2026-005	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	3.337	0.067	2.02	3.000	3.600
2026-005	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	3.333	0.060	1.79	3.000	3.600
2026-005	3	ISE DILUT.	203	ROCHE	93	ROCHE	70	3.387	0.073	2.14	3.100	3.700
2026-005	4	ISE UNLIL.	165	VITROS	63	KODAK	48	3.330	0.077	2.31	3.000	3.600
2026-005	4	ISE UNLIL.	165	VITROS	156	Kit 32	97	3.306	0.061	1.84	3.000	3.600
2026-005	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	26	3.412	0.134	3.93	3.100	3.700
2026-005	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	26	3.317	0.177	5.34	3.000	3.600
2026-005	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	3.228	0.065	2.01	2.900	3.500

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	5	IMT	219	APELLICA	143	SIEMENS	32	3.250	0.126	3.87	3.000	3.600
2026-005	5	IMT	219	APELLICA	143	SIEMENS	32	3.194	0.129	4.05	2.900	3.500
2026-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	71	3.280	0.066	2.02	3.000	3.600
023	SODIUM		CLIA TEST ID #: 475			EVALUATION CRITERIA: TARGET VALUE 4.00						
2026-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	121.520	2.300	1.89	118.000	126.000
2026-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	122.519	1.772	1.45	119.000	127.000
2026-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	122.333	1.748	1.43	118.000	126.000
2026-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	65	122.375	2.095	1.71	118.000	126.000
2026-001	4	ISE UNLIL.	165	VITROS	63	KODAK	45	118.068	1.498	1.27	114.000	122.000
2026-001	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	118.263	1.637	1.38	114.000	122.000
2026-001	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	26	123.846	2.381	1.92	120.000	128.000
2026-001	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	120.333	1.826	1.52	116.000	124.000
2026-001	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	121.667	3.091	2.54	118.000	126.000
2026-001	5	IMT	197	ARCHITECT	1	ABBOTT	10	123.800	1.600	1.29	120.000	128.000
2026-001	5	IMT	219	APELLICA	143	SIEMENS	32	123.781	1.781	1.44	120.000	128.000
2026-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	125.169	2.014	1.61	121.000	129.000
2026-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	149.680	2.853	1.91	146.000	154.000
2026-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	150.926	3.254	2.16	147.000	155.000
2026-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	153.250	1.920	1.25	149.000	157.000
2026-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	65	151.313	2.738	1.81	147.000	155.000
2026-002	4	ISE UNLIL.	165	VITROS	63	KODAK	45	155.511	3.016	1.94	152.000	160.000
2026-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	154.949	3.073	1.98	151.000	159.000
2026-002	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	26	155.400	2.668	1.72	151.000	159.000
2026-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	150.667	3.091	2.05	147.000	155.000
2026-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	153.000	2.625	1.72	149.000	157.000
2026-002	5	IMT	197	ARCHITECT	1	ABBOTT	10	154.300	2.452	1.59	150.000	158.000
2026-002	5	IMT	219	APELLICA	143	SIEMENS	32	150.069	3.118	2.08	146.000	154.000
2026-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	151.606	2.139	1.41	148.000	156.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
023	SODIUM	CLIA TEST ID #: 475		EVALUATION CRITERIA: TARGET VALUE 4.00								
2026-003	3	ISE DILUTE	184 INTEGRA	93	ROCHE	25	125.920	2.560	2.03	122.000	130.000	
2026-003	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	27	126.741	1.878	1.48	123.000	131.000	
2026-003	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	12	126.250	2.203	1.75	122.000	130.000	
2026-003	3	ISE DILUTE	203 ROCHE	93	ROCHE	65	126.766	2.090	1.65	123.000	131.000	
2026-003	4	ISE UNLIL.	165 VITROS	63	KODAK	45	124.533	1.543	1.24	121.000	129.000	
2026-003	4	ISE UNLIL.	165 VITROS	156	Kit 32	100	124.172	1.627	1.31	120.000	128.000	
2026-003	4	ISE UNLIL.	191 RX-SERIES	126	RANLIL	26	128.440	2.137	1.66	124.000	132.000	
2026-003	4	ISE UNLIL.	220 Medica E.	130	MEDICA	18	125.667	2.186	1.74	122.000	130.000	
2026-003	4	ISE UNLIL.	220 Medica E.	130	MEDICA	18	127.333	0.471	0.37	123.000	131.000	
2026-003	5	IMT	197 ARCHITECT	1	ABBOTT	10	127.800	2.135	1.67	124.000	132.000	
2026-003	5	IMT	219 ATELLICA	143	SIEMENS	32	127.613	1.878	1.47	124.000	132.000	
2026-003	6	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	72	128.931	1.719	1.33	125.000	133.000	
2026-004	3	ISE DILUTE	184 INTEGRA	93	ROCHE	25	159.040	2.807	1.76	155.000	163.000	
2026-004	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	27	159.519	2.425	1.52	156.000	164.000	
2026-004	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	12	163.583	3.252	1.99	160.000	168.000	
2026-004	3	ISE DILUTE	203 ROCHE	93	ROCHE	65	161.344	3.275	2.03	157.000	165.000	
2026-004	4	ISE UNLIL.	165 VITROS	63	KODAK	45	168.636	3.955	2.35	165.000	173.000	
2026-004	4	ISE UNLIL.	165 VITROS	156	Kit 32	100	167.180	3.157	1.89	163.000	171.000	
2026-004	4	ISE UNLIL.	191 RX-SERIES	126	RANLIL	26	164.231	3.566	2.17	160.000	168.000	
2026-004	4	ISE UNLIL.	220 Medica E.	130	MEDICA	18	160.333	1.247	0.78	156.000	164.000	
2026-004	4	ISE UNLIL.	220 Medica E.	130	MEDICA	18	164.278	4.120	2.51	160.000	168.000	
2026-004	5	IMT	197 ARCHITECT	1	ABBOTT	10	165.500	6.217	3.76	162.000	170.000	
2026-004	5	IMT	219 ATELLICA	143	SIEMENS	32	138.688	52.525	37.87	135.000	143.000	
2026-004	6	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	72	160.986	2.611	1.62	157.000	165.000	
2026-005	3	ISE DILUTE	184 INTEGRA	93	ROCHE	25	132.080	2.855	2.16	128.000	136.000	
2026-005	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	27	133.481	2.587	1.94	129.000	137.000	
2026-005	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	12	134.333	2.248	1.67	130.000	138.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	65	133.438	2.391	1.79	129.000	137.000
2026-005	4	ISE UNDIL.	165	VITROS	63	KODAK	45	132.114	2.461	1.86	128.000	136.000
2026-005	4	ISE UNDIL.	165	VITROS	156	Kit 32	100	131.303	2.057	1.57	127.000	135.000
2026-005	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	135.769	2.900	2.14	132.000	140.000
2026-005	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	132.500	1.893	1.43	129.000	137.000
2026-005	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	133.000	2.160	1.62	129.000	137.000
2026-005	5	IMT	197	ARCHITECT	1	ABBOTT	10	133.900	1.578	1.18	130.000	138.000
2026-005	5	IMT	219	ATELLICA	143	SIEMENS	32	133.355	2.208	1.66	129.000	137.000
2026-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	72	134.972	2.369	1.75	131.000	139.000
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %						
2026-001	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	2.209	0.087	3.96	2.000	2.400
2026-001	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	2.250	0.050	2.22	2.100	2.400
2026-001	1	BIURET	165	VITROS	63	KODAK	130	2.206	0.073	3.33	2.000	2.400
2026-001	1	BIURET	184	INTEGRA	93	ROCHE	16	2.050	0.170	8.27	1.900	2.200
2026-001	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	26	2.238	0.344	15.38	2.100	2.400
2026-001	1	BIURET	191	RX-SERIES	126	RANDOX	21	2.125	0.167	7.86	2.000	2.300
2026-001	1	BIURET	197	ARCHITECT	1	ABBOTT	20	2.055	0.050	2.42	1.900	2.200
2026-001	1	BIURET	203	ROCHE	93	ROCHE	56	2.104	0.073	3.48	1.900	2.300
2026-001	1	BIURET	219	ATELLICA	143	SIEMENS	33	2.109	0.071	3.38	1.900	2.300
2026-001	1	BIURET	220	Medica E.	130	MEDICA	15	2.067	0.107	5.20	1.900	2.200
2026-001	3	BIURET COL	203	ROCHE	93	ROCHE	15	2.113	0.096	4.53	1.900	2.300
2026-002	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	7.175	0.268	3.74	6.600	7.700
2026-002	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	7.053	0.165	2.33	6.500	7.600
2026-002	1	BIURET	165	VITROS	63	KODAK	130	6.581	0.172	2.61	6.100	7.100
2026-002	1	BIURET	184	INTEGRA	93	ROCHE	16	6.531	0.252	3.86	6.000	7.100
2026-002	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	26	6.815	0.209	3.06	6.300	7.400
2026-002	1	BIURET	191	RX-SERIES	126	RANDOX	21	6.795	0.140	2.05	6.300	7.300
2026-002	1	BIURET	197	ARCHITECT	1	ABBOTT	20	6.910	0.167	2.42	6.400	7.500
2026-002	1	BIURET	203	ROCHE	93	ROCHE	56	6.763	0.159	2.35	6.200	7.300

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-002	1	BIURET	219	ATELLICA	143	SIEMENS	33	6.839	0.182	2.67	6.300	7.400
2026-002	1	BIURET	220	Medica E.	130	MEDICA	15	6.607	0.217	3.29	6.100	7.100
2026-002	3	BIURET COL	203	ROCHE	93	ROCHE	15	6.767	0.212	3.13	6.200	7.300
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %						
2026-003	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	3.187	0.087	2.72	2.900	3.400
2026-003	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	3.275	0.083	2.53	3.000	3.500
2026-003	1	BIURET	165	VITROS	63	KODAK	130	3.147	0.084	2.66	2.900	3.400
2026-003	1	BIURET	184	INTEGRA	93	ROCHE	16	2.888	0.200	6.91	2.700	3.100
2026-003	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	26	3.035	0.083	2.73	2.800	3.300
2026-003	1	BIURET	191	RX-SERIES	126	RANDOX	21	3.045	0.132	4.34	2.800	3.300
2026-003	1	BIURET	197	ARCHITECT	1	ABBOTT	20	3.010	0.070	2.33	2.800	3.300
2026-003	1	BIURET	203	ROCHE	93	ROCHE	56	3.053	0.093	3.05	2.800	3.300
2026-003	1	BIURET	219	ATELLICA	143	SIEMENS	33	3.076	0.107	3.49	2.800	3.300
2026-003	1	BIURET	220	Medica E.	130	MEDICA	15	2.947	0.131	4.44	2.700	3.200
2026-003	3	BIURET COL	203	ROCHE	93	ROCHE	15	3.040	0.120	3.95	2.800	3.300
2026-004	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	8.600	0.235	2.73	7.900	9.300
2026-004	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	8.629	0.181	2.09	7.900	9.300
2026-004	1	BIURET	165	VITROS	63	KODAK	130	8.086	0.225	2.78	7.400	8.700
2026-004	1	BIURET	184	INTEGRA	93	ROCHE	16	7.850	0.272	3.46	7.200	8.500
2026-004	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	26	8.273	0.168	2.03	7.600	8.900
2026-004	1	BIURET	191	RX-SERIES	126	RANDOX	21	8.252	0.281	3.40	7.600	8.900
2026-004	1	BIURET	197	ARCHITECT	1	ABBOTT	20	8.474	0.148	1.75	7.800	9.200
2026-004	1	BIURET	203	ROCHE	93	ROCHE	56	8.141	0.232	2.85	7.500	8.800
2026-004	1	BIURET	219	ATELLICA	143	SIEMENS	33	8.300	0.217	2.61	7.600	9.000
2026-004	1	BIURET	220	Medica E.	130	MEDICA	15	7.967	0.309	3.88	7.300	8.600
2026-004	3	BIURET COL	203	ROCHE	93	ROCHE	15	8.140	0.215	2.65	7.500	8.800
2026-005	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	4.204	0.103	2.44	3.900	4.500
2026-005	1	BIURET	38	SIEMENS DI	143	SIEMENS	70	4.250	0.087	2.04	3.900	4.600

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2026-005	1	BIURET	165 VITROS	63	KODAK	130	4.082	0.113	2.77	3.800	4.400	
2026-005	1	BIURET	184 INTEGRA	93	ROCHE	16	3.880	0.156	4.01	3.600	4.200	
2026-005	1	BIURET	186 BECK. COUL	76	AU-BECKMAN	26	3.984	0.083	2.09	3.700	4.300	
2026-005	1	BIURET	191 RX-SERIES	126	RANDOX	21	4.071	0.161	3.95	3.700	4.400	
2026-005	1	BIURET	197 ARCHITECT	1	ABBOTT	20	4.005	0.059	1.47	3.700	4.300	
2026-005	1	BIURET	203 ROCHE	93	ROCHE	56	4.023	0.124	3.08	3.700	4.300	
2026-005	1	BIURET	219 ATELLICA	143	SIEMENS	33	4.063	0.111	2.73	3.700	4.400	
2026-005	1	BIURET	220 Medica E.	130	MEDICA	15	3.900	0.137	3.50	3.600	4.200	
2026-005	3	BIURET COL	203 ROCHE	93	ROCHE	15	4.027	0.134	3.33	3.700	4.300	
025 TRIGLYCERIDES		CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 15 %								
2026-001	2	ENZ. COLO.	165 VITROS	63	KODAK	131	110.477	4.643	4.20	94.000	127.000	
2026-001	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	12	105.583	2.629	2.49	90.000	121.000	
2026-001	2	ENZ. COLO.	203 ROCHE	93	ROCHE	35	103.057	2.056	1.99	88.000	119.000	
2026-001	2	ENZ. COLO.	220 Medica E.	130	MEDICA	15	98.733	6.797	6.88	84.000	114.000	
2026-001	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	69	93.618	3.063	3.27	80.000	108.000	
2026-001	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	69	100.000	1.633	1.63	85.000	115.000	
2026-001	5	HANTZCH-C)	197 ARCHITECT	1	ABBOTT	12	94.500	1.607	1.70	80.000	109.000	
2026-001	9	GPO TRIND.	186 BECK. COUL	76	AU-BECKMAN	26	104.346	3.902	3.74	89.000	120.000	
2026-001	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	20	102.000	7.994	7.84	87.000	117.000	
2026-001	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	20	95.333	6.848	7.18	81.000	110.000	
2026-001	10	ENZYM. GPO	184 INTEGRA	93	ROCHE	13	104.692	1.976	1.89	89.000	120.000	
2026-001	10	ENZYM. GPO	203 ROCHE	93	ROCHE	31	103.033	2.041	1.98	88.000	118.000	
2026-001	10	ENZYM. GPO	219 ATELLICA	143	SIEMENS	33	102.818	4.246	4.13	87.000	118.000	
2026-002	2	ENZ. COLO.	165 VITROS	63	KODAK	131	263.115	14.366	5.46	224.000	303.000	
2026-002	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	12	233.250	7.451	3.19	198.000	268.000	
2026-002	2	ENZ. COLO.	203 ROCHE	93	ROCHE	35	231.500	5.595	2.42	197.000	266.000	
2026-002	2	ENZ. COLO.	220 Medica E.	130	MEDICA	15	214.733	9.161	4.27	183.000	247.000	
2026-002	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	69	238.333	2.357	0.99	203.000	274.000	
2026-002	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	69	228.662	5.511	2.41	194.000	263.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-002	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	221.083	3.730	1.69	188.000	254.000
2026-002	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	243.423	9.035	3.71	207.000	280.000
2026-002	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	210.333	12.257	5.83	179.000	242.000
2026-002	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	229.650	17.591	7.66	195.000	264.000
2026-002	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	229.692	4.213	1.83	195.000	264.000
2026-002	10	ENZYM. GPO	203	ROCHE	93	ROCHE	31	229.710	5.299	2.31	195.000	264.000
2026-002	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	235.455	6.801	2.89	200.000	271.000
025 TRIGLYCERIDES			CLIA TEST ID #: 495			EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-003	2	ENZ. COLO.	165	VITROS	63	KODAK	131	140.664	5.846	4.16	120.000	162.000
2026-003	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	130.917	3.068	2.34	111.000	151.000
2026-003	2	ENZ. COLO.	203	ROCHE	93	ROCHE	35	128.647	2.909	2.26	109.000	148.000
2026-003	2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	119.800	5.600	4.67	102.000	138.000
2026-003	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	69	120.182	3.060	2.55	102.000	138.000
2026-003	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	69	128.000	4.320	3.38	109.000	147.000
2026-003	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	118.750	2.241	1.89	101.000	137.000
2026-003	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	131.077	5.129	3.91	111.000	151.000
2026-003	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	126.050	10.195	8.09	107.000	145.000
2026-003	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	124.667	9.741	7.81	106.000	143.000
2026-003	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	129.538	2.707	2.09	110.000	149.000
2026-003	10	ENZYM. GPO	203	ROCHE	93	ROCHE	31	128.968	3.393	2.63	110.000	148.000
2026-003	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	129.000	4.599	3.57	110.000	148.000
2026-004	2	ENZ. COLO.	165	VITROS	63	KODAK	131	310.840	16.869	5.43	264.000	357.000
2026-004	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	269.333	8.055	2.99	229.000	310.000
2026-004	2	ENZ. COLO.	203	ROCHE	93	ROCHE	35	270.486	6.784	2.51	230.000	311.000
2026-004	2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	254.067	13.757	5.41	216.000	292.000
2026-004	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	69	284.333	2.055	0.72	242.000	327.000
2026-004	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	69	272.147	6.062	2.23	231.000	313.000
2026-004	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	262.667	10.726	4.08	223.000	302.000
2026-004	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	285.962	9.618	3.36	243.000	329.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-004	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	261.000	24.097	9.23	222.000	300.000
2026-004	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	268.450	21.143	7.88	228.000	309.000
2026-004	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	266.923	7.032	2.63	227.000	307.000
2026-004	10	ENZYM. GPO	203	ROCHE	93	ROCHE	31	269.419	6.313	2.34	229.000	310.000
2026-004	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	276.667	8.661	3.13	235.000	318.000
025 TRIGLYCERIDES			CLIA TEST ID #: 495			EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-005	2	ENZ. COLO.	165	VITROS	63	KODAK	131	172.992	7.822	4.52	147.000	199.000
2026-005	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	159.000	3.512	2.21	135.000	183.000
2026-005	2	ENZ. COLO.	203	ROCHE	93	ROCHE	35	156.343	3.513	2.25	133.000	180.000
2026-005	2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	146.067	7.234	4.95	124.000	168.000
2026-005	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	69	148.985	3.546	2.38	127.000	171.000
2026-005	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	69	158.667	2.494	1.57	135.000	182.000
2026-005	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	145.917	2.957	2.03	124.000	168.000
2026-005	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	160.154	5.201	3.25	136.000	184.000
2026-005	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	153.600	12.835	8.36	131.000	177.000
2026-005	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	148.667	11.785	7.93	126.000	171.000
2026-005	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	157.846	3.779	2.39	134.000	182.000
2026-005	10	ENZYM. GPO	203	ROCHE	93	ROCHE	31	156.452	3.775	2.41	133.000	180.000
2026-005	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	157.394	5.251	3.34	134.000	181.000
026 UREA NITROGEN (BUN)			CLIA TEST ID #: 505			EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2026-001	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	6.500	0.707	10.88	5.000	9.000
2026-001	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	6.411	0.679	10.59	4.000	8.000
2026-001	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	6.759	0.502	7.43	5.000	9.000
2026-001	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	6.926	0.378	5.45	5.000	9.000
2026-001	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	7.000	0.000	0.00	5.000	9.000
2026-001	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	6.870	0.850	12.37	5.000	9.000
2026-001	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	6.571	0.495	7.53	5.000	9.000
2026-001	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	6.868	0.380	5.53	5.000	9.000
2026-001	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	6.500	0.707	10.88	5.000	9.000
2026-001	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	7.000	0.559	7.99	5.000	9.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-001	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	15	7.067	0.442	6.26	5.000	9.000
2026-001	8	UREASE QUI	165	VITROS	63	KODAK	146	6.571	0.495	7.53	5.000	9.000
2026-001	8	UREASE QUI	165	VITROS	63	KODAK	146	6.062	0.392	6.47	4.000	8.000
2026-001	10	UREASE 37	220	Medica E.	130	MEDICA	18	6.833	0.601	8.79	5.000	9.000
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2026-002	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	33.315	1.432	4.30	30.000	36.000
2026-002	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	30.750	1.199	3.90	28.000	34.000
2026-002	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	33.241	1.633	4.91	30.000	36.000
2026-002	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	33.667	0.471	1.40	31.000	37.000
2026-002	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	33.481	1.500	4.48	30.000	36.000
2026-002	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	30.000	3.703	12.34	27.000	33.000
2026-002	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	31.391	1.928	6.14	29.000	34.000
2026-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	30.750	1.199	3.90	28.000	34.000
2026-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	32.897	0.987	3.00	30.000	36.000
2026-002	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	32.125	1.317	4.10	29.000	35.000
2026-002	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	15	34.667	0.869	2.51	32.000	38.000
2026-002	8	UREASE QUI	165	VITROS	63	KODAK	146	33.274	1.144	3.44	30.000	36.000
2026-002	8	UREASE QUI	165	VITROS	63	KODAK	146	30.000	3.703	12.34	27.000	33.000
2026-002	10	UREASE 37	220	Medica E.	130	MEDICA	18	31.944	1.026	3.21	29.000	35.000
2026-003	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	11.375	0.696	6.12	9.000	13.000
2026-003	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	11.616	0.752	6.47	10.000	14.000
2026-003	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	11.724	0.690	5.88	10.000	14.000
2026-003	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	12.333	0.667	5.41	10.000	14.000
2026-003	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	12.000	0.000	0.00	10.000	14.000
2026-003	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	12.000	1.063	8.86	10.000	14.000
2026-003	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	11.571	0.495	4.28	10.000	14.000
2026-003	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	11.868	0.512	4.31	10.000	14.000
2026-003	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	11.375	0.696	6.12	9.000	13.000
2026-003	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	12.188	0.682	5.59	10.000	14.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	15	12.333	0.596	4.83	10.000	14.000
2026-003	8	UREASE QUI	165	VITROS	63	KODAK	146	11.571	0.495	4.28	10.000	14.000
2026-003	8	UREASE QUI	165	VITROS	63	KODAK	146	11.651	0.556	4.77	10.000	14.000
2026-003	10	UREASE 37	220	Medica E.	130	MEDICA	18	11.944	0.621	5.20	10.000	14.000
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2026-004	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	42.216	1.833	4.34	38.000	46.000
2026-004	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	39.000	1.323	3.39	35.000	43.000
2026-004	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	41.828	1.782	4.26	38.000	46.000
2026-004	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	42.667	0.471	1.10	39.000	47.000
2026-004	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	41.815	1.765	4.22	38.000	46.000
2026-004	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	39.429	1.178	2.99	36.000	43.000
2026-004	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	39.522	2.465	6.24	36.000	43.000
2026-004	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	39.000	1.323	3.39	35.000	43.000
2026-004	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	41.200	1.294	3.14	37.000	45.000
2026-004	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	39.469	1.392	3.53	36.000	43.000
2026-004	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	15	44.067	2.265	5.14	40.000	48.000
2026-004	8	UREASE QUI	165	VITROS	63	KODAK	146	42.145	1.276	3.03	38.000	46.000
2026-004	8	UREASE QUI	165	VITROS	63	KODAK	146	39.429	1.178	2.99	36.000	43.000
2026-004	10	UREASE 37	220	Medica E.	130	MEDICA	18	40.000	1.856	4.64	36.000	44.000
2026-005	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	17.000	0.707	4.16	15.000	19.000
2026-005	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	74	17.219	0.798	4.63	15.000	19.000
2026-005	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	17.310	0.700	4.04	15.000	19.000
2026-005	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	17.704	0.710	4.01	16.000	20.000
2026-005	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	17.667	0.471	2.67	16.000	20.000
2026-005	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	17.304	0.997	5.76	15.000	19.000
2026-005	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	23	17.286	0.452	2.61	15.000	19.000
2026-005	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	17.319	0.670	3.87	15.000	19.000
2026-005	2	UREAS.GLDH	203	ROCHE	93	ROCHE	70	17.000	0.707	4.16	15.000	19.000
2026-005	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	17.563	0.704	4.01	16.000	20.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	15	17.600	0.712	4.04	16.000	20.000
2026-005	8	UREASE QUI	165	VITROS	63	KODAK	146	17.286	0.452	2.61	15.000	19.000
2026-005	8	UREASE QUI	165	VITROS	63	KODAK	146	17.076	0.633	3.71	15.000	19.000
2026-005	10	UREASE 37	220	Medica E.	130	MEDICA	18	17.389	0.826	4.75	15.000	19.000
027	URIC ACID		CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 10 %					
2026-001	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	1.661	0.132	7.94	1.500	1.800
2026-001	2	URICASE	165	VITROS	63	KODAK	89	1.665	0.062	3.74	1.500	1.800
2026-001	2	URICASE	184	INTEGRA	93	ROCHE	10	1.700	0.148	8.72	1.500	1.900
2026-001	2	URICASE	203	ROCHE	93	ROCHE	37	1.594	0.053	3.33	1.400	1.800
2026-001	2	URICASE	219	ATELLICA	143	SIEMENS	27	1.746	0.050	2.85	1.600	1.900
2026-001	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.817	0.050	2.75	1.600	2.000
2026-001	6	ENZY. COL	203	ROCHE	93	ROCHE	19	1.589	0.045	2.81	1.400	1.700
2026-002	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	8.819	0.281	3.18	7.900	9.700
2026-002	2	URICASE	165	VITROS	63	KODAK	89	8.822	0.232	2.63	7.900	9.700
2026-002	2	URICASE	184	INTEGRA	93	ROCHE	10	9.000	0.249	2.77	8.100	9.900
2026-002	2	URICASE	203	ROCHE	93	ROCHE	37	8.661	0.228	2.63	7.800	9.500
2026-002	2	URICASE	219	ATELLICA	143	SIEMENS	27	9.089	0.231	2.55	8.200	10.000
2026-002	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	8.983	0.134	1.50	8.100	9.900
2026-002	6	ENZY. COL	203	ROCHE	93	ROCHE	19	8.721	0.274	3.15	7.800	9.600
2026-003	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	2.997	0.108	3.61	2.700	3.300
2026-003	2	URICASE	165	VITROS	63	KODAK	89	3.013	0.088	2.91	2.700	3.300
2026-003	2	URICASE	184	INTEGRA	93	ROCHE	10	3.140	0.092	2.92	2.800	3.500
2026-003	2	URICASE	203	ROCHE	93	ROCHE	37	3.028	0.069	2.28	2.700	3.300
2026-003	2	URICASE	219	ATELLICA	143	SIEMENS	27	3.230	0.076	2.36	2.900	3.600
2026-003	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	3.267	0.058	1.77	2.900	3.600
2026-003	6	ENZY. COL	203	ROCHE	93	ROCHE	19	2.984	0.087	2.93	2.700	3.300
2026-004	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	11.254	0.381	3.39	10.100	12.400

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS			NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-004	2	URICASE	165	VITROS	63	KODAK	89	11.174	0.285	2.55	10.100	12.300
2026-004	2	URICASE	184	INTEGRA	93	ROCHE	10	11.030	0.310	2.81	9.900	12.100
2026-004	2	URICASE	203	ROCHE	93	ROCHE	37	10.900	0.335	3.07	9.800	12.000
2026-004	2	URICASE	219	ATELLICA	143	SIEMENS	27	11.396	0.225	1.98	10.300	12.500
2026-004	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	11.117	0.192	1.73	10.000	12.200
2026-004	6	ENZY. COL	203	ROCHE	93	ROCHE	19	10.868	0.337	3.10	9.800	12.000
027	URIC ACID		CLIA TEST ID #: 515			EVALUATION CRITERIA: TARGET VALUE 10 %						
2026-005	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	4.531	0.152	3.36	4.100	5.000
2026-005	2	URICASE	165	VITROS	63	KODAK	89	4.491	0.125	2.79	4.000	4.900
2026-005	2	URICASE	184	INTEGRA	93	ROCHE	10	4.770	0.283	5.93	4.300	5.200
2026-005	2	URICASE	203	ROCHE	93	ROCHE	37	4.533	0.143	3.16	4.100	5.000
2026-005	2	URICASE	219	ATELLICA	143	SIEMENS	27	4.763	0.099	2.07	4.300	5.200
2026-005	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	4.761	0.089	1.87	4.300	5.200
2026-005	6	ENZY. COL	203	ROCHE	93	ROCHE	19	4.521	0.144	3.18	4.100	5.000
135	GGT (GAMMA GLU. TRA)		CLIA TEST ID #: 411			EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}						
2026-001	5	KINETIC 37	165	VITROS	63	KODAK	25	21.083	1.351	6.41	16.000	26.000
2026-001	5	KINETIC 37	165	VITROS	63	KODAK	25	14.333	1.247	8.70	9.000	19.000
2026-001	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	15.500	0.866	5.59	11.000	21.000
2026-002	5	KINETIC 37	165	VITROS	63	KODAK	25	339.667	18.373	5.41	289.000	391.000
2026-002	5	KINETIC 37	165	VITROS	63	KODAK	25	487.333	14.960	3.07	414.000	560.000
2026-002	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	369.917	15.500	4.19	314.000	425.000
2026-003	5	KINETIC 37	165	VITROS	63	KODAK	25	129.958	3.397	2.61	110.000	149.000
2026-003	5	KINETIC 37	165	VITROS	63	KODAK	25	81.333	2.625	3.23	69.000	94.000
2026-003	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	88.417	3.378	3.82	75.000	102.000
2026-004	5	KINETIC 37	165	VITROS	63	KODAK	25	444.333	14.704	3.31	378.000	511.000
2026-004	5	KINETIC 37	165	VITROS	63	KODAK	25	603.417	22.807	3.78	513.000	694.000
2026-004	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	479.667	19.985	4.17	408.000	552.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 411	EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}									
2026-005	5 KINETIC 37	165 VITROS	63 KODAK	25	235.583	7.285	3.09	200.000	271.000			
2026-005	5 KINETIC 37	165 VITROS	63 KODAK	25	149.667	5.249	3.51	127.000	172.000			
2026-005	5 KINETIC 37	219 ATELLICA	143 SIEMENS	12	161.583	7.643	4.73	137.000	186.000			
136	LACTIC ACID	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %									
2026-001	1 LACTATE-P.	165 VITROS	63 KODAK	27	0.500	0.000	0.00	0.400	0.600			
2026-002	1 LACTATE-P.	165 VITROS	63 KODAK	27	4.615	0.130	2.81	3.700	5.500			
2026-003	1 LACTATE-P.	165 VITROS	63 KODAK	27	0.978	0.042	4.25	0.800	1.200			
2026-004	1 LACTATE-P.	165 VITROS	63 KODAK	27	5.781	0.173	3.00	4.600	6.900			
2026-005	1 LACTATE-P.	165 VITROS	63 KODAK	27	1.922	0.079	4.09	1.500	2.300			
137	LIPASE											
2026-001	1 COLORIMET.	203 ROCHE	93 ROCHE	19	18.053	0.887	4.91	14.000	22.000			
2026-001	1 COLORIMET.	219 ATELLICA	143 SIEMENS	19	20.684	1.591	7.69	17.000	25.000			
2026-001	2 ENZIMATIC	165 VITROS	63 KODAK	82	156.585	7.182	4.59	125.000	188.000			
2026-001	4 ENZ/COLOR	186 BECK. COUL	76 AU-BECKMAN	10	16.200	1.327	8.19	13.000	19.000			
2026-001	4 ENZ/COLOR	203 ROCHE	93 ROCHE	15	17.933	1.062	5.92	14.000	22.000			
2026-001	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	12	17.500	1.258	7.19	14.000	21.000			
2026-002	1 COLORIMET.	203 ROCHE	93 ROCHE	19	83.895	3.726	4.44	67.000	101.000			
2026-002	1 COLORIMET.	219 ATELLICA	143 SIEMENS	19	90.632	3.587	3.96	73.000	109.000			
2026-002	2 ENZIMATIC	165 VITROS	63 KODAK	82	760.476	49.868	6.56	608.000	913.000			
2026-002	4 ENZ/COLOR	186 BECK. COUL	76 AU-BECKMAN	10	83.600	4.341	5.19	67.000	100.000			
2026-002	4 ENZ/COLOR	203 ROCHE	93 ROCHE	15	83.600	3.179	3.80	67.000	100.000			
2026-002	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	12	80.750	4.225	5.23	65.000	97.000			

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
137	LIPASE	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-003	1	COLORIMET.	203	ROCHE	93	ROCHE	19	31.105	1.714	5.51	25.000	37.000
2026-003	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	35.316	2.272	6.43	28.000	42.000
2026-003	2	ENZIMATIC	165	VITROS	63	KODAK	82	288.350	15.232	5.28	231.000	346.000
2026-003	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	29.900	1.700	5.69	24.000	36.000
2026-003	4	ENZ/COLOR	203	ROCHE	93	ROCHE	15	31.533	1.500	4.76	25.000	38.000
2026-003	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	30.917	1.847	5.97	25.000	37.000
2026-004	1	COLORIMET.	203	ROCHE	93	ROCHE	19	104.526	4.235	4.05	84.000	125.000
2026-004	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	111.263	5.408	4.86	89.000	134.000
2026-004	2	ENZIMATIC	165	VITROS	63	KODAK	82	940.939	58.783	6.25	753.000	1129.000
2026-004	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	103.200	4.622	4.48	83.000	124.000
2026-004	4	ENZ/COLOR	203	ROCHE	93	ROCHE	15	102.133	3.896	3.82	82.000	123.000
2026-004	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	101.250	4.952	4.89	81.000	122.000
2026-005	1	COLORIMET.	203	ROCHE	93	ROCHE	19	45.579	2.008	4.41	36.000	55.000
2026-005	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	49.842	3.438	6.90	40.000	60.000
2026-005	2	ENZIMATIC	165	VITROS	63	KODAK	82	417.593	22.410	5.37	334.000	501.000
2026-005	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	44.300	2.238	5.05	35.000	53.000
2026-005	4	ENZ/COLOR	203	ROCHE	93	ROCHE	15	45.533	1.784	3.92	36.000	55.000
2026-005	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	44.417	1.977	4.45	36.000	53.000
138	PHOSPHORUS	CLIA TEST ID #: 460				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2026-001	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	1.446	0.083	5.71	1.100	1.700
2026-001	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	1.714	0.083	4.86	1.400	2.000
2026-001	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	1.515	0.067	4.42	1.200	1.800
2026-001	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	1.350	0.087	6.42	1.100	1.700
2026-001	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	1.385	0.124	8.92	1.100	1.700
2026-001	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	1.311	0.053	4.06	1.000	1.600
2026-001	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	1.362	0.061	4.49	1.100	1.700

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
138	PHOSPHORUS	CLIA TEST ID #: 460				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2026-002	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	5.086	0.173	3.39	4.600	5.600
2026-002	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	4.722	0.109	2.32	4.200	5.200
2026-002	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	4.322	0.134	3.10	3.900	4.800
2026-002	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	4.442	0.171	3.84	4.000	4.900
2026-002	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	4.655	0.215	4.61	4.200	5.100
2026-002	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	4.463	0.113	2.53	4.000	4.900
2026-002	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	4.617	0.134	2.91	4.200	5.100
2026-003	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	2.146	0.086	3.99	1.800	2.400
2026-003	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	2.429	0.070	2.88	2.100	2.700
2026-003	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.188	0.088	4.04	1.900	2.500
2026-003	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	2.033	0.103	5.05	1.700	2.300
2026-003	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	2.068	0.146	7.05	1.800	2.400
2026-003	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	1.994	0.065	3.26	1.700	2.300
2026-003	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	2.060	0.084	4.08	1.800	2.400
2026-004	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	6.286	0.217	3.45	5.700	6.900
2026-004	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	5.714	0.176	3.08	5.100	6.300
2026-004	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	5.188	0.154	2.97	4.700	5.700
2026-004	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	5.383	0.207	3.85	4.800	5.900
2026-004	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	5.586	0.161	2.89	5.000	6.100
2026-004	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	5.418	0.154	2.84	4.900	6.000
2026-004	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	5.627	0.150	2.67	5.100	6.200
2026-005	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	2.819	0.114	4.03	2.500	3.100
2026-005	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	3.157	0.073	2.31	2.800	3.500
2026-005	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.765	0.091	3.30	2.500	3.100
2026-005	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	2.658	0.132	4.97	2.400	3.000
2026-005	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	2.718	0.134	4.92	2.400	3.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-005	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	2.636	0.072	2.74	2.300	2.900
2026-005	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	2.747	0.088	3.22	2.400	3.000
169	CO2	CLIA TEST ID #: 351				EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-001	1	Generic Me	184	INTEGRA	93	ROCHE	10	19.000	1.414	7.44	15.000	23.000
2026-001	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	19.955	0.928	4.65	16.000	24.000
2026-001	1	Generic Me	203	ROCHE	93	ROCHE	25	19.760	1.176	5.95	16.000	24.000
2026-001	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	22.947	1.923	8.38	18.000	28.000
2026-001	2	ENZYMATIC	165	VITROS	63	KODAK	44	20.233	1.217	6.01	16.000	24.000
2026-001	2	ENZYMATIC	165	VITROS	63	KODAK	44	19.000	0.500	2.63	15.000	23.000
2026-001	2	ENZYMATIC	165	VITROS	156	Kit 32	84	20.179	1.217	6.03	16.000	24.000
2026-001	2	ENZYMATIC	203	ROCHE	93	ROCHE	14	19.500	0.906	4.65	16.000	23.000
2026-001	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	22.000	1.619	7.36	18.000	26.000
2026-001	4	PEP CARBOX	197	ARCHITECT	1	ABBOTT	10	20.000	3.712	18.56	16.000	24.000
2026-002	1	Generic Me	184	INTEGRA	93	ROCHE	10	25.200	2.315	9.19	20.000	30.000
2026-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	28.609	2.650	9.26	23.000	34.000
2026-002	1	Generic Me	203	ROCHE	93	ROCHE	25	26.680	2.258	8.46	21.000	32.000
2026-002	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	30.018	2.115	7.05	24.000	36.000
2026-002	2	ENZYMATIC	165	VITROS	63	KODAK	44	26.625	1.111	4.17	21.000	32.000
2026-002	2	ENZYMATIC	165	VITROS	63	KODAK	44	27.535	1.783	6.48	22.000	33.000
2026-002	2	ENZYMATIC	165	VITROS	156	Kit 32	84	27.595	1.897	6.87	22.000	33.000
2026-002	2	ENZYMATIC	203	ROCHE	93	ROCHE	14	25.571	1.450	5.67	20.000	31.000
2026-002	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	29.069	1.929	6.63	23.000	35.000
2026-002	4	PEP CARBOX	197	ARCHITECT	1	ABBOTT	10	27.556	2.671	9.69	22.000	33.000
2026-003	1	Generic Me	184	INTEGRA	93	ROCHE	10	18.800	1.720	9.15	15.000	23.000
2026-003	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	19.739	0.943	4.78	16.000	24.000
2026-003	1	Generic Me	203	ROCHE	93	ROCHE	25	19.292	1.947	10.09	15.000	23.000
2026-003	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	22.614	1.833	8.11	18.000	27.000
2026-003	2	ENZYMATIC	165	VITROS	63	KODAK	44	19.256	1.278	6.63	15.000	23.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-003	2	ENZYMATIC	165	VITROS	63	KODAK	44	18.625	1.218	6.54	15.000 22.000	
2026-003	2	ENZYMATIC	165	VITROS	156	Kit 32	84	19.274	1.530	7.94	15.000 23.000	
2026-003	2	ENZYMATIC	203	ROCHE	93	ROCHE	14	18.429	0.904	4.90	15.000 22.000	
2026-003	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	22.069	1.856	8.41	18.000 26.000	
2026-003	4	PEP CARBOX	197	ARCHITECT	1	ABBOTT	10	18.778	2.780	14.80	15.000 23.000	
169	CO2	CLIA TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %								
2026-004	1	Generic Me	184	INTEGRA	93	ROCHE	10	28.300	2.492	8.81	23.000 34.000	
2026-004	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	32.348	2.631	8.13	26.000 39.000	
2026-004	1	Generic Me	203	ROCHE	93	ROCHE	25	29.800	2.514	8.44	24.000 36.000	
2026-004	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	33.211	2.580	7.77	27.000 40.000	
2026-004	2	ENZYMATIC	165	VITROS	63	KODAK	44	30.500	0.866	2.84	24.000 37.000	
2026-004	2	ENZYMATIC	165	VITROS	63	KODAK	44	30.512	2.193	7.19	24.000 37.000	
2026-004	2	ENZYMATIC	165	VITROS	156	Kit 32	84	30.679	1.928	6.29	25.000 37.000	
2026-004	2	ENZYMATIC	203	ROCHE	93	ROCHE	14	29.071	1.791	6.16	23.000 35.000	
2026-004	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	32.897	2.023	6.15	26.000 39.000	
2026-004	4	PEP CARBOX	197	ARCHITECT	1	ABBOTT	10	31.222	3.154	10.10	25.000 37.000	
2026-005	1	Generic Me	184	INTEGRA	93	ROCHE	10	20.000	1.673	8.37	16.000 24.000	
2026-005	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	21.565	1.313	6.09	17.000 26.000	
2026-005	1	Generic Me	203	ROCHE	93	ROCHE	25	20.583	1.525	7.41	16.000 25.000	
2026-005	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	23.768	1.592	6.70	19.000 29.000	
2026-005	2	ENZYMATIC	165	VITROS	63	KODAK	44	21.140	1.665	7.87	17.000 25.000	
2026-005	2	ENZYMATIC	165	VITROS	63	KODAK	44	20.750	0.829	4.00	17.000 25.000	
2026-005	2	ENZYMATIC	165	VITROS	156	Kit 32	84	21.345	1.622	7.60	17.000 26.000	
2026-005	2	ENZYMATIC	203	ROCHE	93	ROCHE	14	19.643	1.042	5.31	16.000 24.000	
2026-005	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	23.103	1.749	7.57	18.000 28.000	
2026-005	4	PEP CARBOX	197	ARCHITECT	1	ABBOTT	10	21.778	3.392	15.58	17.000 26.000	
170	DIRECT BILIRUBIN	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}								
2026-001	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	35	0.071	0.045	63.25	0 0.200	
2026-001	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	11	0.100	0.000	0.00	0.100 0.100	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2026-001	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.004	0.021	461.88	0	0.100			
2026-001	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.100	0.044	43.64	0.000	0.200			
2026-001	14 VANADATE O	219 ATELLICA	143 SIEMENS	29	0.100	0.000	0.00	0.100	0.100			
170 DIRECT BILIRUBIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}									
2026-002	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	35	0.847	0.074	8.70	0.600	1.100			
2026-002	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	1.309	0.198	15.09	0.700	1.900			
2026-002	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.543	0.141	25.88	0.100	1.000			
2026-002	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	1.343	0.137	10.17	0.900	1.800			
2026-002	14 VANADATE O	219 ATELLICA	143 SIEMENS	29	1.686	0.249	14.75	0.900	2.400			
2026-003	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	35	0.203	0.038	18.58	0.100	0.300			
2026-003	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	0.355	0.050	14.04	0.200	0.500			
2026-003	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.037	0.090	244.88	0	0.300			
2026-003	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.314	0.035	11.13	0.200	0.400			
2026-003	14 VANADATE O	219 ATELLICA	143 SIEMENS	29	0.462	0.072	15.47	0.200	0.700			
2026-004	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	35	1.068	0.072	6.71	0.900	1.300			
2026-004	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	1.636	0.219	13.36	1.000	2.300			
2026-004	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.761	0.195	25.68	0.200	1.300			
2026-004	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	1.671	0.148	8.88	1.200	2.100			
2026-004	14 VANADATE O	219 ATELLICA	143 SIEMENS	29	2.066	0.290	14.06	1.200	2.900			
2026-005	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	35	0.391	0.044	11.21	0.300	0.500			
2026-005	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	0.636	0.088	13.85	0.400	0.900			
2026-005	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.120	0.136	113.79	0	0.500			
2026-005	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.614	0.071	11.55	0.400	0.800			
2026-005	14 VANADATE O	219 ATELLICA	143 SIEMENS	29	0.817	0.123	15.10	0.400	1.200			

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 15 WHOLE BLOOD GLUCOSE				
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
157	WHOLE BLOOD GLUCOSE	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	10	% OR 6.00	{GREATER}				
2026-101	23	ABBOTT PRE		24	206.625	9.999	4.84	186.000	227.000	
2026-101	27	STAT SRIP.		104	139.000	2.121	1.53	125.000	153.000	
2026-101	27	STAT SRIP.		104	131.971	11.070	8.39	119.000	145.000	
2026-101	33	AC.CHEK II		35	180.686	6.773	3.75	163.000	199.000	
2026-101	34	FREE STYL		33	219.500	9.614	4.38	198.000	241.000	
2026-102	23	ABBOTT PRE		24	498.870	2.626	0.53	449.000	549.000	
2026-102	27	STAT SRIP.		104	275.893	27.081	9.82	248.000	303.000	
2026-102	27	STAT SRIP.		104	288.000	7.013	2.44	259.000	317.000	
2026-102	33	AC.CHEK II		35	487.486	18.985	3.89	439.000	536.000	
2026-102	34	FREE STYL		33	500.000	0.000	0.00	450.000	550.000	
2026-103	23	ABBOTT PRE		24	90.167	3.145	3.49	81.000	99.000	
2026-103	27	STAT SRIP.		104	60.000	2.165	3.61	54.000	66.000	
2026-103	27	STAT SRIP.		104	70.578	3.954	5.60	64.000	78.000	
2026-103	33	AC.CHEK II		35	85.571	2.940	3.44	77.000	94.000	
2026-103	34	FREE STYL		33	96.576	5.716	5.92	87.000	106.000	
2026-104	23	ABBOTT PRE		24	89.917	3.303	3.67	81.000	99.000	
2026-104	27	STAT SRIP.		104	70.769	4.060	5.74	64.000	78.000	
2026-104	27	STAT SRIP.		104	60.000	2.345	3.91	54.000	66.000	
2026-104	33	AC.CHEK II		35	85.429	2.960	3.46	77.000	94.000	
2026-104	34	FREE STYL		33	96.531	4.093	4.24	87.000	106.000	
2026-105	23	ABBOTT PRE		24	204.833	7.255	3.54	184.000	225.000	
2026-105	27	STAT SRIP.		104	139.000	4.062	2.92	125.000	153.000	
2026-105	27	STAT SRIP.		104	131.779	10.402	7.89	119.000	145.000	
2026-105	33	AC.CHEK II		35	181.457	5.915	3.26	163.000	200.000	
2026-105	34	FREE STYL		33	220.656	10.294	4.67	199.000	243.000	

Participant Summary

MONTH 2 OF YEAR 2026

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 17 NR WHOLE BLOOD GLUCO								
493 NR WHOLE BLOOD GLUCO		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}				
2026-106	34 FREE STYL		10	228.800	5.963	2.61	206.000	252.000
2026-107	34 FREE STYL		10	96.300	2.410	2.50	87.000	106.000
2026-108	34 FREE STYL		10	98.100	2.914	2.97	88.000	108.000
2026-109	34 FREE STYL		10	500.000	0.000	0.00	450.000	550.000
2026-110	34 FREE STYL		10	229.700	7.484	3.26	207.000	253.000
SPEC: 10 CHEMISTRY SUB: 20 BLOOD GASES GRP: 30 BLOOD GASES								
ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
007 BLOOD GASES-pCO2		CLIA TEST ID #: 335		EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}				
2026-051	265 ROCHE COBA		30	64.821	1.418	2.19	59.600	70.000
2026-051	265 ROCHE COBA		30	62.033	2.549	4.11	57.000	67.000
2026-052	265 ROCHE COBA		30	38.833	0.873	2.25	33.800	43.800
2026-052	265 ROCHE COBA		30	42.128	0.940	2.23	37.100	47.100
2026-053	265 ROCHE COBA		30	22.172	0.578	2.61	17.200	27.200
2026-053	265 ROCHE COBA		30	19.533	0.170	0.87	14.500	24.500
2026-054	265 ROCHE COBA		30	60.800	2.238	3.68	55.800	65.800
2026-054	265 ROCHE COBA		30	65.797	1.404	2.13	60.500	71.100

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
007	BLOOD GASES-pCO2		CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}							
2026-055	265	ROCHE COBA			30	42.207	0.704	1.67	37.200	47.200	
2026-055	265	ROCHE COBA			30	38.733	0.309	0.80	33.700	43.700	
008	BLOOD GASES-pH		CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE 0.04							
2026-051	265	ROCHE COBA			30	7.162	0.009	0.12	7.122	7.202	
2026-052	265	ROCHE COBA			30	7.418	0.008	0.11	7.378	7.458	
2026-053	265	ROCHE COBA			30	7.616	0.008	0.10	7.576	7.656	
2026-054	265	ROCHE COBA			30	7.158	0.009	0.12	7.118	7.198	
2026-055	265	ROCHE COBA			30	7.419	0.006	0.08	7.380	7.460	
009	BLOOD GASES-pO2		CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 15 % OR 15.00 {GREATER}							
2026-051	265	ROCHE COBA			30	56.410	18.288	32.42	41.400	71.400	
2026-051	265	ROCHE COBA			30	66.667	3.972	5.96	51.700	81.700	
2026-052	265	ROCHE COBA			30	116.778	6.892	5.90	99.300	134.300	
2026-052	265	ROCHE COBA			30	111.517	10.029	8.99	94.800	128.200	
2026-053	265	ROCHE COBA			30	179.117	7.257	4.05	152.200	206.000	
2026-053	265	ROCHE COBA			30	171.667	8.260	4.81	145.900	197.400	
2026-054	265	ROCHE COBA			30	68.000	4.422	6.50	53.000	83.000	
2026-054	265	ROCHE COBA			30	51.973	18.862	36.29	37.000	67.000	
2026-055	265	ROCHE COBA			30	110.487	8.624	7.81	93.900	127.100	
2026-055	265	ROCHE COBA			30	120.222	9.953	8.28	102.200	138.300	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 30 ENDOCRINOLOGY

GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE	18	%	OR 2.00	{GREATER}		
2026-031	115 VITROS ECI			10	3.700	0.184	4.98	1.700	5.700
2026-031	116 ROCHE COBA			16	5.275	0.334	6.34	3.300	7.300
2026-031	125 B.C.ACCESS			10	5.620	0.556	9.90	3.600	7.600
2026-031	149 ARC i2000s			13	4.862	0.276	5.68	2.900	6.900
2026-031	169 ATELLICA			10	5.270	0.352	6.68	3.300	7.300
2026-032	115 VITROS ECI			10	25.870	0.815	3.15	21.200	30.500
2026-032	116 ROCHE COBA			16	29.494	1.644	5.57	24.200	34.800
2026-032	125 B.C.ACCESS			10	32.210	2.567	7.97	26.400	38.000
2026-032	149 ARC i2000s			13	29.838	1.253	4.20	24.500	35.200
2026-032	169 ATELLICA			10	29.510	1.654	5.61	24.200	34.800
2026-033	115 VITROS ECI			10	8.150	0.353	4.33	6.200	10.200
2026-033	116 ROCHE COBA			16	10.306	0.580	5.63	8.300	12.300
2026-033	125 B.C.ACCESS			10	10.680	1.153	10.80	8.700	12.700
2026-033	149 ARC i2000s			13	9.777	0.481	4.92	7.800	11.800
2026-033	169 ATELLICA			10	10.270	0.603	5.88	8.300	12.300
2026-034	115 VITROS ECI			10	32.650	1.251	3.83	26.800	38.500
2026-034	116 ROCHE COBA			16	36.838	1.775	4.82	30.200	43.500
2026-034	125 B.C.ACCESS			10	40.720	4.395	10.79	33.400	48.000
2026-034	149 ARC i2000s			13	37.438	1.774	4.74	30.700	44.200
2026-034	169 ATELLICA			10	36.740	2.253	6.13	30.100	43.400
2026-035	115 VITROS ECI			10	12.760	0.472	3.70	10.500	15.100
2026-035	116 ROCHE COBA			16	15.406	0.907	5.89	12.600	18.200
2026-035	125 B.C.ACCESS			10	16.420	1.323	8.06	13.500	19.400
2026-035	149 ARC i2000s			13	15.031	1.084	7.21	12.300	17.700

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-035	169	APELLICA		10	15.420	1.153	7.48	12.600	18.200	
030	FREE THYROXINE		CLIA TEST ID #: 545		EVALUATION CRITERIA: TARGET VALUE	15 %	OR 0.30	{GREATER}		
2026-031	115	VITROS ECI		50	1.886	0.125	6.62	1.600	2.200	
2026-031	116	ROCHE COBA		51	0.880	0.044	5.04	0.600	1.200	
2026-031	116	ROCHE COBA		51	1.033	0.047	4.56	0.700	1.300	
2026-031	125	B.C.ACCESS		38	0.865	0.071	8.16	0.600	1.200	
2026-031	125	B.C.ACCESS		38	0.900	0.000	0.00	0.600	1.200	
2026-031	149	ARC i2000s		22	0.827	0.062	7.45	0.500	1.100	
2026-031	160	SIEMENS EX		40	0.883	0.063	7.12	0.600	1.200	
2026-031	169	APELLICA		27	0.944	0.057	6.00	0.600	1.200	
2026-032	115	VITROS ECI		50	6.120	0.297	4.85	5.200	7.000	
2026-032	116	ROCHE COBA		51	3.533	0.262	7.43	3.000	4.100	
2026-032	116	ROCHE COBA		51	2.859	0.109	3.81	2.400	3.300	
2026-032	125	B.C.ACCESS		38	2.833	0.047	1.66	2.400	3.300	
2026-032	125	B.C.ACCESS		38	2.281	0.157	6.90	1.900	2.600	
2026-032	149	ARC i2000s		22	2.377	0.144	6.07	2.000	2.700	
2026-032	160	SIEMENS EX		40	2.800	0.157	5.59	2.400	3.200	
2026-032	169	APELLICA		27	2.485	0.130	5.22	2.100	2.900	
2026-033	115	VITROS ECI		50	3.344	0.185	5.52	2.800	3.800	
2026-033	116	ROCHE COBA		51	1.522	0.083	5.46	1.200	1.800	
2026-033	116	ROCHE COBA		51	1.800	0.141	7.86	1.500	2.100	
2026-033	125	B.C.ACCESS		38	1.354	0.113	8.34	1.100	1.700	
2026-033	125	B.C.ACCESS		38	1.500	0.000	0.00	1.200	1.800	
2026-033	149	ARC i2000s		22	1.314	0.081	6.20	1.000	1.600	
2026-033	160	SIEMENS EX		40	1.485	0.098	6.57	1.200	1.800	
2026-033	169	APELLICA		27	1.458	0.057	3.89	1.200	1.800	
2026-034	115	VITROS ECI		50	6.672	0.260	3.90	5.700	7.700	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-034	116	ROCHE COBA		51	4.100	0.141	3.45	3.500	4.700	
2026-034	116	ROCHE COBA		51	3.262	0.135	4.15	2.800	3.800	
2026-034	125	B.C.ACCESS		38	3.233	0.047	1.46	2.700	3.700	
2026-034	125	B.C.ACCESS		38	2.532	0.180	7.11	2.200	2.900	
2026-034	149	ARC i2000s		22	2.677	0.266	9.94	2.300	3.100	
2026-034	160	SIEMENS EX		40	3.148	0.158	5.02	2.700	3.600	
2026-034	169	APELLICA		27	2.819	0.106	3.74	2.400	3.200	
030	FREE THYROXINE		CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}						
2026-035	115	VITROS ECI		50	4.322	0.254	5.88	3.700	5.000	
2026-035	116	ROCHE COBA		51	1.926	0.069	3.57	1.600	2.200	
2026-035	116	ROCHE COBA		51	2.567	0.287	11.17	2.200	3.000	
2026-035	125	B.C.ACCESS		38	1.933	0.094	4.88	1.600	2.200	
2026-035	125	B.C.ACCESS		38	1.668	0.116	6.98	1.400	2.000	
2026-035	149	ARC i2000s		22	1.714	0.101	5.91	1.400	2.000	
2026-035	160	SIEMENS EX		40	1.915	0.104	5.42	1.600	2.200	
2026-035	169	APELLICA		27	1.767	0.054	3.08	1.500	2.100	
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}						
2026-031	115	VITROS ECI		24	2.400	0.000	0.00	0	5.400	
2026-031	116	ROCHE COBA		19	0.933	0.111	11.85	0	3.900	
2026-031	169	APELLICA		14	2.300	0.462	20.11	0	5.300	
2026-032	115	VITROS ECI		24	435.879	23.755	5.45	357.400	514.300	
2026-032	116	ROCHE COBA		19	519.289	23.163	4.46	425.800	612.800	
2026-032	169	APELLICA		14	607.600	34.501	5.68	498.200	717.000	
2026-033	115	VITROS ECI		24	84.542	4.894	5.79	69.300	99.800	
2026-033	116	ROCHE COBA		19	103.621	6.979	6.74	85.000	122.300	
2026-033	169	APELLICA		14	124.621	8.067	6.47	102.200	147.100	
2026-034	115	VITROS ECI		24	586.333	28.134	4.80	480.800	691.900	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-034	116	ROCHE COBA		19	680.316	28.144	4.14	557.900	802.800	
2026-034	169	APELLICA		14	755.936	42.335	5.60	619.900	892.000	
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}						
2026-035	115	VITROS ECI		24	174.729	11.094	6.35	143.300	206.200	
2026-035	116	ROCHE COBA		19	212.779	11.196	5.26	174.500	251.100	
2026-035	169	APELLICA		14	251.521	10.926	4.34	206.200	296.800	
035	PROLACTIN		CLIA TEST ID #: 563	EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-031	116	ROCHE COBA		15	0.780	0.054	6.94	0.600	0.900	
2026-031	125	B.C.ACCESS		10	0.720	0.087	12.11	0.600	0.900	
2026-031	169	APELLICA		10	0.970	0.078	8.05	0.800	1.200	
2026-032	116	ROCHE COBA		15	51.313	2.880	5.61	41.100	61.600	
2026-032	125	B.C.ACCESS		10	29.280	2.117	7.23	23.400	35.100	
2026-032	169	APELLICA		10	27.400	0.643	2.35	21.900	32.900	
2026-033	116	ROCHE COBA		15	10.587	0.644	6.08	8.500	12.700	
2026-033	125	B.C.ACCESS		10	7.010	0.539	7.69	5.600	8.400	
2026-033	169	APELLICA		10	6.490	0.230	3.54	5.200	7.800	
2026-034	116	ROCHE COBA		15	67.527	3.292	4.88	54.000	81.000	
2026-034	125	B.C.ACCESS		10	37.570	2.134	5.68	30.100	45.100	
2026-034	169	APELLICA		10	36.140	1.453	4.02	28.900	43.400	
2026-035	116	ROCHE COBA		15	20.933	1.175	5.61	16.700	25.100	
2026-035	125	B.C.ACCESS		10	13.370	0.728	5.45	10.700	16.000	
2026-035	169	APELLICA		10	11.910	0.330	2.77	9.500	14.300	
037	TESTOSTERONE		CLIA TEST ID #: 570	EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}						
2026-031	116	ROCHE COBA		11	114.450	6.857	5.99	80.100	148.800	
2026-031	149	ARC i2000s		11	118.425	4.732	4.00	82.900	154.000	
2026-031	169	APELLICA		10	115.729	7.158	6.18	81.000	150.400	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
037	TESTOSTERONE	CLIA TEST ID #: 570	EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}						
2026-032	116 ROCHE COBA			11	1304.625	85.825	6.58	913.200	1696.000
2026-032	149 ARC i2000s			11	1403.888	150.548	10.72	982.700	1825.100
2026-032	169 ATELLICA			10	910.171	127.766	14.04	637.100	1183.200
2026-033	116 ROCHE COBA			11	409.200	16.656	4.07	286.400	532.000
2026-033	149 ARC i2000s			11	346.900	16.820	4.85	242.800	451.000
2026-033	169 ATELLICA			10	291.157	18.769	6.45	203.800	378.500
2026-034	116 ROCHE COBA			11	1496.500	33.805	2.26	1047.600	1945.500
2026-034	149 ARC i2000s			11	1487.875	32.080	2.16	1041.500	1934.200
2026-034	169 ATELLICA			10	1094.657	174.720	15.96	766.300	1423.100
2026-035	116 ROCHE COBA			11	691.713	28.722	4.15	484.200	899.200
2026-035	149 ARC i2000s			11	633.075	51.636	8.16	443.200	823.000
2026-035	169 ATELLICA			10	546.700	61.530	11.25	382.700	710.700
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2026-031	115 VITROS ECI			58	0.200	0.000	0.00	0.000	0.400
2026-031	116 ROCHE COBA			60	0.300	0.050	16.67	0.100	0.500
2026-031	116 ROCHE COBA			60	0.343	0.053	15.38	0.100	0.500
2026-031	125 B.C.ACCESS			47	0.287	0.039	13.66	0.100	0.500
2026-031	149 ARC i2000s			25	0.200	0.000	0.00	0.000	0.400
2026-031	160 SIEMENS EX			59	0.241	0.049	20.41	0.000	0.400
2026-031	160 SIEMENS EX			59	0.300	0.050	16.67	0.100	0.500
2026-031	169 ATELLICA			30	0.280	0.040	14.29	0.100	0.500
2026-032	115 VITROS ECI			58	4.738	0.160	3.37	3.800	5.700
2026-032	116 ROCHE COBA			60	6.527	0.271	4.16	5.200	7.800
2026-032	116 ROCHE COBA			60	5.975	0.792	13.25	4.800	7.200
2026-032	125 B.C.ACCESS			47	5.872	0.274	4.67	4.700	7.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-032	149	ARC i2000s		25	4.540	0.332	7.32	3.600	5.400	
2026-032	160	SIEMENS EX		59	5.975	0.792	13.25	4.800	7.200	
2026-032	160	SIEMENS EX		59	5.595	0.328	5.86	4.500	6.700	
2026-032	169	ATELLICA		30	5.653	0.194	3.44	4.500	6.800	
039 THYRO. STI. HOR.-TSH			CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2026-033	115	VITROS ECI		58	1.221	0.055	4.50	1.000	1.500	
2026-033	116	ROCHE COBA		60	1.563	0.255	16.30	1.300	1.900	
2026-033	116	ROCHE COBA		60	1.739	0.118	6.78	1.400	2.100	
2026-033	125	B.C.ACCESS		47	1.370	0.083	6.07	1.100	1.600	
2026-033	149	ARC i2000s		25	1.108	0.049	4.45	0.900	1.300	
2026-033	160	SIEMENS EX		59	1.390	0.093	6.72	1.100	1.700	
2026-033	160	SIEMENS EX		59	1.563	0.255	16.30	1.300	1.900	
2026-033	169	ATELLICA		30	1.407	0.057	4.08	1.100	1.700	
2026-034	115	VITROS ECI		58	5.955	0.181	3.04	4.800	7.100	
2026-034	116	ROCHE COBA		60	8.136	0.358	4.40	6.500	9.800	
2026-034	116	ROCHE COBA		60	7.725	0.993	12.86	6.200	9.300	
2026-034	125	B.C.ACCESS		47	7.681	0.402	5.23	6.100	9.200	
2026-034	149	ARC i2000s		25	5.817	0.253	4.35	4.700	7.000	
2026-034	160	SIEMENS EX		59	7.725	0.993	12.86	6.200	9.300	
2026-034	160	SIEMENS EX		59	7.132	0.456	6.39	5.700	8.600	
2026-034	169	ATELLICA		30	7.190	0.272	3.79	5.800	8.600	
2026-035	115	VITROS ECI		58	2.245	0.081	3.62	1.800	2.700	
2026-035	116	ROCHE COBA		60	2.788	0.326	11.69	2.200	3.300	
2026-035	116	ROCHE COBA		60	3.112	0.173	5.55	2.500	3.700	
2026-035	125	B.C.ACCESS		47	2.562	0.138	5.37	2.000	3.100	
2026-035	149	ARC i2000s		25	2.032	0.129	6.34	1.600	2.400	
2026-035	160	SIEMENS EX		59	2.788	0.326	11.69	2.200	3.300	
2026-035	160	SIEMENS EX		59	2.541	0.162	6.37	2.000	3.000	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-035	169	APELLICA		30	2.553	0.096	3.75	2.000	3.100	
040 THYROXINE (T4)			CLIA TEST ID #: 595						EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}	
2026-031	32	SIEM DIME.		38	2.550	0.585	22.95	1.600	3.600	
2026-031	115	VITROS ECI		46	1.787	0.102	5.73	0.800	2.800	
2026-031	116	ROCHE COBA		45	2.452	0.245	10.01	1.500	3.500	
2026-031	125	B.C.ACCESS		36	2.181	0.272	12.46	1.200	3.200	
2026-031	149	ARC i2000s		21	1.748	0.222	12.69	0.700	2.700	
2026-031	169	APELLICA		27	2.104	0.230	10.91	1.100	3.100	
2026-032	32	SIEM DIME.		38	13.605	0.747	5.49	10.900	16.300	
2026-032	115	VITROS ECI		46	11.278	0.534	4.74	9.000	13.500	
2026-032	116	ROCHE COBA		45	12.316	0.818	6.64	9.900	14.800	
2026-032	125	B.C.ACCESS		36	12.497	0.855	6.84	10.000	15.000	
2026-032	149	ARC i2000s		21	12.581	0.711	5.65	10.100	15.100	
2026-032	169	APELLICA		27	12.104	0.778	6.43	9.700	14.500	
2026-033	32	SIEM DIME.		38	4.637	0.492	10.60	3.600	5.600	
2026-033	115	VITROS ECI		46	3.891	0.188	4.84	2.900	4.900	
2026-033	116	ROCHE COBA		45	4.622	0.398	8.62	3.600	5.600	
2026-033	125	B.C.ACCESS		36	5.066	0.636	12.56	4.100	6.100	
2026-033	149	ARC i2000s		21	3.981	0.244	6.13	3.000	5.000	
2026-033	169	APELLICA		27	4.370	0.222	5.09	3.400	5.400	
2026-034	32	SIEM DIME.		38	17.276	0.806	4.66	13.800	20.700	
2026-034	115	VITROS ECI		46	13.802	0.670	4.86	11.000	16.600	
2026-034	116	ROCHE COBA		45	15.229	1.021	6.71	12.200	18.300	
2026-034	125	B.C.ACCESS		36	14.719	1.268	8.61	11.800	17.700	
2026-034	149	ARC i2000s		21	15.724	1.422	9.05	12.600	18.900	
2026-034	169	APELLICA		27	14.063	0.733	5.21	11.300	16.900	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
040 THYROXINE (T4)		CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE	20	% OR 1.00	{GREATER}			
2026-035	32 SIEM DIME.			38	6.961	0.520	7.48	5.600	8.400
2026-035	115 VITROS ECI			46	5.900	0.306	5.19	4.700	7.100
2026-035	116 ROCHE COBA			45	6.740	0.548	8.13	5.400	8.100
2026-035	125 B.C.ACCESS			36	7.342	0.745	10.15	5.900	8.800
2026-035	149 ARC i2000s			21	6.376	0.321	5.03	5.100	7.700
2026-035	169 ATELLICA			27	6.644	0.322	4.85	5.300	8.000
141 FOLATE		CLIA TEST ID #: 541	EVALUATION CRITERIA: TARGET VALUE	30	% OR 1.00	{GREATER}			
2026-031	115 VITROS ECI			17	1.018	0.212	20.84	0.000	2.000
2026-031	116 ROCHE COBA			23	2.000	0.000	0.00	1.000	3.000
2026-031	125 B.C.ACCESS			11	1.036	0.088	8.50	0.000	2.000
2026-031	149 ARC i2000s			14	1.214	0.818	67.33	0.200	2.200
2026-031	169 ATELLICA			10	1.014	0.236	23.23	0.000	2.000
2026-031	169 ATELLICA			10	0.530	0.179	33.80	0	1.500
2026-032	115 VITROS ECI			17	8.535	1.150	13.48	6.000	11.100
2026-032	116 ROCHE COBA			23	6.948	0.716	10.30	4.900	9.000
2026-032	125 B.C.ACCESS			11	9.927	0.808	8.14	6.900	12.900
2026-032	149 ARC i2000s			14	10.493	0.837	7.98	7.300	13.600
2026-032	169 ATELLICA			10	8.230	1.046	12.71	5.800	10.700
2026-032	169 ATELLICA			10	5.314	0.871	16.39	3.700	6.900
2026-033	115 VITROS ECI			17	1.982	0.345	17.41	1.000	3.000
2026-033	116 ROCHE COBA			23	2.000	0.000	0.00	1.000	3.000
2026-033	125 B.C.ACCESS			11	2.545	0.389	15.29	1.500	3.500
2026-033	149 ARC i2000s			14	2.171	0.446	20.55	1.200	3.200
2026-033	169 ATELLICA			10	1.771	0.148	8.38	0.800	2.800
2026-033	169 ATELLICA			10	0.940	0.326	34.70	0	1.900
2026-034	115 VITROS ECI			17	11.424	1.713	15.00	8.000	14.900

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-034	116	ROCHE COBA		23	9.891	1.065	10.77	6.900	12.900	
2026-034	125	B.C.ACCESS		11	13.000	1.077	8.28	9.100	16.900	
2026-034	149	ARC i2000s		14	13.729	0.857	6.24	9.600	17.800	
2026-034	169	APELLICA		10	15.620	6.309	40.39	10.900	20.300	
2026-034	169	APELLICA		10	6.929	0.932	13.44	4.900	9.000	
141	FOLATE		CLIA TEST ID #: 541		EVALUATION CRITERIA: TARGET VALUE 30 % OR 1.00 {GREATER}					
2026-035	115	VITROS ECI		17	3.341	0.464	13.89	2.300	4.300	
2026-035	116	ROCHE COBA		23	2.478	0.454	18.32	1.500	3.500	
2026-035	125	B.C.ACCESS		11	4.418	0.480	10.87	3.100	5.700	
2026-035	149	ARC i2000s		14	4.236	0.486	11.48	3.000	5.500	
2026-035	169	APELLICA		10	2.729	0.237	8.70	1.700	3.700	
2026-035	169	APELLICA		10	2.480	0.510	20.54	1.500	3.500	
142	hLH (HUMAN LUT. HOR)		CLIA TEST ID #: 560		EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-031	116	ROCHE COBA		14	2.607	0.144	5.51	2.100	3.100	
2026-031	125	B.C.ACCESS		10	1.700	0.184	10.85	1.400	2.000	
2026-031	149	ARC i2000s		10	1.390	0.094	6.79	1.100	1.700	
2026-031	169	APELLICA		10	1.800	0.141	7.86	1.400	2.200	
2026-032	116	ROCHE COBA		14	29.207	1.422	4.87	23.400	35.000	
2026-032	125	B.C.ACCESS		10	27.710	3.773	13.62	22.200	33.300	
2026-032	149	ARC i2000s		10	19.380	1.605	8.28	15.500	23.300	
2026-032	169	APELLICA		10	24.710	1.287	5.21	19.800	29.700	
2026-033	116	ROCHE COBA		14	8.550	0.398	4.65	6.800	10.300	
2026-033	125	B.C.ACCESS		10	7.310	0.801	10.95	5.800	8.800	
2026-033	149	ARC i2000s		10	5.040	0.291	5.76	4.000	6.000	
2026-033	169	APELLICA		10	6.900	0.332	4.81	5.500	8.300	
2026-034	116	ROCHE COBA		14	36.914	1.384	3.75	29.500	44.300	
2026-034	125	B.C.ACCESS		10	34.580	5.876	16.99	27.700	41.500	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-034	149	ARC i2000s		10	24.910	1.520	6.10	19.900	29.900
2026-034	169	APELLICA		10	30.180	1.927	6.38	24.100	36.200
142 hLH (HUMAN LUT. HOR)		CLIA TEST ID #: 560		EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-035	116	ROCHE COBA		14	14.293	0.628	4.40	11.400	17.200
2026-035	125	B.C.ACCESS		10	13.180	1.399	10.62	10.500	15.800
2026-035	149	ARC i2000s		10	8.700	0.819	9.41	7.000	10.400
2026-035	169	APELLICA		10	12.000	0.551	4.59	9.600	14.400

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)								
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART #	# LABS	# "SF"	Score	
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
031 hCG-QUALITATIVE												
2026-031	113	BIO-SIGN		001	001	001	001	001 - NEGATIVE	18	18	18	100
2026-031	142	INSTANT VI		001	001	001	001	001 - NEGATIVE	24	24	24	100
2026-031	150	AIM STEP		001	001	001	001	001 - NEGATIVE	116	115	115	100
2026-031	150	AIM STEP		001	001	001	001	002 - POSITIVE	116	1	115	0
2026-031	164	HCG Alere		001	001	001	001	001 - NEGATIVE	83	83	83	100
2026-031	166	FaStep		001	001	001	001	001 - NEGATIVE	12	12	12	100
2026-031	168	STANBIO 20		001	001	001	001	001 - NEGATIVE	14	14	14	100
2026-032	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	18	18	18	100
2026-032	142	INSTANT VI		002	002	002	002	002 - POSITIVE	24	24	24	100
2026-032	150	AIM STEP		002	002	002	002	002 - POSITIVE	116	116	116	100
2026-032	164	HCG Alere		002	002	002	002	002 - POSITIVE	83	83	83	100
2026-032	166	FaStep		002	002	002	002	002 - POSITIVE	12	12	12	100
2026-032	168	STANBIO 20		002	002	002	002	002 - POSITIVE	14	14	14	100
2026-033	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	18	18	18	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-033	142	INSTANT VI		002 002	002 002		002 - POSITIVE	24	24	24	100	
2026-033	150	AIM STEP		002 002	002 002		002 - POSITIVE	116	116	116	100	
2026-033	164	HCG Alere		002 002	002 002		002 - POSITIVE	83	83	83	100	
2026-033	166	FaStep		002 002	002 002		002 - POSITIVE	12	12	12	100	
2026-033	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100	
	031	hCG-QUALITATIVE										
2026-034	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	18	18	18	100	
2026-034	142	INSTANT VI		002 002	002 002		002 - POSITIVE	24	24	24	100	
2026-034	150	AIM STEP		002 002	002 002		001 - NEGATIVE	116	1	115	0	
2026-034	150	AIM STEP		002 002	002 002		002 - POSITIVE	116	115	115	100	
2026-034	164	HCG Alere		002 002	002 002		002 - POSITIVE	83	83	83	100	
2026-034	166	FaStep		002 002	002 002		002 - POSITIVE	12	12	12	100	
2026-034	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100	
2026-035	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	18	18	18	100	
2026-035	142	INSTANT VI		002 002	002 002		002 - POSITIVE	24	24	24	100	
2026-035	150	AIM STEP		002 002	002 002		001 - NEGATIVE	116	1	115	0	
2026-035	150	AIM STEP		002 002	002 002		002 - POSITIVE	116	115	115	100	
2026-035	164	HCG Alere		002 002	002 002		002 - POSITIVE	83	83	83	100	
2026-035	166	FaStep		002 002	002 002		002 - POSITIVE	12	12	12	100	
2026-035	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100	
SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
151 hCG ONLY QUALITATIVE													
2026-021	018	BIO SIGN		002	002	002	002	002 - POSITIVE	25	25	25	100	
2026-021	114	INSTANT VI		002	002	002	002	002 - POSITIVE	48	48	48	100	
2026-021	118	AIM STEP		002	002	002	002	002 - POSITIVE	254	254	254	100	
2026-021	130	ALERE HCG		002	002	002	002	002 - POSITIVE	98	98	98	100	
2026-021	133	FaStep		002	002	002	002	002 - POSITIVE	34	34	34	100	
2026-021	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	46	46	46	100	
2026-021	135	STANBIO 20		002	002	002	002	002 - POSITIVE	10	10	10	100	
2026-021	136	CLARITY		002	002	002	002	002 - POSITIVE	25	25	25	100	
2026-021	137	CARDINAL		002	002	002	002	002 - POSITIVE	23	23	23	100	
2026-022	018	BIO SIGN		002	002	002	002	002 - POSITIVE	25	25	25	100	
2026-022	114	INSTANT VI		002	002	002	002	002 - POSITIVE	48	48	48	100	
2026-022	118	AIM STEP		002	002	002	002	002 - POSITIVE	254	254	254	100	
2026-022	130	ALERE HCG		002	002	002	002	002 - POSITIVE	98	98	98	100	
2026-022	133	FaStep		002	002	002	002	002 - POSITIVE	34	34	34	100	
2026-022	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	46	46	46	100	
2026-022	135	STANBIO 20		002	002	002	002	002 - POSITIVE	10	10	10	100	
2026-022	136	CLARITY		002	002	002	002	002 - POSITIVE	25	25	25	100	
2026-022	137	CARDINAL		002	002	002	002	002 - POSITIVE	23	23	23	100	
2026-023	018	BIO SIGN		002	002	002	002	002 - POSITIVE	25	25	25	100	
2026-023	114	INSTANT VI		002	002	002	002	002 - POSITIVE	48	48	48	100	
2026-023	118	AIM STEP		002	002	002	002	002 - POSITIVE	254	254	254	100	
2026-023	130	ALERE HCG		002	002	002	002	002 - POSITIVE	98	98	98	100	
2026-023	133	FaStep		002	002	002	002	002 - POSITIVE	34	34	34	100	
2026-023	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	46	46	46	100	
2026-023	135	STANBIO 20		002	002	002	002	002 - POSITIVE	10	10	10	100	
2026-023	136	CLARITY		002	002	002	002	002 - POSITIVE	25	25	25	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-023	137	CARDINAL		002 002	002 002		002 - POSITIVE	23	23	23	100	
151 hCG ONLY QUALITATIVE												
2026-024	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2026-024	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	48	48	48	100	
2026-024	118	AIM STEP		001 001	001 001		001 - NEGATIVE	254	254	254	100	
2026-024	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	98	97	97	100	
2026-024	130	ALERE HCG		001 001	001 001		002 - POSITIVE	98	1	97	0	
2026-024	133	FaStep		001 001	001 001		001 - NEGATIVE	34	34	34	100	
2026-024	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	46	46	46	100	
2026-024	135	STANBIO 20		001 001	001 001		001 - NEGATIVE	10	10	10	100	
2026-024	136	CLARITY		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2026-024	137	CARDINAL		001 001	001 001		001 - NEGATIVE	23	23	23	100	
2026-025	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2026-025	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	48	48	48	100	
2026-025	118	AIM STEP		001 001	001 001		001 - NEGATIVE	254	254	254	100	
2026-025	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	98	98	98	100	
2026-025	133	FaStep		001 001	001 001		001 - NEGATIVE	34	34	34	100	
2026-025	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	46	46	46	100	
2026-025	135	STANBIO 20		001 001	001 001		001 - NEGATIVE	10	10	10	100	
2026-025	136	CLARITY		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2026-025	137	CARDINAL		001 001	001 001		001 - NEGATIVE	23	23	23	100	

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)					
ANALYTE												
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
173 T3 UPTAKE												
CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 18 %								
2026-031	1	%U	84	VITROS ECI	1	25-35	40	64.654	1.261	1.95	53.020	76.290

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-031	1 %U	91	B.C.ACCESS	2	35-45	12	52.542	3.900	7.42	43.080	62.000	
2026-031	2 TUV	95	Arc i2000s	3	0.7 - 1.2	15	0.415	0.041	9.86	0.340	0.490	
2026-031	4 %	32	DIMENSION	2	35-45	37	40.979	1.369	3.34	33.600	48.350	
2026-031	4 %	106	ATELLICA	1	25-35	22	61.511	3.601	5.85	50.440	72.580	
2026-031	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.672	0.064	9.56	0.550	0.790	
173 T3 UPTAKE		CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 18 %						
2026-032	1 %U	84	VITROS ECI	1	25-35	40	51.560	1.257	2.44	42.280	60.840	
2026-032	1 %U	91	B.C.ACCESS	2	35-45	12	46.383	2.832	6.10	38.030	54.730	
2026-032	2 TUV	95	Arc i2000s	3	0.7 - 1.2	15	1.078	0.067	6.20	0.880	1.270	
2026-032	4 %	32	DIMENSION	2	35-45	37	39.917	1.520	3.81	32.730	47.100	
2026-032	4 %	106	ATELLICA	1	25-35	22	36.680	1.726	4.71	30.080	43.280	
2026-032	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.514	0.081	15.84	0.420	0.610	
2026-033	1 %U	84	VITROS ECI	1	25-35	40	64.641	1.255	1.94	53.010	76.280	
2026-033	1 %U	91	B.C.ACCESS	2	35-45	12	51.017	2.722	5.34	41.830	60.200	
2026-033	2 TUV	95	Arc i2000s	3	0.7 - 1.2	15	0.591	0.045	7.66	0.480	0.700	
2026-033	4 %	32	DIMENSION	2	35-45	37	40.403	1.501	3.72	33.130	47.680	
2026-033	4 %	106	ATELLICA	1	25-35	22	54.065	2.726	5.04	44.330	63.800	
2026-033	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.602	0.073	12.06	0.490	0.710	
2026-034	1 %U	84	VITROS ECI	1	25-35	40	46.772	1.091	2.33	38.350	55.190	
2026-034	1 %U	91	B.C.ACCESS	2	35-45	12	44.683	2.527	5.66	36.640	52.730	
2026-034	2 TUV	95	Arc i2000s	3	0.7 - 1.2	15	1.198	0.098	8.20	0.980	1.410	
2026-034	4 %	32	DIMENSION	2	35-45	37	39.837	1.447	3.63	32.670	47.010	
2026-034	4 %	106	ATELLICA	1	25-35	22	33.140	1.317	3.97	27.170	39.110	
2026-034	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.467	0.081	17.40	0.380	0.550	
2026-035	1 %U	84	VITROS ECI	1	25-35	40	64.467	1.308	2.03	52.860	76.070	
2026-035	1 %U	91	B.C.ACCESS	2	35-45	12	49.150	2.950	6.00	40.300	58.000	
2026-035	2 TUV	95	Arc i2000s	3	0.7 - 1.2	15	0.759	0.044	5.74	0.620	0.900	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-035	4 %	32	DIMENSION	2	35-45	37	40.575	1.454	3.58	33.270	47.880		
2026-035	4 %	106	ATELLICA	1	25-35	22	48.149	2.237	4.65	39.480	56.820		
2026-035	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.578	0.074	12.77	0.470	0.680		

SPEC: 10 CHEMISTRY SUB: 40 TOXICOLOGY GRP: 60 TOXICOLOGY

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
043 DIGOXIN		CLIA TEST ID #: 645		EVALUATION CRITERIA: TARGET VALUE		15	% OR 0.20	{GREATER}					
2026-031	50 VITROS					17	0.400	0.000	0.00	0.200	0.600		
2026-032	50 VITROS					17	1.306	0.087	6.68	1.100	1.500		
2026-033	50 VITROS					17	0.465	0.076	16.41	0.300	0.700		
2026-034	50 VITROS					17	1.759	0.084	4.80	1.500	2.000		
2026-035	50 VITROS					17	0.588	0.090	15.30	0.400	0.800		
045 FERRITIN		CLIA TEST ID #: 410		EVALUATION CRITERIA: TARGET VALUE		20	%						
2026-031	50 VITROS					22	10.218	0.383	3.75	8.200	12.300		
2026-031	90 ROCHE COBA					18	15.822	1.188	7.51	12.700	19.000		
2026-031	98 ARC i200sr					11	15.073	1.350	8.96	12.100	18.100		

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-031	105	ATELLICA		17	10.547	0.659	6.25	8.400	12.700	
045	FERRITIN		CLIA TEST ID #: 410		EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-032	50	VITROS		22	143.682	6.983	4.86	114.900	172.400	
2026-032	90	ROCHE COBA		18	240.850	16.264	6.75	192.700	289.000	
2026-032	98	ARC i200sr		11	254.827	12.913	5.07	203.900	305.800	
2026-032	105	ATELLICA		17	177.447	7.576	4.27	142.000	212.900	
2026-033	50	VITROS		22	34.736	1.433	4.13	27.800	41.700	
2026-033	90	ROCHE COBA		18	60.750	6.206	10.22	48.600	72.900	
2026-033	98	ARC i200sr		11	64.627	5.140	7.95	51.700	77.600	
2026-033	105	ATELLICA		17	41.429	4.506	10.88	33.100	49.700	
2026-034	50	VITROS		22	186.727	7.990	4.28	149.400	224.100	
2026-034	90	ROCHE COBA		18	314.806	21.128	6.71	251.800	377.800	
2026-034	98	ARC i200sr		11	333.491	21.938	6.58	266.800	400.200	
2026-034	105	ATELLICA		17	226.747	13.425	5.92	181.400	272.100	
2026-035	50	VITROS		22	62.232	3.438	5.53	49.800	74.700	
2026-035	90	ROCHE COBA		18	107.206	7.274	6.79	85.800	128.600	
2026-035	98	ARC i200sr		11	116.936	8.463	7.24	93.500	140.300	
2026-035	105	ATELLICA		17	77.176	3.854	4.99	61.700	92.600	
046	GENTAMICIN		CLIA TEST ID #: 665		EVALUATION CRITERIA: TARGET VALUE 25 %					
2026-031	50	VITROS		17	0.600	0.000	0.00	0.500	0.800	
2026-032	50	VITROS		17	11.129	0.501	4.51	8.300	13.900	
2026-033	50	VITROS		17	2.253	0.070	3.09	1.700	2.800	
2026-034	50	VITROS		17	14.956	0.639	4.27	11.200	18.700	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
046	GENTAMICIN		CLIA TEST ID #: 665		EVALUATION CRITERIA: TARGET VALUE 25 %					
2026-035	50 VITROS			17	4.441	0.150	3.37	3.300	5.600	
050	PHENYTOIN		CLIA TEST ID #: 695		EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}					
2026-031	50 VITROS			17	2.863	0.533	18.60	0.900	4.900	
2026-032	50 VITROS			17	31.776	2.066	6.50	27.000	36.500	
2026-033	50 VITROS			17	6.353	0.259	4.08	4.400	8.400	
2026-034	50 VITROS			17	36.353	1.639	4.51	30.900	41.800	
2026-035	50 VITROS			17	13.206	0.624	4.72	11.200	15.200	
127	VANCOMYCIN		CLIA TEST ID #: 756							
2026-031	50 VITROS			22	5.000	0.000	0.00	3.000	7.000	
2026-031	92 ROCHE COBA			11	4.000	0.000	0.00	2.000	6.000	
2026-032	50 VITROS			22	38.886	2.572	6.61	33.100	44.700	
2026-032	92 ROCHE COBA			11	37.736	1.175	3.11	32.100	43.400	
2026-033	50 VITROS			22	7.841	0.672	8.57	5.800	9.800	
2026-033	92 ROCHE COBA			11	7.527	0.766	10.18	5.500	9.500	
2026-034	50 VITROS			22	50.336	3.244	6.44	42.800	57.900	
2026-034	92 ROCHE COBA			11	49.836	2.153	4.32	42.400	57.300	
2026-035	50 VITROS			22	14.882	1.075	7.22	12.600	17.100	
2026-035	92 ROCHE COBA			11	15.582	0.995	6.39	13.200	17.900	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
065 URINA-PROTEIN QUANT.			CLIA TEST ID #: 0						EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}	
2026-061	58	VITROS	46	139.565	10.047	7.20	104.700	174.500		
2026-061	62	SIEM DIM.	37	107.781	2.750	2.55	80.800	134.700		
2026-061	79	BECK. COUL	20	96.995	2.063	2.13	72.700	121.200		
2026-061	93	ARCHITECT	16	92.967	2.331	2.51	69.700	116.200		
2026-061	113	ROCHE COBA	45	86.898	2.247	2.59	65.200	108.600		
2026-061	146	APELLICA	24	104.126	2.072	1.99	78.100	130.200		
2026-062	58	VITROS	46	5.022	0.147	2.94	0.000	10.000		
2026-062	62	SIEM DIM.	36	22.094	2.640	11.95	16.600	27.600		
2026-062	79	BECK. COUL	20	5.267	0.475	9.02	0.300	10.300		
2026-062	93	ARCHITECT	16	6.820	0.075	1.10	1.800	11.800		
2026-062	113	ROCHE COBA	45	4.244	0.999	23.54	0	9.200		
2026-062	146	APELLICA	24	22.675	2.109	9.30	17.000	28.300		
2026-063	58	VITROS	46	155.183	10.204	6.58	116.400	194.000		
2026-063	62	SIEM DIM.	36	112.446	1.816	1.61	84.300	140.600		
2026-063	79	BECK. COUL	20	98.184	2.008	2.04	73.600	122.700		
2026-063	93	ARCHITECT	16	91.673	1.918	2.09	68.800	114.600		
2026-063	113	ROCHE COBA	45	86.156	1.824	2.12	64.600	107.700		
2026-063	146	APELLICA	24	109.830	2.579	2.35	82.400	137.300		
2026-064	58	VITROS	46	183.822	8.723	4.75	137.900	229.800		
2026-064	62	SIEM DIM.	36	124.489	2.301	1.85	93.400	155.600		
2026-064	79	BECK. COUL	20	106.437	3.191	3.00	79.800	133.000		
2026-064	93	ARCHITECT	16	106.140	3.622	3.41	79.600	132.700		
2026-064	113	ROCHE COBA	45	99.687	2.170	2.18	74.800	124.600		
2026-064	146	APELLICA	24	121.148	2.950	2.44	90.900	151.400		
2026-065	58	VITROS	46	5.000	0.000	0.00	0.000	10.000		

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-065	62	SIEM DIM.		37	14.924	1.471	9.86	9.900	19.900
2026-065	79	BECK. COUL		20	4.578	0.472	10.31	0	9.600
2026-065	93	ARCHITECT		16	6.819	0.073	1.06	1.800	11.800
2026-065	113	ROCHE COBA		45	4.362	0.858	19.66	0	9.400
2026-065	146	ATELLICA		24	14.648	1.521	10.38	9.600	19.600
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2026-061	11	AMES NM10S		30	1.023	0.003	0.27	1.015	1.031
2026-061	13	BAYER CLI		16	1.021	0.003	0.27	1.013	1.030
2026-061	67	URISCAN		54	1.021	0.003	0.31	1.011	1.030
2026-061	72	URS-9-TECO		50	1.020	0.004	0.44	1.007	1.034
2026-061	80	ROCHE (CHE		36	1.015	0.000	0.00	1.015	1.015
2026-061	89	AIMSTRIP		164	1.020	0.002	0.17	1.015	1.025
2026-061	94	CLINITEK		102	1.023	0.003	0.27	1.015	1.031
2026-061	102	ACON LAB		110	1.020	0.001	0.14	1.016	1.025
2026-061	131	iCHEM VELO		42	1.025	0.001	0.07	1.022	1.027
2026-061	140	MISSION A		36	1.020	0.003	0.28	1.012	1.029
2026-061	145	CLINITEK		45	1.031	0.001	0.08	1.028	1.033
2026-061	147	Mission120		35	1.022	0.002	0.24	1.015	1.029
2026-061	148	Mission500		159	1.020	0.002	0.15	1.016	1.025
2026-061	151	Clari. Uro		32	1.019	0.002	0.19	1.013	1.025
2026-062	11	AMES NM10S		30	1.016	0.003	0.32	1.006	1.026
2026-062	13	BAYER CLI		16	1.015	0.003	0.27	1.006	1.023
2026-062	67	URISCAN		54	1.013	0.002	0.24	1.006	1.020
2026-062	72	URS-9-TECO		50	1.015	0.004	0.41	1.002	1.027
2026-062	80	ROCHE (CHE		36	1.010	0.002	0.21	1.004	1.017
2026-062	89	AIMSTRIP		164	1.014	0.003	0.33	1.004	1.024
2026-062	94	CLINITEK		102	1.015	0.003	0.31	1.006	1.024
2026-062	102	ACON LAB		110	1.015	0.003	0.31	1.006	1.024
2026-062	131	iCHEM VELO		42	1.026	0.001	0.08	1.023	1.028

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-062	140	MISSION A		36	1.016	0.003	0.32	1.006	1.025
2026-062	145	CLINITEK		45	1.032	0.001	0.08	1.029	1.034
2026-062	147	Mission120		35	1.019	0.002	0.23	1.012	1.026
2026-062	148	Mission500		159	1.015	0.003	0.29	1.007	1.024
2026-062	151	Clari. Uro		32	1.014	0.002	0.22	1.008	1.021
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2026-063	11	AMES NM10S		30	1.019	0.003	0.31	1.010	1.029
2026-063	13	BAYER CLI		16	1.018	0.003	0.25	1.010	1.025
2026-063	67	URISCAN		54	1.016	0.002	0.23	1.009	1.023
2026-063	72	URS-9-TECO		50	1.017	0.004	0.42	1.004	1.030
2026-063	80	ROCHE (CHE		36	1.011	0.002	0.22	1.005	1.018
2026-063	89	AIMSTRIP		164	1.016	0.002	0.22	1.010	1.023
2026-063	94	CLINITEK		102	1.019	0.003	0.28	1.010	1.028
2026-063	102	ACON LAB		110	1.017	0.003	0.27	1.009	1.025
2026-063	131	iCHEM VELO		42	1.025	0.001	0.09	1.022	1.028
2026-063	140	MISSION A		36	1.016	0.002	0.24	1.009	1.024
2026-063	145	CLINITEK		45	1.028	0.001	0.06	1.026	1.030
2026-063	147	Mission120		35	1.020	0.000	0.00	1.020	1.020
2026-063	148	Mission500		159	1.017	0.002	0.23	1.010	1.024
2026-063	151	Clari. Uro		32	1.015	0.002	0.19	1.009	1.021
2026-064	11	AMES NM10S		30	1.017	0.003	0.33	1.007	1.027
2026-064	13	BAYER CLI		16	1.017	0.002	0.23	1.010	1.024
2026-064	67	URISCAN		54	1.014	0.002	0.21	1.008	1.021
2026-064	72	URS-9-TECO		50	1.018	0.004	0.37	1.006	1.029
2026-064	80	ROCHE (CHE		36	1.010	0.002	0.20	1.004	1.016
2026-064	89	AIMSTRIP		164	1.016	0.004	0.35	1.005	1.027
2026-064	94	CLINITEK		102	1.017	0.003	0.27	1.009	1.026
2026-064	102	ACON LAB		110	1.016	0.003	0.33	1.006	1.026
2026-064	131	iCHEM VELO		42	1.028	0.001	0.10	1.025	1.031

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-064	140	MISSION A		36	1.015	0.004	0.37	1.004	1.026
2026-064	145	CLINITEK		45	1.032	0.001	0.06	1.030	1.034
2026-064	147	Mission120		35	1.019	0.002	0.21	1.013	1.025
2026-064	148	Mission500		159	1.017	0.003	0.26	1.009	1.025
2026-064	151	Clari. Uro		32	1.012	0.002	0.23	1.005	1.019
067 URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD					
2026-065	11	AMES NM10S		30	1.021	0.002	0.20	1.015	1.027
2026-065	13	BAYER CLI		16	1.018	0.003	0.34	1.008	1.029
2026-065	67	URISCAN		54	1.020	0.003	0.29	1.012	1.029
2026-065	72	URS-9-TECO		50	1.019	0.006	0.58	1.001	1.036
2026-065	80	ROCHE (CHE		36	1.017	0.002	0.23	1.010	1.024
2026-065	89	AIMSTRIP		164	1.019	0.003	0.26	1.011	1.027
2026-065	94	CLINITEK		102	1.020	0.003	0.31	1.010	1.029
2026-065	102	ACON LAB		110	1.021	0.003	0.26	1.013	1.029
2026-065	131	iCHEM VELO		42	1.026	0.001	0.07	1.024	1.029
2026-065	140	MISSION A		36	1.021	0.003	0.25	1.013	1.028
2026-065	145	CLINITEK		45	1.033	0.001	0.07	1.031	1.035
2026-065	147	Mission120		35	1.020	0.002	0.18	1.015	1.026
2026-065	148	Mission500		159	1.021	0.002	0.22	1.015	1.028
2026-065	151	Clari. Uro		32	1.023	0.003	0.30	1.013	1.032
166 MICROALBUMIN		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2026-061	58	VITROS		60	835.832	30.451	3.64	626.900	1044.800
2026-061	62	SIEM DIM.		62	824.665	52.517	6.37	618.500	1030.800
2026-061	79	BECK. COUL		21	769.950	107.572	13.97	577.500	962.400
2026-061	93	ARCHITECT		20	818.016	19.388	2.37	613.500	1022.500
2026-061	95	INTEGRA		19	821.705	33.340	4.06	616.300	1027.100
2026-061	113	ROCHE COBA		52	792.378	62.558	7.90	594.300	990.500
2026-061	146	ATELLICA		28	667.357	20.584	3.08	500.500	834.200
2026-061	154	CS400DIRUI		12	639.775	115.424	18.04	479.800	799.700

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
166	MICROALBUMIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	%	OR	5.00	{GREATER}		
2026-062	58	VITROS		60	6.000	0.000	0.00	1.000	11.000	
2026-062	62	SIEM DIM.		62	2.045	0.830	40.60	0	7.000	
2026-062	79	BECK. COUL		21	2.352	3.048	129.56	0	7.400	
2026-062	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000	
2026-062	95	INTEGRA		19	3.374	1.345	39.88	0	8.400	
2026-062	113	ROCHE COBA		52	10.617	3.829	36.06	5.600	15.600	
2026-062	146	ATELLICA		28	3.000	0.000	0.00	0	8.000	
2026-062	154	CS400DIRUI		12	1.942	2.324	119.67	0	6.900	
2026-063	58	VITROS		60	813.507	34.933	4.29	610.100	1016.900	
2026-063	62	SIEM DIM.		62	817.710	51.455	6.29	613.300	1022.100	
2026-063	79	BECK. COUL		21	770.585	108.022	14.02	577.900	963.200	
2026-063	93	ARCHITECT		20	811.405	16.537	2.04	608.600	1014.300	
2026-063	95	INTEGRA		19	796.700	30.906	3.88	597.500	995.900	
2026-063	113	ROCHE COBA		52	781.714	62.036	7.94	586.300	977.100	
2026-063	146	ATELLICA		28	665.396	26.642	4.00	499.000	831.700	
2026-063	154	CS400DIRUI		12	625.192	109.550	17.52	468.900	781.500	
2026-064	58	VITROS		60	894.983	40.680	4.55	671.200	1118.700	
2026-064	62	SIEM DIM.		62	892.293	53.377	5.98	669.200	1115.400	
2026-064	79	BECK. COUL		21	833.740	138.699	16.64	625.300	1042.200	
2026-064	93	ARCHITECT		20	887.215	20.633	2.33	665.400	1109.000	
2026-064	95	INTEGRA		19	876.779	31.163	3.55	657.600	1096.000	
2026-064	113	ROCHE COBA		52	856.500	66.784	7.80	642.400	1070.600	
2026-064	146	ATELLICA		28	727.496	19.485	2.68	545.600	909.400	
2026-064	154	CS400DIRUI		12	674.592	145.008	21.50	505.900	843.200	
2026-065	58	VITROS		60	6.017	0.129	2.15	1.000	11.000	
2026-065	62	SIEM DIM.		62	3.707	0.961	25.94	0	8.700	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-065	79	BECK. COUL		21	2.367	3.057	129.17	0	7.400
2026-065	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000
2026-065	95	INTEGRA		19	3.353	1.317	39.29	0	8.400
2026-065	113	ROCHE COBA		52	10.615	3.834	36.12	5.600	15.600
2026-065	146	ATELLICA		28	3.000	0.000	0.00	0	8.000
2026-065	154	CS400DIRUI		12	2.991	2.327	77.81	0	8.000
167	CREATININE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}				
2026-061	58	VITROS		67	3.197	0.024	0.76	0	8.200
2026-061	62	SIEM DIM.		60	8.957	5.493	61.33	4.000	14.000
2026-061	79	BECK. COUL		21	0.490	0.419	85.59	0	5.500
2026-061	93	ARCHITECT		19	2.516	0.036	1.45	0	7.500
2026-061	95	INTEGRA		19	0.426	0.361	84.69	0	5.400
2026-061	113	ROCHE COBA		53	3.516	1.355	38.54	0	8.500
2026-061	146	ATELLICA		29	3.000	0.000	0.00	0	8.000
2026-061	154	CS400DIRUI		11	0.827	0.996	120.34	0	5.800
2026-062	58	VITROS		67	235.506	10.518	4.47	176.600	294.400
2026-062	62	SIEM DIM.		60	234.359	5.904	2.52	175.800	292.900
2026-062	79	BECK. COUL		21	207.010	7.165	3.46	155.300	258.800
2026-062	93	ARCHITECT		19	223.305	9.808	4.39	167.500	279.100
2026-062	95	INTEGRA		19	241.117	9.808	4.07	180.800	301.400
2026-062	113	ROCHE COBA		53	235.781	9.132	3.87	176.800	294.700
2026-062	146	ATELLICA		29	214.483	7.546	3.52	160.900	268.100
2026-062	154	CS400DIRUI		11	203.391	18.922	9.30	152.500	254.200
2026-063	58	VITROS		67	226.255	6.129	2.71	169.700	282.800
2026-063	62	SIEM DIM.		60	238.216	7.670	3.22	178.700	297.800
2026-063	79	BECK. COUL		21	209.110	6.773	3.24	156.800	261.400
2026-063	93	ARCHITECT		19	225.721	9.147	4.05	169.300	282.200
2026-063	95	INTEGRA		19	242.528	9.585	3.95	181.900	303.200

Participant Summary
MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026-063	113	ROCHE COBA		53	238.811	9.882	4.14	179.100	298.500		
2026-063	146	ATELLICA		29	217.632	6.437	2.96	163.200	272.000		
2026-063	154	CS400DIRUI		11	209.355	19.154	9.15	157.000	261.700		
167	CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2026-064	58	VITROS		67	254.710	6.868	2.70	191.000	318.400		
2026-064	62	SIEM DIM.		60	254.707	7.842	3.08	191.000	318.400		
2026-064	79	BECK. COUL		21	212.214	8.610	4.06	159.200	265.300		
2026-064	93	ARCHITECT		19	244.695	10.078	4.12	183.500	305.900		
2026-064	95	INTEGRA		19	262.167	10.905	4.16	196.600	327.700		
2026-064	113	ROCHE COBA		53	257.019	9.728	3.78	192.800	321.300		
2026-064	146	ATELLICA		29	233.348	6.836	2.93	175.000	291.700		
2026-064	154	CS400DIRUI		11	226.745	15.961	7.04	170.100	283.400		
2026-065	58	VITROS		67	3.132	0.611	19.50	0	8.100		
2026-065	62	SIEM DIM.		60	8.965	5.468	60.99	4.000	14.000		
2026-065	79	BECK. COUL		21	0.420	0.475	113.09	0	5.400		
2026-065	93	ARCHITECT		19	2.516	0.036	1.45	0	7.500		
2026-065	95	INTEGRA		19	0.163	0.306	187.82	0	5.200		
2026-065	113	ROCHE COBA		53	3.844	1.965	51.12	0	8.800		
2026-065	146	ATELLICA		29	3.000	0.000	0.00	0	8.000		
2026-065	154	CS400DIRUI		11	0.340	0.441	129.68	0	5.300		

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS						
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score	
SAMPLE	RESULT	RESULT	RESULT	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
057 URINALYSIS-BILIRUBIN												
2026-061	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	30	30	30	100
2026-061	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	16	16	16	100
2026-061	067	URISCAN		057	057	057	057	057 - NEGATIVE	53	53	53	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-061	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	51	51	51	100	
2026-061	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2026-061	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	161	160	160	100	
2026-061	089	AIMSTRIP		057 057	057 057		058 - TRACES, 1+	161	1	160	0	
2026-061	094	CLINITEK		057 057	057 057		057 - NEGATIVE	102	102	102	100	
2026-061	102	ACON LAB		057 057	057 057		057 - NEGATIVE	107	107	107	100	
2026-061	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	42	42	42	100	
2026-061	140	MISSION A		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2026-061	145	CLINITEK		057 057	057 057		057 - NEGATIVE	45	45	45	100	
2026-061	147	Mission120		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2026-061	148	Mission500		057 057	057 057		057 - NEGATIVE	161	161	161	100	
2026-061	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	34	34	34	100	
057 URINALYSIS-BILIRUBIN												
2026-062	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	30	30	30	100	
2026-062	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	16	16	16	100	
2026-062	067	URISCAN		057 057	057 057		057 - NEGATIVE	53	53	53	100	
2026-062	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	51	51	51	100	
2026-062	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2026-062	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	161	161	161	100	
2026-062	094	CLINITEK		057 057	057 057		057 - NEGATIVE	102	102	102	100	
2026-062	102	ACON LAB		057 057	057 057		057 - NEGATIVE	107	107	107	100	
2026-062	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	42	42	42	100	
2026-062	140	MISSION A		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2026-062	145	CLINITEK		057 057	057 057		057 - NEGATIVE	45	45	45	100	
2026-062	147	Mission120		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2026-062	148	Mission500		057 057	057 057		057 - NEGATIVE	161	161	161	100	
2026-062	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2026-063	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	30	30	30	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	16	16	16	100	
2026-063	067	URISCAN		057 057	057 057		057 - NEGATIVE	53	53	53	100	
2026-063	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	51	51	51	100	
2026-063	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2026-063	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	161	161	161	100	
2026-063	094	CLINITEK		057 057	057 057		057 - NEGATIVE	102	102	102	100	
2026-063	102	ACON LAB		057 057	057 057		057 - NEGATIVE	107	107	107	100	
2026-063	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	42	42	42	100	
2026-063	140	MISSION A		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2026-063	145	CLINITEK		057 057	057 057		057 - NEGATIVE	45	45	45	100	
2026-063	147	Mission120		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2026-063	148	Mission500		057 057	057 057		057 - NEGATIVE	161	161	161	100	
2026-063	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	34	34	34	100	
057 URINALYSIS-BILIRUBIN												
2026-064	011	AMES NM10S		058 060	057 059		058 - TRACES, 1+	30	4	30	100	
2026-064	011	AMES NM10S		058 060	057 059		059 - 2+	30	23	30	100	
2026-064	011	AMES NM10S		058 060	057 059		060 - 3+	30	3	30	100	
2026-064	013	BAYER CLI		058 060	057 059		058 - TRACES, 1+	16	2	16	100	
2026-064	013	BAYER CLI		058 060	057 059		059 - 2+	16	14	16	100	
2026-064	067	URISCAN		057 059	057 059		057 - NEGATIVE	53	9	52	100	
2026-064	067	URISCAN		057 059	057 059		058 - TRACES, 1+	53	37	52	100	
2026-064	067	URISCAN		057 059	057 059		059 - 2+	53	6	52	100	
2026-064	067	URISCAN		057 059	057 059		060 - 3+	53	1	52	0	
2026-064	072	URS-9-TECO		058 060	057 059		057 - NEGATIVE	51	1	51	100	
2026-064	072	URS-9-TECO		058 060	057 059		058 - TRACES, 1+	51	20	51	100	
2026-064	072	URS-9-TECO		058 060	057 059		059 - 2+	51	27	51	100	
2026-064	072	URS-9-TECO		058 060	057 059		060 - 3+	51	3	51	100	
2026-064	080	ROCHE (CHE		057 059	057 059		058 - TRACES, 1+	35	21	29	100	
2026-064	080	ROCHE (CHE		057 059	057 059		059 - 2+	35	8	29	100	
2026-064	080	ROCHE (CHE		057 059	057 059		060 - 3+	35	6	29	0	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-064	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	161	1	153	100	
2026-064	089	AIMSTRIP		057 059	057 059		058 - TRACES,1+	161	102	153	100	
2026-064	089	AIMSTRIP		057 059	057 059		059 - 2+	161	50	153	100	
2026-064	089	AIMSTRIP		057 059	057 059		060 - 3+	161	8	153	0	
2026-064	094	CLINITEK		058 060	057 059		057 - NEGATIVE	102	2	102	100	
2026-064	094	CLINITEK		058 060	057 059		058 - TRACES,1+	102	13	102	100	
2026-064	094	CLINITEK		058 060	057 059		059 - 2+	102	86	102	100	
2026-064	094	CLINITEK		058 060	057 059		060 - 3+	102	1	102	100	
2026-064	102	ACON LAB		057 059	057 059		058 - TRACES,1+	107	65	101	100	
2026-064	102	ACON LAB		057 059	057 059		059 - 2+	107	36	101	100	
2026-064	102	ACON LAB		057 059	057 059		060 - 3+	107	6	101	0	
2026-064	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	42	40	42	100	
2026-064	131	iCHEM VELO		057 057	057 059		058 - TRACES,1+	42	2	42	100	
2026-064	140	MISSION A		057 059	057 059		057 - NEGATIVE	34	1	31	100	
2026-064	140	MISSION A		057 059	057 059		058 - TRACES,1+	34	18	31	100	
2026-064	140	MISSION A		057 059	057 059		059 - 2+	34	12	31	100	
2026-064	140	MISSION A		057 059	057 059		060 - 3+	34	3	31	0	
2026-064	145	CLINITEK		057 057	057 059		057 - NEGATIVE	45	45	45	100	
2026-064	147	Mission120		058 060	057 059		058 - TRACES,1+	37	18	37	100	
2026-064	147	Mission120		058 060	057 059		059 - 2+	37	19	37	100	
2026-064	148	Mission500		057 059	057 059		057 - NEGATIVE	161	1	160	100	
2026-064	148	Mission500		057 059	057 059		058 - TRACES,1+	161	118	160	100	
2026-064	148	Mission500		057 059	057 059		059 - 2+	161	41	160	100	
2026-064	148	Mission500		057 059	057 059		060 - 3+	161	1	160	0	
2026-064	151	Clari. Uro		057 059	057 059		058 - TRACES,1+	34	25	33	100	
2026-064	151	Clari. Uro		057 059	057 059		059 - 2+	34	8	33	100	
2026-064	151	Clari. Uro		057 059	057 059		060 - 3+	34	1	33	0	
057 URINALYSIS-BILIRUBIN												
2026-065	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	30	30	30	100	
2026-065	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	16	16	16	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	067	URISCAN		057	057	057	057	53	53	53	100	
2026-065	072	URS-9-TECO		057	057	057	057	51	51	51	100	
2026-065	080	ROCHE (CHE		057	057	057	057	35	35	35	100	
2026-065	089	AIMSTRIP		057	057	057	057	161	160	160	100	
2026-065	089	AIMSTRIP		057	057	057	057	161	1	160	0	
2026-065	094	CLINITEK		057	057	057	057	102	101	101	100	
2026-065	094	CLINITEK		057	057	057	057	102	1	101	0	
2026-065	102	ACON LAB		057	057	057	057	107	107	107	100	
2026-065	131	iCHEM VELO		057	057	057	057	42	42	42	100	
2026-065	140	MISSION A		057	057	057	057	34	34	34	100	
2026-065	145	CLINITEK		057	057	057	057	45	45	45	100	
2026-065	147	Mission120		057	057	057	057	37	37	37	100	
2026-065	148	Mission500		057	057	057	057	161	161	161	100	
2026-065	151	Clari. Uro		057	057	057	057	34	34	34	100	
058 URINALYSIS-GLUCOSE												
2026-061	011	AMES NM10S		076	078	076	078	29	1	28	0	
2026-061	011	AMES NM10S		076	078	076	078	29	6	28	100	
2026-061	011	AMES NM10S		076	078	076	078	29	22	28	100	
2026-061	013	BAYER CLI		075	077	076	078	16	9	16	100	
2026-061	013	BAYER CLI		075	077	076	078	16	6	16	100	
2026-061	013	BAYER CLI		075	077	076	078	16	1	16	100	
2026-061	067	URISCAN		077	078	076	078	53	5	53	100	
2026-061	067	URISCAN		077	078	076	078	53	11	53	100	
2026-061	067	URISCAN		077	078	076	078	53	37	53	100	
2026-061	072	URS-9-TECO		076	078	076	078	51	4	47	0	
2026-061	072	URS-9-TECO		076	078	076	078	51	12	47	100	
2026-061	072	URS-9-TECO		076	078	076	078	51	32	47	100	
2026-061	072	URS-9-TECO		076	078	076	078	51	3	47	100	
2026-061	080	ROCHE (CHE		076	078	076	078	36	34	36	100	
2026-061	080	ROCHE (CHE		076	078	076	078	36	2	36	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-061	089	AIMSTRIP		076 078	076 078		075 - 250mg/dl-+	164	1	163	0	
2026-061	089	AIMSTRIP		076 078	076 078		076 - 500mg/dl2+	164	55	163	100	
2026-061	089	AIMSTRIP		076 078	076 078		077 - 1000mg/dl	164	107	163	100	
2026-061	089	AIMSTRIP		076 078	076 078		078 - 2000mg/dl	164	1	163	100	
2026-061	094	CLINITEK		076 078	076 078		075 - 250mg/dl-+	102	1	101	0	
2026-061	094	CLINITEK		076 078	076 078		076 - 500mg/dl2+	102	31	101	100	
2026-061	094	CLINITEK		076 078	076 078		077 - 1000mg/dl	102	69	101	100	
2026-061	094	CLINITEK		076 078	076 078		078 - 2000mg/dl	102	1	101	100	
2026-061	102	ACON LAB		076 078	076 078		076 - 500mg/dl2+	109	33	109	100	
2026-061	102	ACON LAB		076 078	076 078		077 - 1000mg/dl	109	61	109	100	
2026-061	102	ACON LAB		076 078	076 078		078 - 2000mg/dl	109	15	109	100	
2026-061	131	iCHEM VELO		075 077	076 078		074 - TRACES	42	1	41	0	
2026-061	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	42	38	41	100	
2026-061	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	42	3	41	100	
2026-061	140	MISSION A		076 078	076 078		075 - 250mg/dl-+	36	2	34	0	
2026-061	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	36	6	34	100	
2026-061	140	MISSION A		076 078	076 078		077 - 1000mg/dl	36	20	34	100	
2026-061	140	MISSION A		076 078	076 078		078 - 2000mg/dl	36	8	34	100	
2026-061	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	45	1	45	100	
2026-061	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	45	42	45	100	
2026-061	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	45	2	45	100	
2026-061	147	Mission120		076 078	076 078		076 - 500mg/dl2+	35	3	35	100	
2026-061	147	Mission120		076 078	076 078		077 - 1000mg/dl	35	17	35	100	
2026-061	147	Mission120		076 078	076 078		078 - 2000mg/dl	35	15	35	100	
2026-061	148	Mission500		076 078	076 078		075 - 250mg/dl-+	160	1	159	0	
2026-061	148	Mission500		076 078	076 078		076 - 500mg/dl2+	160	35	159	100	
2026-061	148	Mission500		076 078	076 078		077 - 1000mg/dl	160	80	159	100	
2026-061	148	Mission500		076 078	076 078		078 - 2000mg/dl	160	44	159	100	
2026-061	151	Clari. Uro		076 078	076 078		076 - 500mg/dl2+	33	8	33	100	
2026-061	151	Clari. Uro		076 078	076 078		077 - 1000mg/dl	33	25	33	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
058 URINALYSIS-GLUCOSE													
2026-062	011 AMES NM10S			076 078	076 078		076 - 500mg/dl2+	29	7	29	100		
2026-062	011 AMES NM10S			076 078	076 078		077 - 1000mg/dl	29	22	29	100		
2026-062	013 BAYER CLI			076 078	076 078		075 - 250mg/dl-+	16	1	15	0		
2026-062	013 BAYER CLI			076 078	076 078		076 - 500mg/dl2+	16	6	15	100		
2026-062	013 BAYER CLI			076 078	076 078		077 - 1000mg/dl	16	7	15	100		
2026-062	013 BAYER CLI			076 078	076 078		078 - 2000mg/dl	16	2	15	100		
2026-062	067 URISCAN			077 078	076 078		076 - 500mg/dl2+	53	8	53	100		
2026-062	067 URISCAN			077 078	076 078		077 - 1000mg/dl	53	11	53	100		
2026-062	067 URISCAN			077 078	076 078		078 - 2000mg/dl	53	34	53	100		
2026-062	072 URS-9-TECO			076 078	076 078		075 - 250mg/dl-+	51	1	50	0		
2026-062	072 URS-9-TECO			076 078	076 078		076 - 500mg/dl2+	51	16	50	100		
2026-062	072 URS-9-TECO			076 078	076 078		077 - 1000mg/dl	51	29	50	100		
2026-062	072 URS-9-TECO			076 078	076 078		078 - 2000mg/dl	51	5	50	100		
2026-062	080 ROCHE (CHE			076 078	076 078		075 - 250mg/dl-+	36	1	35	0		
2026-062	080 ROCHE (CHE			076 078	076 078		076 - 500mg/dl2+	36	1	35	100		
2026-062	080 ROCHE (CHE			076 078	076 078		077 - 1000mg/dl	36	32	35	100		
2026-062	080 ROCHE (CHE			076 078	076 078		078 - 2000mg/dl	36	2	35	100		
2026-062	089 AIMSTRIP			076 078	076 078		075 - 250mg/dl-+	164	4	160	0		
2026-062	089 AIMSTRIP			076 078	076 078		076 - 500mg/dl2+	164	55	160	100		
2026-062	089 AIMSTRIP			076 078	076 078		077 - 1000mg/dl	164	104	160	100		
2026-062	089 AIMSTRIP			076 078	076 078		078 - 2000mg/dl	164	1	160	100		
2026-062	094 CLINITEK			076 078	076 078		075 - 250mg/dl-+	102	3	99	0		
2026-062	094 CLINITEK			076 078	076 078		076 - 500mg/dl2+	102	23	99	100		
2026-062	094 CLINITEK			076 078	076 078		077 - 1000mg/dl	102	75	99	100		
2026-062	094 CLINITEK			076 078	076 078		078 - 2000mg/dl	102	1	99	100		
2026-062	102 ACON LAB			076 078	076 078		076 - 500mg/dl2+	109	34	109	100		
2026-062	102 ACON LAB			076 078	076 078		077 - 1000mg/dl	109	55	109	100		
2026-062	102 ACON LAB			076 078	076 078		078 - 2000mg/dl	109	20	109	100		
2026-062	131 iCHEM VELO			075 077	076 078		076 - 500mg/dl2+	42	39	42	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-062	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	42	3	42	100	
2026-062	140	MISSION A		076 078	076 078		075 - 250mg/dl-+	36	1	35	0	
2026-062	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	36	6	35	100	
2026-062	140	MISSION A		076 078	076 078		077 - 1000mg/dl	36	20	35	100	
2026-062	140	MISSION A		076 078	076 078		078 - 2000mg/dl	36	9	35	100	
2026-062	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	45	12	45	100	
2026-062	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	45	32	45	100	
2026-062	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	45	1	45	100	
2026-062	147	Mission120		076 078	076 078		076 - 500mg/dl2+	35	2	35	100	
2026-062	147	Mission120		076 078	076 078		077 - 1000mg/dl	35	19	35	100	
2026-062	147	Mission120		076 078	076 078		078 - 2000mg/dl	35	14	35	100	
2026-062	148	Mission500			076 078		076 - 500mg/dl2+	160	37	160	100	
2026-062	148	Mission500			076 078		077 - 1000mg/dl	160	59	160	100	
2026-062	148	Mission500			076 078		078 - 2000mg/dl	160	64	160	100	
2026-062	151	Clari. Uro		076 078	076 078		075 - 250mg/dl-+	33	1	32	0	
2026-062	151	Clari. Uro		076 078	076 078		076 - 500mg/dl2+	33	5	32	100	
2026-062	151	Clari. Uro		076 078	076 078		077 - 1000mg/dl	33	27	32	100	
058 URINALYSIS-GLUCOSE												
2026-063	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	29	29	29	100	
2026-063	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	16	16	16	100	
2026-063	067	URISCAN		073 073	073 073		073 - NEGATIVE	53	52	52	100	
2026-063	067	URISCAN		073 073	073 073		077 - 1000mg/dl	53	1	52	0	
2026-063	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	51	51	51	100	
2026-063	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	36	36	36	100	
2026-063	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	164	164	164	100	
2026-063	094	CLINITEK		073 073	073 073		073 - NEGATIVE	102	102	102	100	
2026-063	102	ACON LAB		073 073	073 073		073 - NEGATIVE	109	109	109	100	
2026-063	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	42	42	42	100	
2026-063	140	MISSION A		073 073	073 073		073 - NEGATIVE	36	36	36	100	
2026-063	145	CLINITEK		073 073	073 073		073 - NEGATIVE	45	45	45	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	147	Mission120		073 073	073 073		073 - NEGATIVE	35	35	35	100	
2026-063	148	Mission500		073 073	073 073		073 - NEGATIVE	160	160	160	100	
2026-063	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	33	33	33	100	
058 URINALYSIS-GLUCOSE												
2026-064	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	29	29	29	100	
2026-064	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	16	16	16	100	
2026-064	067	URISCAN		073 073	073 073		073 - NEGATIVE	53	51	51	100	
2026-064	067	URISCAN		073 073	073 073		074 - TRACES	53	1	51	0	
2026-064	067	URISCAN		073 073	073 073		077 - 1000mg/dl	53	1	51	0	
2026-064	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	51	51	51	100	
2026-064	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	36	36	36	100	
2026-064	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	164	163	163	100	
2026-064	089	AIMSTRIP		073 073	073 073		074 - TRACES	164	1	163	0	
2026-064	094	CLINITEK		073 073	073 073		073 - NEGATIVE	102	100	100	100	
2026-064	094	CLINITEK		073 073	073 073		074 - TRACES	102	1	100	0	
2026-064	094	CLINITEK		073 073	073 073		075 - 250mg/dl-+	102	1	100	0	
2026-064	102	ACON LAB		073 073	073 073		073 - NEGATIVE	109	109	109	100	
2026-064	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	42	42	42	100	
2026-064	140	MISSION A		073 073	073 073		073 - NEGATIVE	36	35	35	100	
2026-064	140	MISSION A		073 073	073 073		075 - 250mg/dl-+	36	1	35	0	
2026-064	145	CLINITEK		073 073	073 073		073 - NEGATIVE	45	45	45	100	
2026-064	147	Mission120		073 073	073 073		073 - NEGATIVE	35	35	35	100	
2026-064	148	Mission500		073 073	073 073		073 - NEGATIVE	160	157	157	100	
2026-064	148	Mission500		073 073	073 073		075 - 250mg/dl-+	160	2	157	0	
2026-064	148	Mission500		073 073	073 073		077 - 1000mg/dl	160	1	157	0	
2026-064	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	33	33	33	100	
2026-065	011	AMES NM10S		074 076	074 076		073 - NEGATIVE	29	1	28	0	
2026-065	011	AMES NM10S		074 076	074 076		074 - TRACES	29	11	28	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-065	011	AMES NM10S		074 076	074 076		075 - 250mg/dl-+	29	17	28	100
2026-065	013	BAYER CLI		074 076	074 076		074 - TRACES	16	3	16	100
2026-065	013	BAYER CLI		074 076	074 076		075 - 250mg/dl-+	16	13	16	100
2026-065	067	URISCAN		075 077	074 076		073 - NEGATIVE	53	2	49	0
2026-065	067	URISCAN		075 077	074 076		074 - TRACES	53	3	49	100
2026-065	067	URISCAN		075 077	074 076		075 - 250mg/dl-+	53	13	49	100
2026-065	067	URISCAN		075 077	074 076		076 - 500mg/dl2+	53	26	49	100
2026-065	067	URISCAN		075 077	074 076		077 - 1000mg/dl	53	7	49	100
2026-065	067	URISCAN		075 077	074 076		078 - 2000mg/dl	53	2	49	0
2026-065	072	URS-9-TECO		074 076	074 076		073 - NEGATIVE	51	7	44	0
2026-065	072	URS-9-TECO		074 076	074 076		074 - TRACES	51	19	44	100
2026-065	072	URS-9-TECO		074 076	074 076		075 - 250mg/dl-+	51	23	44	100
2026-065	072	URS-9-TECO		074 076	074 076		076 - 500mg/dl2+	51	2	44	100
2026-065	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	36	34	36	100
2026-065	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	36	2	36	100
2026-065	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	164	3	161	0
2026-065	089	AIMSTRIP		074 076	074 076		074 - TRACES	164	23	161	100
2026-065	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	164	138	161	100
2026-065	094	CLINITEK		074 076	074 076		073 - NEGATIVE	102	3	99	0
2026-065	094	CLINITEK		074 076	074 076		074 - TRACES	102	48	99	100
2026-065	094	CLINITEK		074 076	074 076		075 - 250mg/dl-+	102	51	99	100
2026-065	102	ACON LAB		074 076	074 076		073 - NEGATIVE	109	3	105	0
2026-065	102	ACON LAB		074 076	074 076		074 - TRACES	109	13	105	100
2026-065	102	ACON LAB		074 076	074 076		075 - 250mg/dl-+	109	89	105	100
2026-065	102	ACON LAB		074 076	074 076		076 - 500mg/dl2+	109	3	105	100
2026-065	102	ACON LAB		074 076	074 076		077 - 1000mg/dl	109	1	105	0
2026-065	131	iCHEM VELO		075 077	074 076		076 - 500mg/dl2+	42	39	42	100
2026-065	131	iCHEM VELO		075 077	074 076		077 - 1000mg/dl	42	3	42	100
2026-065	140	MISSION A		074 076	074 076		074 - TRACES	36	2	36	100
2026-065	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	36	33	36	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	140	MISSION A		074 076	074 076		076 - 500mg/dl2+	36	1	36	100	
2026-065	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	45	2	45	100	
2026-065	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	45	42	45	100	
2026-065	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	45	1	45	100	
2026-065	147	Mission120		074 076	074 076		074 - TRACES	35	5	35	100	
2026-065	147	Mission120		074 076	074 076		075 - 250mg/dl-+	35	28	35	100	
2026-065	147	Mission120		074 076	074 076		076 - 500mg/dl2+	35	2	35	100	
2026-065	148	Mission500		074 076	074 076		073 - NEGATIVE	160	2	157	0	
2026-065	148	Mission500		074 076	074 076		074 - TRACES	160	8	157	100	
2026-065	148	Mission500		074 076	074 076		075 - 250mg/dl-+	160	149	157	100	
2026-065	148	Mission500		074 076	074 076		078 - 2000mg/dl	160	1	157	0	
2026-065	151	Clari. Uro		074 076	074 076		074 - TRACES	33	4	33	100	
2026-065	151	Clari. Uro		074 076	074 076		075 - 250mg/dl-+	33	29	33	100	
059 URINALYS.HG.OR BLOOD												
2026-061	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	29	1	29	100	
2026-061	011	AMES NM10S		068 069	068 069		069 - POS.(3+))	29	28	29	100	
2026-061	013	BAYER CLI		068 069	068 069		069 - POS.(3+))	16	16	16	100	
2026-061	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	53	5	53	100	
2026-061	067	URISCAN		068 069	068 069		069 - POS.(3+))	53	48	53	100	
2026-061	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	50	2	50	100	
2026-061	072	URS-9-TECO		068 069	068 069		069 - POS.(3+))	50	48	50	100	
2026-061	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	35	3	35	100	
2026-061	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+))	35	32	35	100	
2026-061	089	AIMSTRIP		068 069	068 069		066 - NEGATIVE	164	2	162	0	
2026-061	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	164	2	162	100	
2026-061	089	AIMSTRIP		068 069	068 069		069 - POS.(3+))	164	160	162	100	
2026-061	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	102	3	102	100	
2026-061	094	CLINITEK		068 069	068 069		069 - POS.(3+))	102	99	102	100	
2026-061	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	111	2	111	100	
2026-061	102	ACON LAB		068 069	068 069		069 - POS.(3+))	111	109	111	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-061	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	42	2	42	100	
2026-061	131	iCHEM VELO		068 069	068 069		069 - POS.(3+)	42	40	42	100	
2026-061	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	34	1	34	100	
2026-061	140	MISSION A		068 069	068 069		069 - POS.(3+)	34	33	34	100	
2026-061	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	45	4	45	100	
2026-061	145	CLINITEK		068 069	068 069		069 - POS.(3+)	45	41	45	100	
2026-061	147	Mission120		068 069	068 069		069 - POS.(3+)	36	36	36	100	
2026-061	148	Mission500		068 069	068 069		069 - POS.(3+)	160	160	160	100	
2026-061	151	Clari. Uro		068 069	068 069		069 - POS.(3+)	33	33	33	100	
059 URINALYS.HG.OR BLOOD												
2026-062	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	29	29	29	100	
2026-062	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	16	16	16	100	
2026-062	067	URISCAN		066 066	066 066		066 - NEGATIVE	53	53	53	100	
2026-062	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	50	50	50	100	
2026-062	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	35	35	35	100	
2026-062	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	164	162	162	100	
2026-062	089	AIMSTRIP		066 066	066 066		069 - POS.(3+)	164	2	162	0	
2026-062	094	CLINITEK		066 066	066 066		066 - NEGATIVE	102	102	102	100	
2026-062	102	ACON LAB		066 066	066 066		066 - NEGATIVE	111	111	111	100	
2026-062	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	42	42	42	100	
2026-062	140	MISSION A		066 066	066 066		066 - NEGATIVE	34	34	34	100	
2026-062	145	CLINITEK		066 066	066 066		066 - NEGATIVE	45	45	45	100	
2026-062	147	Mission120		066 066	066 066		066 - NEGATIVE	36	36	36	100	
2026-062	148	Mission500		066 066	066 066		066 - NEGATIVE	160	160	160	100	
2026-062	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2026-063	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	29	4	29	100	
2026-063	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	29	25	29	100	
2026-063	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	16	16	16	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	53	5	53	100	
2026-063	067	URISCAN		068 069	068 069		069 - POS.(3+))	53	48	53	100	
2026-063	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	50	2	50	100	
2026-063	072	URS-9-TECO		068 069	068 069		069 - POS.(3+))	50	48	50	100	
2026-063	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	35	3	35	100	
2026-063	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+))	35	32	35	100	
2026-063	089	AIMSTRIP		068 069	068 069		066 - NEGATIVE	164	1	163	0	
2026-063	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	164	3	163	100	
2026-063	089	AIMSTRIP		068 069	068 069		069 - POS.(3+))	164	160	163	100	
2026-063	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	102	6	102	100	
2026-063	094	CLINITEK		068 069	068 069		069 - POS.(3+))	102	96	102	100	
2026-063	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	111	1	111	100	
2026-063	102	ACON LAB		068 069	068 069		069 - POS.(3+))	111	110	111	100	
2026-063	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	42	3	42	100	
2026-063	131	iCHEM VELO		068 069	068 069		069 - POS.(3+))	42	39	42	100	
2026-063	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	34	1	34	100	
2026-063	140	MISSION A		068 069	068 069		069 - POS.(3+))	34	33	34	100	
2026-063	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	45	2	45	100	
2026-063	145	CLINITEK		068 069	068 069		069 - POS.(3+))	45	43	45	100	
2026-063	147	Mission120		068 069	068 069		069 - POS.(3+))	36	36	36	100	
2026-063	148	Mission500		068 069	068 069		068 - POS.(1-2+)	160	1	160	100	
2026-063	148	Mission500		068 069	068 069		069 - POS.(3+))	160	159	160	100	
2026-063	151	Clari. Uro		068 069	068 069		069 - POS.(3+))	33	33	33	100	
059 URINALYS.HG.OR BLOOD												
2026-064	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	29	2	29	100	
2026-064	011	AMES NM10S		068 069	068 069		069 - POS.(3+))	29	27	29	100	
2026-064	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	16	1	16	100	
2026-064	013	BAYER CLI		068 069	068 069		069 - POS.(3+))	16	15	16	100	
2026-064	067	URISCAN		068 069	068 069		067 - TRACES	53	1	52	0	
2026-064	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	53	8	52	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-064	067 URISCAN			068 069	068 069		069 - POS.(3+))	53	44	52	100	
2026-064	072 URS-9-TECO			068 069	068 069		068 - POS.(1-2+)	50	9	50	100	
2026-064	072 URS-9-TECO			068 069	068 069		069 - POS.(3+))	50	41	50	100	
2026-064	080 ROCHE (CHE			068 069	068 069		068 - POS.(1-2+)	35	3	35	100	
2026-064	080 ROCHE (CHE			068 069	068 069		069 - POS.(3+))	35	32	35	100	
2026-064	089 AIMSTRIP			068 069	068 069		068 - POS.(1-2+)	164	6	164	100	
2026-064	089 AIMSTRIP			068 069	068 069		069 - POS.(3+))	164	158	164	100	
2026-064	094 CLINITEK			068 069	068 069		066 - NEGATIVE	102	1	101	0	
2026-064	094 CLINITEK			068 069	068 069		068 - POS.(1-2+)	102	6	101	100	
2026-064	094 CLINITEK			068 069	068 069		069 - POS.(3+))	102	95	101	100	
2026-064	102 ACON LAB			068 069	068 069		068 - POS.(1-2+)	111	1	111	100	
2026-064	102 ACON LAB			068 069	068 069		069 - POS.(3+))	111	110	111	100	
2026-064	131 iCHEM VELO			067 069	068 069		067 - TRACES	42	1	42	100	
2026-064	131 iCHEM VELO			067 069	068 069		068 - POS.(1-2+)	42	38	42	100	
2026-064	131 iCHEM VELO			067 069	068 069		069 - POS.(3+))	42	3	42	100	
2026-064	140 MISSION A			068 069	068 069		066 - NEGATIVE	34	1	33	0	
2026-064	140 MISSION A			068 069	068 069		068 - POS.(1-2+)	34	1	33	100	
2026-064	140 MISSION A			068 069	068 069		069 - POS.(3+))	34	32	33	100	
2026-064	145 CLINITEK			068 069	068 069		068 - POS.(1-2+)	45	5	45	100	
2026-064	145 CLINITEK			068 069	068 069		069 - POS.(3+))	45	40	45	100	
2026-064	147 Mission120			068 069	068 069		068 - POS.(1-2+)	36	1	36	100	
2026-064	147 Mission120			068 069	068 069		069 - POS.(3+))	36	35	36	100	
2026-064	148 Mission500			068 069	068 069		069 - POS.(3+))	160	160	160	100	
2026-064	151 Clari. Uro			068 069	068 069		069 - POS.(3+))	33	33	33	100	
059 URINALYS.HG.OR BLOOD												
2026-065	011 AMES NM10S			066 066	066 066		066 - NEGATIVE	29	29	29	100	
2026-065	013 BAYER CLI			066 066	066 066		066 - NEGATIVE	16	16	16	100	
2026-065	067 URISCAN			066 066	066 066		066 - NEGATIVE	53	53	53	100	
2026-065	072 URS-9-TECO			066 066	066 066		066 - NEGATIVE	50	50	50	100	
2026-065	080 ROCHE (CHE			066 066	066 066		066 - NEGATIVE	35	35	35	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	089 AIMSTRIP			066 066	066 066		066 - NEGATIVE	164	163	163	100	
2026-065	089 AIMSTRIP			066 066	066 066		068 - POS.(1-2+)	164	1	163	0	
2026-065	094 CLINITEK			066 066	066 066		066 - NEGATIVE	102	100	100	100	
2026-065	094 CLINITEK			066 066	066 066		067 - TRACES	102	1	100	0	
2026-065	094 CLINITEK			066 066	066 066		069 - POS.(3+)	102	1	100	0	
2026-065	102 ACON LAB			066 066	066 066		066 - NEGATIVE	111	111	111	100	
2026-065	131 iCHEM VELO			066 066	066 066		066 - NEGATIVE	42	42	42	100	
2026-065	140 MISSION A			066 066	066 066		066 - NEGATIVE	34	34	34	100	
2026-065	145 CLINITEK			066 066	066 066		066 - NEGATIVE	45	45	45	100	
2026-065	147 Mission120			066 066	066 066		066 - NEGATIVE	36	36	36	100	
2026-065	148 Mission500			066 066	066 066		066 - NEGATIVE	160	159	159	100	
2026-065	148 Mission500			066 066	066 066		069 - POS.(3+)	160	1	159	0	
2026-065	151 Clari. Uro			066 066	066 066		066 - NEGATIVE	33	33	33	100	
060 URINALYSIS-KETONES												
2026-061	011 AMES NM10S			090 090	090 090		090 - NEGATIVE	29	29	29	100	
2026-061	013 BAYER CLI			090 090	090 090		090 - NEGATIVE	16	16	16	100	
2026-061	067 URISCAN			090 090	090 090		090 - NEGATIVE	53	53	53	100	
2026-061	072 URS-9-TECO			090 090	090 090		090 - NEGATIVE	49	49	49	100	
2026-061	080 ROCHE (CHE			090 090	090 090		090 - NEGATIVE	36	36	36	100	
2026-061	089 AIMSTRIP			090 090	090 090		090 - NEGATIVE	164	164	164	100	
2026-061	094 CLINITEK			090 090	090 090		090 - NEGATIVE	102	102	102	100	
2026-061	102 ACON LAB			090 090	090 090		090 - NEGATIVE	110	110	110	100	
2026-061	131 iCHEM VELO			090 090	090 090		090 - NEGATIVE	42	42	42	100	
2026-061	140 MISSION A			090 090	090 090		090 - NEGATIVE	38	38	38	100	
2026-061	145 CLINITEK			090 090	090 090		090 - NEGATIVE	45	45	45	100	
2026-061	147 Mission120			090 090	090 090		090 - NEGATIVE	35	35	35	100	
2026-061	148 Mission500			090 090	090 090		090 - NEGATIVE	159	159	159	100	
2026-061	151 Clari. Uro			090 090	090 090		090 - NEGATIVE	33	33	33	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
060 URINALYSIS-KETONES													
2026-062	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	29	29	29	100		
2026-062	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	16	16	16	100		
2026-062	067	URISCAN		090 090	090 090		090 - NEGATIVE	53	53	53	100		
2026-062	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	49	49	49	100		
2026-062	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100		
2026-062	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	164	164	164	100		
2026-062	094	CLINITEK		090 090	090 090		090 - NEGATIVE	102	102	102	100		
2026-062	102	ACON LAB		090 090	090 090		090 - NEGATIVE	110	110	110	100		
2026-062	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	42	42	42	100		
2026-062	140	MISSION A		090 090	090 090		090 - NEGATIVE	38	38	38	100		
2026-062	145	CLINITEK		090 090	090 090		090 - NEGATIVE	45	45	45	100		
2026-062	147	Mission120		090 090	090 090		090 - NEGATIVE	35	35	35	100		
2026-062	148	Mission500		090 090	090 090		090 - NEGATIVE	159	159	159	100		
2026-062	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	33	33	33	100		
2026-063	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	29	29	29	100		
2026-063	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	16	16	16	100		
2026-063	067	URISCAN		090 090	090 090		090 - NEGATIVE	53	53	53	100		
2026-063	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	49	48	48	100		
2026-063	072	URS-9-TECO		090 090	090 090		091 - TRACE	49	1	48	0		
2026-063	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100		
2026-063	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	164	164	164	100		
2026-063	094	CLINITEK		090 090	090 090		090 - NEGATIVE	102	102	102	100		
2026-063	102	ACON LAB		090 090	090 090		090 - NEGATIVE	110	110	110	100		
2026-063	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	42	42	42	100		
2026-063	140	MISSION A		090 090	090 090		090 - NEGATIVE	38	38	38	100		
2026-063	145	CLINITEK		090 090	090 090		090 - NEGATIVE	45	45	45	100		
2026-063	147	Mission120		090 090	090 090		090 - NEGATIVE	35	35	35	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2026-063	148	Mission500		090 090	090 090		090 - NEGATIVE	159	159	159	100		
2026-063	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	33	33	33	100		
060 URINALYSIS-KETONES													
2026-064	011	AMES NM10S		093 094	093 094		093 - MOD. (2+)	29	2	29	100		
2026-064	011	AMES NM10S		093 094	093 094		094 - LARGE-3-4+	29	27	29	100		
2026-064	013	BAYER CLI		093 094	093 094		094 - LARGE-3-4+	16	16	16	100		
2026-064	067	URISCAN		093 094	093 094		093 - MOD. (2+)	53	12	53	100		
2026-064	067	URISCAN		093 094	093 094		094 - LARGE-3-4+	53	41	53	100		
2026-064	072	URS-9-TECO		093 094	093 094		093 - MOD. (2+)	49	2	49	100		
2026-064	072	URS-9-TECO		093 094	093 094		094 - LARGE-3-4+	49	47	49	100		
2026-064	080	ROCHE (CHE		093 094	093 094		093 - MOD. (2+)	36	3	36	100		
2026-064	080	ROCHE (CHE		093 094	093 094		094 - LARGE-3-4+	36	33	36	100		
2026-064	089	AIMSTRIP		093 094	093 094		092 - SMALL (1+)	164	2	162	0		
2026-064	089	AIMSTRIP		093 094	093 094		094 - LARGE-3-4+	164	162	162	100		
2026-064	094	CLINITEK		093 094	093 094		093 - MOD. (2+)	102	6	102	100		
2026-064	094	CLINITEK		093 094	093 094		094 - LARGE-3-4+	102	96	102	100		
2026-064	102	ACON LAB		093 094	093 094		093 - MOD. (2+)	110	2	110	100		
2026-064	102	ACON LAB		093 094	093 094		094 - LARGE-3-4+	110	108	110	100		
2026-064	131	iCHEM VELO		093 094	093 094		093 - MOD. (2+)	42	20	42	100		
2026-064	131	iCHEM VELO		093 094	093 094		094 - LARGE-3-4+	42	22	42	100		
2026-064	140	MISSION A		093 094	093 094		093 - MOD. (2+)	38	2	38	100		
2026-064	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	38	36	38	100		
2026-064	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	45	45	45	100		
2026-064	147	Mission120		093 094	093 094		094 - LARGE-3-4+	35	35	35	100		
2026-064	148	Mission500		093 094	093 094		090 - NEGATIVE	159	1	157	0		
2026-064	148	Mission500		093 094	093 094		092 - SMALL (1+)	159	1	157	0		
2026-064	148	Mission500		093 094	093 094		093 - MOD. (2+)	159	1	157	100		
2026-064	148	Mission500		093 094	093 094		094 - LARGE-3-4+	159	156	157	100		
2026-064	151	Clari. Uro		093 094	093 094		093 - MOD. (2+)	33	1	33	100		
2026-064	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	33	32	33	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
060 URINALYSIS-KETONES													
2026-065	011 AMES NM10S			092 094	092 094		092 - SMALL (1+)	29	4	29	100		
2026-065	011 AMES NM10S			092 094	092 094		093 - MOD. (2+)	29	20	29	100		
2026-065	011 AMES NM10S			092 094	092 094		094 - LARGE-3-4+	29	5	29	100		
2026-065	013 BAYER CLI			092 094	092 094		092 - SMALL (1+)	16	7	16	100		
2026-065	013 BAYER CLI			092 094	092 094		093 - MOD. (2+)	16	9	16	100		
2026-065	067 URISCAN			092 094	092 094		092 - SMALL (1+)	53	4	53	100		
2026-065	067 URISCAN			092 094	092 094		093 - MOD. (2+)	53	40	53	100		
2026-065	067 URISCAN			092 094	092 094		094 - LARGE-3-4+	53	9	53	100		
2026-065	072 URS-9-TECO			092 094	092 094		092 - SMALL (1+)	49	3	49	100		
2026-065	072 URS-9-TECO			092 094	092 094		093 - MOD. (2+)	49	39	49	100		
2026-065	072 URS-9-TECO			092 094	092 094		094 - LARGE-3-4+	49	7	49	100		
2026-065	080 ROCHE (CHE			092 094	092 094		092 - SMALL (1+)	36	10	36	100		
2026-065	080 ROCHE (CHE			092 094	092 094		093 - MOD. (2+)	36	22	36	100		
2026-065	080 ROCHE (CHE			092 094	092 094		094 - LARGE-3-4+	36	4	36	100		
2026-065	089 AIMSTRIP			092 094	092 094		090 - NEGATIVE	164	1	162	0		
2026-065	089 AIMSTRIP			092 094	092 094		091 - TRACE	164	1	162	0		
2026-065	089 AIMSTRIP			092 094	092 094		092 - SMALL (1+)	164	21	162	100		
2026-065	089 AIMSTRIP			092 094	092 094		093 - MOD. (2+)	164	104	162	100		
2026-065	089 AIMSTRIP			092 094	092 094		094 - LARGE-3-4+	164	37	162	100		
2026-065	094 CLINITEK			092 094	092 094		091 - TRACE	102	1	101	0		
2026-065	094 CLINITEK			092 094	092 094		092 - SMALL (1+)	102	20	101	100		
2026-065	094 CLINITEK			092 094	092 094		093 - MOD. (2+)	102	75	101	100		
2026-065	094 CLINITEK			092 094	092 094		094 - LARGE-3-4+	102	6	101	100		
2026-065	102 ACON LAB			092 094	092 094		090 - NEGATIVE	110	1	109	0		
2026-065	102 ACON LAB			092 094	092 094		092 - SMALL (1+)	110	13	109	100		
2026-065	102 ACON LAB			092 094	092 094		093 - MOD. (2+)	110	73	109	100		
2026-065	102 ACON LAB			092 094	092 094		094 - LARGE-3-4+	110	23	109	100		
2026-065	131 iCHEM VELO			091 093	092 094		092 - SMALL (1+)	42	34	42	100		
2026-065	131 iCHEM VELO			091 093	092 094		093 - MOD. (2+)	42	8	42	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	140 MISSION A			092 094	092 094		090 - NEGATIVE	38	1	37	0	
2026-065	140 MISSION A			092 094	092 094		092 - SMALL (1+)	38	3	37	100	
2026-065	140 MISSION A			092 094	092 094		093 - MOD. (2+)	38	19	37	100	
2026-065	140 MISSION A			092 094	092 094		094 - LARGE-3-4+	38	15	37	100	
2026-065	145 CLINITEK			092 094	092 094		092 - SMALL (1+)	45	3	45	100	
2026-065	145 CLINITEK			092 094	092 094		093 - MOD. (2+)	45	41	45	100	
2026-065	145 CLINITEK			092 094	092 094		094 - LARGE-3-4+	45	1	45	100	
2026-065	147 Mission120			093 094	092 094		092 - SMALL (1+)	35	1	35	100	
2026-065	147 Mission120			093 094	092 094		093 - MOD. (2+)	35	16	35	100	
2026-065	147 Mission120			093 094	092 094		094 - LARGE-3-4+	35	18	35	100	
2026-065	148 Mission500			092 094	092 094		090 - NEGATIVE	159	1	158	0	
2026-065	148 Mission500			092 094	092 094		092 - SMALL (1+)	159	3	158	100	
2026-065	148 Mission500			092 094	092 094		093 - MOD. (2+)	159	138	158	100	
2026-065	148 Mission500			092 094	092 094		094 - LARGE-3-4+	159	17	158	100	
2026-065	151 Clari. Uro			092 094	092 094		091 - TRACE	33	1	32	0	
2026-065	151 Clari. Uro			092 094	092 094		092 - SMALL (1+)	33	1	32	100	
2026-065	151 Clari. Uro			092 094	092 094		093 - MOD. (2+)	33	24	32	100	
2026-065	151 Clari. Uro			092 094	092 094		094 - LARGE-3-4+	33	7	32	100	
061 URINALYSIS-NITRATE												
2026-061	011 AMES NM10S			070 070	070 070		070 - NEGATIVE	29	29	29	100	
2026-061	013 BAYER CLI			070 070	070 070		070 - NEGATIVE	17	17	17	100	
2026-061	067 URISCAN			070 070	070 070		070 - NEGATIVE	53	53	53	100	
2026-061	072 URS-9-TECO			070 070	070 070		070 - NEGATIVE	50	50	50	100	
2026-061	080 ROCHE (CHE			070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-061	089 AIMSTRIP			070 070	070 070		070 - NEGATIVE	164	164	164	100	
2026-061	094 CLINITEK			070 070	070 070		070 - NEGATIVE	102	102	102	100	
2026-061	102 ACON LAB			070 070	070 070		070 - NEGATIVE	110	110	110	100	
2026-061	131 iCHEM VELO			070 070	070 070		070 - NEGATIVE	42	42	42	100	
2026-061	140 MISSION A			070 070	070 070		070 - NEGATIVE	35	35	35	100	
2026-061	145 CLINITEK			070 070	070 070		070 - NEGATIVE	45	45	45	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-061	147	Mission120		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-061	148	Mission500		070 070	070 070		070 - NEGATIVE	159	159	159	100	
2026-061	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	33	33	33	100	
061 URINALYSIS-NITRATE												
2026-062	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	29	29	29	100	
2026-062	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	17	17	17	100	
2026-062	067	URISCAN		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2026-062	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	50	50	50	100	
2026-062	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-062	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	164	164	164	100	
2026-062	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	102	102	100	
2026-062	102	ACON LAB		070 070	070 070		070 - NEGATIVE	110	110	110	100	
2026-062	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	42	42	42	100	
2026-062	140	MISSION A		070 070	070 070		070 - NEGATIVE	35	35	35	100	
2026-062	145	CLINITEK		070 070	070 070		070 - NEGATIVE	45	45	45	100	
2026-062	147	Mission120		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-062	148	Mission500		070 070	070 070		070 - NEGATIVE	159	159	159	100	
2026-062	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	33	33	33	100	
2026-063	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	29	29	29	100	
2026-063	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	17	17	17	100	
2026-063	067	URISCAN		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2026-063	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	50	50	50	100	
2026-063	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-063	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	164	164	164	100	
2026-063	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	102	102	100	
2026-063	102	ACON LAB		070 070	070 070		070 - NEGATIVE	110	110	110	100	
2026-063	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	42	42	42	100	
2026-063	140	MISSION A		070 070	070 070		070 - NEGATIVE	35	35	35	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	145	CLINITEK		070 070	070 070		070 - NEGATIVE	45	45	45	100	
2026-063	147	Mission120		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-063	148	Mission500		070 070	070 070		070 - NEGATIVE	159	159	159	100	
2026-063	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	33	33	33	100	
061 URINALYSIS-NITRATE												
2026-064	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	29	29	29	100	
2026-064	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	17	17	17	100	
2026-064	067	URISCAN		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2026-064	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	50	50	50	100	
2026-064	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-064	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	164	164	164	100	
2026-064	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	101	101	100	
2026-064	094	CLINITEK		070 070	070 070		072 - POSITIVE	102	1	101	0	
2026-064	102	ACON LAB		070 070	070 070		070 - NEGATIVE	110	110	110	100	
2026-064	131	ICHEM VELO		070 070	070 070		070 - NEGATIVE	42	42	42	100	
2026-064	140	MISSION A		070 070	070 070		070 - NEGATIVE	35	34	34	100	
2026-064	140	MISSION A		070 070	070 070		072 - POSITIVE	35	1	34	0	
2026-064	145	CLINITEK		070 070	070 070		070 - NEGATIVE	45	45	45	100	
2026-064	147	Mission120		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2026-064	148	Mission500		070 070	070 070		070 - NEGATIVE	159	159	159	100	
2026-064	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	33	33	33	100	
2026-065	011	AMES NM10S		071 072	071 072		072 - POSITIVE	29	29	29	100	
2026-065	013	BAYER CLI		071 072	071 072		072 - POSITIVE	17	17	17	100	
2026-065	067	URISCAN		071 072	071 072		072 - POSITIVE	53	53	53	100	
2026-065	072	URS-9-TECO		071 072	071 072		072 - POSITIVE	50	50	50	100	
2026-065	080	ROCHE (CHE		071 072	071 072		072 - POSITIVE	36	36	36	100	
2026-065	089	AIMSTRIP		071 072	071 072		071 - WEAK POS.	164	1	164	100	
2026-065	089	AIMSTRIP		071 072	071 072		072 - POSITIVE	164	163	164	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	094	CLINITEK		071 072	071 072		070 - NEGATIVE	102	1	101	0	
2026-065	094	CLINITEK		071 072	071 072		072 - POSITIVE	102	101	101	100	
2026-065	102	ACON LAB		071 072	071 072		072 - POSITIVE	110	110	110	100	
2026-065	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	42	42	42	100	
2026-065	140	MISSION A		071 072	071 072		072 - POSITIVE	35	35	35	100	
2026-065	145	CLINITEK		071 072	071 072		072 - POSITIVE	45	45	45	100	
2026-065	147	Mission120		071 072	071 072		072 - POSITIVE	36	36	36	100	
2026-065	148	Mission500		071 072	071 072		070 - NEGATIVE	159	1	158	0	
2026-065	148	Mission500		071 072	071 072		072 - POSITIVE	159	158	158	100	
2026-065	151	Clari. Uro		071 072	071 072		072 - POSITIVE	33	33	33	100	
062 URINALYSIS-pH												
2026-061	011	AMES NM10S		084 088	083 087		085 - 6.5	29	11	29	100	
2026-061	011	AMES NM10S		084 088	083 087		086 - 7.0	29	18	29	100	
2026-061	013	BAYER CLI		084 088	083 087		085 - 6.5	16	4	16	100	
2026-061	013	BAYER CLI		084 088	083 087		086 - 7.0	16	12	16	100	
2026-061	067	URISCAN		083 087	083 087		082 - 5.0	53	1	52	0	
2026-061	067	URISCAN		083 087	083 087		084 - 6.0	53	7	52	100	
2026-061	067	URISCAN		083 087	083 087		085 - 6.5	53	45	52	100	
2026-061	072	URS-9-TECO		083 087	083 087		084 - 6.0	50	3	50	100	
2026-061	072	URS-9-TECO		083 087	083 087		085 - 6.5	50	40	50	100	
2026-061	072	URS-9-TECO		083 087	083 087		086 - 7.0	50	7	50	100	
2026-061	080	ROCHE (CHE		083 087	083 087		084 - 6.0	36	1	36	100	
2026-061	080	ROCHE (CHE		083 087	083 087		085 - 6.5	36	35	36	100	
2026-061	089	AIMSTRIP		083 087	083 087		084 - 6.0	164	20	164	100	
2026-061	089	AIMSTRIP		083 087	083 087		085 - 6.5	164	112	164	100	
2026-061	089	AIMSTRIP		083 087	083 087		086 - 7.0	164	32	164	100	
2026-061	094	CLINITEK		084 088	083 087		084 - 6.0	102	2	102	100	
2026-061	094	CLINITEK		084 088	083 087		085 - 6.5	102	28	102	100	
2026-061	094	CLINITEK		084 088	083 087		086 - 7.0	102	71	102	100	
2026-061	094	CLINITEK		084 088	083 087		087 - 7.5	102	1	102	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-061	102	ACON LAB		083 087	083 087		082 - 5.0	113	1	111	0	
2026-061	102	ACON LAB		083 087	083 087		083 - 5.5	113	1	111	100	
2026-061	102	ACON LAB		083 087	083 087		084 - 6.0	113	10	111	100	
2026-061	102	ACON LAB		083 087	083 087		085 - 6.5	113	90	111	100	
2026-061	102	ACON LAB		083 087	083 087		086 - 7.0	113	10	111	100	
2026-061	102	ACON LAB		083 087	083 087		088 - 8.0OR MORE	113	1	111	0	
2026-061	131	iCHEM VELO		082 086	083 087		084 - 6.0	42	42	42	100	
2026-061	140	MISSION A		083 087	083 087		084 - 6.0	36	4	36	100	
2026-061	140	MISSION A		083 087	083 087		085 - 6.5	36	30	36	100	
2026-061	140	MISSION A		083 087	083 087		086 - 7.0	36	2	36	100	
2026-061	145	CLINITEK		083 087	083 087		085 - 6.5	45	45	45	100	
2026-061	147	Mission120		083 087	083 087		084 - 6.0	35	2	35	100	
2026-061	147	Mission120		083 087	083 087		085 - 6.5	35	33	35	100	
2026-061	148	Mission500		083 087	083 087		084 - 6.0	157	6	157	100	
2026-061	148	Mission500		083 087	083 087		085 - 6.5	157	148	157	100	
2026-061	148	Mission500		083 087	083 087		086 - 7.0	157	3	157	100	
2026-061	151	Clari. Uro		082 086	083 087		084 - 6.0	33	18	33	100	
2026-061	151	Clari. Uro		082 086	083 087		085 - 6.5	33	13	33	100	
2026-061	151	Clari. Uro		082 086	083 087		086 - 7.0	33	2	33	100	
062 URINALYSIS-pH												
2026-062	011	AMES NM10S		085 088	085 088		086 - 7.0	29	5	29	100	
2026-062	011	AMES NM10S		085 088	085 088		087 - 7.5	29	24	29	100	
2026-062	013	BAYER CLI		085 088	085 088		086 - 7.0	16	5	16	100	
2026-062	013	BAYER CLI		085 088	085 088		087 - 7.5	16	11	16	100	
2026-062	067	URISCAN		084 088	085 088		086 - 7.0	53	41	53	100	
2026-062	067	URISCAN		084 088	085 088		087 - 7.5	53	12	53	100	
2026-062	072	URS-9-TECO		084 088	085 088		086 - 7.0	50	32	50	100	
2026-062	072	URS-9-TECO		084 088	085 088		087 - 7.5	50	18	50	100	
2026-062	080	ROCHE (CHE		084 088	085 088		086 - 7.0	36	36	36	100	
2026-062	089	AIMSTRIP		084 088	085 088		086 - 7.0	164	125	164	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-062	089	AIMSTRIP		084 088	085 088		087 - 7.5	164	39	164	100
2026-062	094	CLINITEK		085 088	085 088		086 - 7.0	102	20	102	100
2026-062	094	CLINITEK		085 088	085 088		087 - 7.5	102	82	102	100
2026-062	102	ACON LAB		084 088	085 088		085 - 6.5	113	1	113	100
2026-062	102	ACON LAB		084 088	085 088		086 - 7.0	113	91	113	100
2026-062	102	ACON LAB		084 088	085 088		087 - 7.5	113	21	113	100
2026-062	131	iCHEM VELO		084 088	085 088		086 - 7.0	42	42	42	100
2026-062	140	MISSION A		084 088	085 088		086 - 7.0	36	29	36	100
2026-062	140	MISSION A		084 088	085 088		087 - 7.5	36	7	36	100
2026-062	145	CLINITEK		085 088	085 088		086 - 7.0	45	1	45	100
2026-062	145	CLINITEK		085 088	085 088		087 - 7.5	45	44	45	100
2026-062	147	Mission120		084 088	085 088		086 - 7.0	35	34	35	100
2026-062	147	Mission120		084 088	085 088		087 - 7.5	35	1	35	100
2026-062	148	Mission500		084 088	085 088		084 - 6.0	157	1	157	100
2026-062	148	Mission500		084 088	085 088		085 - 6.5	157	1	157	100
2026-062	148	Mission500		084 088	085 088		086 - 7.0	157	149	157	100
2026-062	148	Mission500		084 088	085 088		087 - 7.5	157	6	157	100
2026-062	151	Clari. Uro		084 088	085 088		086 - 7.0	33	26	33	100
2026-062	151	Clari. Uro		084 088	085 088		087 - 7.5	33	7	33	100
062 URINALYSIS-pH											
2026-063	011	AMES NM10S		085 088	084 088		086 - 7.0	29	7	29	100
2026-063	011	AMES NM10S		085 088	084 088		087 - 7.5	29	22	29	100
2026-063	013	BAYER CLI		085 088	084 088		086 - 7.0	16	6	16	100
2026-063	013	BAYER CLI		085 088	084 088		087 - 7.5	16	10	16	100
2026-063	067	URISCAN		084 088	084 088		085 - 6.5	53	4	53	100
2026-063	067	URISCAN		084 088	084 088		086 - 7.0	53	43	53	100
2026-063	067	URISCAN		084 088	084 088		087 - 7.5	53	6	53	100
2026-063	072	URS-9-TECO		084 088	084 088		085 - 6.5	50	3	50	100
2026-063	072	URS-9-TECO		084 088	084 088		086 - 7.0	50	34	50	100
2026-063	072	URS-9-TECO		084 088	084 088		087 - 7.5	50	13	50	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	080	ROCHE (CHE		084	088	084	088	086 - 7.0	36	36	36	100
2026-063	089	AIMSTRIP		084	088	084	088	086 - 7.0	164	130	164	100
2026-063	089	AIMSTRIP		084	088	084	088	087 - 7.5	164	34	164	100
2026-063	094	CLINITEK		085	088	084	088	086 - 7.0	102	23	102	100
2026-063	094	CLINITEK		085	088	084	088	087 - 7.5	102	79	102	100
2026-063	102	ACON LAB		084	088	084	088	084 - 6.0	113	1	113	100
2026-063	102	ACON LAB		084	088	084	088	085 - 6.5	113	1	113	100
2026-063	102	ACON LAB		084	088	084	088	086 - 7.0	113	91	113	100
2026-063	102	ACON LAB		084	088	084	088	087 - 7.5	113	20	113	100
2026-063	131	ICHEM VELO		084	088	084	088	086 - 7.0	42	42	42	100
2026-063	140	MISSION A		084	088	084	088	085 - 6.5	36	1	36	100
2026-063	140	MISSION A		084	088	084	088	086 - 7.0	36	33	36	100
2026-063	140	MISSION A		084	088	084	088	087 - 7.5	36	2	36	100
2026-063	145	CLINITEK		085	088	084	088	086 - 7.0	45	15	45	100
2026-063	145	CLINITEK		085	088	084	088	087 - 7.5	45	30	45	100
2026-063	147	Mission120		084	088	084	088	086 - 7.0	35	34	35	100
2026-063	147	Mission120		084	088	084	088	087 - 7.5	35	1	35	100
2026-063	148	Mission500		084	088	084	088	085 - 6.5	157	1	157	100
2026-063	148	Mission500		084	088	084	088	086 - 7.0	157	151	157	100
2026-063	148	Mission500		084	088	084	088	087 - 7.5	157	5	157	100
2026-063	151	Clari. Uro		084	088	084	088	086 - 7.0	33	30	33	100
2026-063	151	Clari. Uro		084	088	084	088	087 - 7.5	33	3	33	100
062 URINALYSIS-pH												
2026-064	011	AMES NM10S		086	088	085	088	087 - 7.5	29	9	29	100
2026-064	011	AMES NM10S		086	088	085	088	088 - 8.0OR MORE	29	20	29	100
2026-064	013	BAYER CLI		085	088	085	088	087 - 7.5	16	9	16	100
2026-064	013	BAYER CLI		085	088	085	088	088 - 8.0OR MORE	16	7	16	100
2026-064	067	URISCAN		085	088	085	088	086 - 7.0	53	6	53	100
2026-064	067	URISCAN		085	088	085	088	087 - 7.5	53	42	53	100
2026-064	067	URISCAN		085	088	085	088	088 - 8.0OR MORE	53	5	53	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-064	072	URS-9-TECO		085 088	085 088		086 - 7.0	50	3	50	100	
2026-064	072	URS-9-TECO		085 088	085 088		087 - 7.5	50	33	50	100	
2026-064	072	URS-9-TECO		085 088	085 088		088 - 8.0OR MORE	50	14	50	100	
2026-064	080	ROCHE (CHE		084 088	085 088		086 - 7.0	36	29	36	100	
2026-064	080	ROCHE (CHE		084 088	085 088		087 - 7.5	36	1	36	100	
2026-064	080	ROCHE (CHE		084 088	085 088		088 - 8.0OR MORE	36	6	36	100	
2026-064	089	AIMSTRIP		085 088	085 088		086 - 7.0	164	2	164	100	
2026-064	089	AIMSTRIP		085 088	085 088		087 - 7.5	164	102	164	100	
2026-064	089	AIMSTRIP		085 088	085 088		088 - 8.0OR MORE	164	60	164	100	
2026-064	094	CLINITEK		086 088	085 088		083 - 5.5	102	1	101	0	
2026-064	094	CLINITEK		086 088	085 088		086 - 7.0	102	1	101	100	
2026-064	094	CLINITEK		086 088	085 088		087 - 7.5	102	37	101	100	
2026-064	094	CLINITEK		086 088	085 088		088 - 8.0OR MORE	102	63	101	100	
2026-064	102	ACON LAB		085 088	085 088		086 - 7.0	113	6	113	100	
2026-064	102	ACON LAB		085 088	085 088		087 - 7.5	113	78	113	100	
2026-064	102	ACON LAB		085 088	085 088		088 - 8.0OR MORE	113	29	113	100	
2026-064	131	iCHEM VELO		084 088	085 088		086 - 7.0	42	42	42	100	
2026-064	140	MISSION A		085 088	085 088		084 - 6.0	36	1	35	0	
2026-064	140	MISSION A		085 088	085 088		086 - 7.0	36	2	35	100	
2026-064	140	MISSION A		085 088	085 088		087 - 7.5	36	28	35	100	
2026-064	140	MISSION A		085 088	085 088		088 - 8.0OR MORE	36	5	35	100	
2026-064	145	CLINITEK		085 088	085 088		087 - 7.5	45	44	45	100	
2026-064	145	CLINITEK		085 088	085 088		088 - 8.0OR MORE	45	1	45	100	
2026-064	147	Mission120		085 088	085 088		087 - 7.5	35	33	35	100	
2026-064	147	Mission120		085 088	085 088		088 - 8.0OR MORE	35	2	35	100	
2026-064	148	Mission500		085 088	085 088		085 - 6.5	157	1	157	100	
2026-064	148	Mission500		085 088	085 088		086 - 7.0	157	4	157	100	
2026-064	148	Mission500		085 088	085 088		087 - 7.5	157	107	157	100	
2026-064	148	Mission500		085 088	085 088		088 - 8.0OR MORE	157	45	157	100	
2026-064	151	Clari. Uro		085 088	085 088		087 - 7.5	33	25	33	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2026-064	151	Clari. Uro		085 088	085 088		088 - 8.00R MORE	33	8	33	100		
062 URINALYSIS-pH													
2026-065	011	AMES NM10S		082 086	080 084		082 - 5.0	29	4	29	100		
2026-065	011	AMES NM10S		082 086	080 084		083 - 5.5	29	11	29	100		
2026-065	011	AMES NM10S		082 086	080 084		084 - 6.0	29	14	29	100		
2026-065	013	BAYER CLI		081 085	080 084		082 - 5.0	16	5	16	100		
2026-065	013	BAYER CLI		081 085	080 084		083 - 5.5	16	7	16	100		
2026-065	013	BAYER CLI		081 085	080 084		084 - 6.0	16	4	16	100		
2026-065	067	URISCAN		080 084	080 084		082 - 5.0	53	46	53	100		
2026-065	067	URISCAN		080 084	080 084		083 - 5.5	53	7	53	100		
2026-065	072	URS-9-TECO		082 086	080 084		082 - 5.0	50	13	50	100		
2026-065	072	URS-9-TECO		082 086	080 084		083 - 5.5	50	8	50	100		
2026-065	072	URS-9-TECO		082 086	080 084		084 - 6.0	50	25	50	100		
2026-065	072	URS-9-TECO		082 086	080 084		085 - 6.5	50	4	50	100		
2026-065	080	ROCHE (CHE		080 084	080 084		082 - 5.0	36	29	36	100		
2026-065	080	ROCHE (CHE		080 084	080 084		084 - 6.0	36	7	36	100		
2026-065	089	AIMSTRIP		082 086	080 084		082 - 5.0	164	16	164	100		
2026-065	089	AIMSTRIP		082 086	080 084		083 - 5.5	164	37	164	100		
2026-065	089	AIMSTRIP		082 086	080 084		084 - 6.0	164	110	164	100		
2026-065	089	AIMSTRIP		082 086	080 084		085 - 6.5	164	1	164	100		
2026-065	094	CLINITEK		082 086	080 084		082 - 5.0	102	10	101	100		
2026-065	094	CLINITEK		082 086	080 084		083 - 5.5	102	35	101	100		
2026-065	094	CLINITEK		082 086	080 084		084 - 6.0	102	56	101	100		
2026-065	094	CLINITEK		082 086	080 084		088 - 8.00R MORE	102	1	101	0		
2026-065	102	ACON LAB		082 086	080 084		082 - 5.0	113	23	113	100		
2026-065	102	ACON LAB		082 086	080 084		083 - 5.5	113	17	113	100		
2026-065	102	ACON LAB		082 086	080 084		084 - 6.0	113	72	113	100		
2026-065	102	ACON LAB		082 086	080 084		085 - 6.5	113	1	113	100		
2026-065	131	iCHEM VELO		080 084	080 084		082 - 5.0	42	42	42	100		
2026-065	140	MISSION A		082 086	080 084		082 - 5.0	36	2	36	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	140	MISSION A		082 086	080 084		083 - 5.5	36	15	36	100	
2026-065	140	MISSION A		082 086	080 084		084 - 6.0	36	19	36	100	
2026-065	145	CLINITEK		081 085	080 084		082 - 5.0	45	17	45	100	
2026-065	145	CLINITEK		081 085	080 084		083 - 5.5	45	28	45	100	
2026-065	147	Mission120		081 085	080 084		082 - 5.0	35	8	35	100	
2026-065	147	Mission120		081 085	080 084		083 - 5.5	35	23	35	100	
2026-065	147	Mission120		081 085	080 084		084 - 6.0	35	4	35	100	
2026-065	148	Mission500		082 086	080 084		082 - 5.0	157	1	157	100	
2026-065	148	Mission500		082 086	080 084		083 - 5.5	157	1	157	100	
2026-065	148	Mission500		082 086	080 084		084 - 6.0	157	154	157	100	
2026-065	148	Mission500		082 086	080 084		086 - 7.0	157	1	157	100	
2026-065	151	Clari. Uro		082 086	080 084		082 - 5.0	33	2	33	100	
2026-065	151	Clari. Uro		082 086	080 084		083 - 5.5	33	5	33	100	
2026-065	151	Clari. Uro		082 086	080 084		084 - 6.0	33	26	33	100	
064 URIN-PROTEIN QUALI.												
2026-061	011	AMES NM10S		053 055	053 055		054 - 2+	30	22	30	100	
2026-061	011	AMES NM10S		053 055	053 055		053 - 1+	30	1	30	100	
2026-061	011	AMES NM10S		053 055	053 055		055 - 3+	30	7	30	100	
2026-061	013	BAYER CLI		053 055	053 055		054 - 2+	16	14	16	100	
2026-061	013	BAYER CLI		053 055	053 055		055 - 3+	16	2	16	100	
2026-061	067	URISCAN		052 054	053 055		054 - 2+	54	24	54	100	
2026-061	067	URISCAN		052 054	053 055		053 - 1+	54	28	54	100	
2026-061	067	URISCAN		052 054	053 055		055 - 3+	54	2	54	100	
2026-061	072	URS-9-TECO		053 055	053 055		054 - 2+	50	39	50	100	
2026-061	072	URS-9-TECO		053 055	053 055		053 - 1+	50	6	50	100	
2026-061	072	URS-9-TECO		053 055	053 055		055 - 3+	50	5	50	100	
2026-061	080	ROCHE (CHE		053 055	053 055		054 - 2+	36	27	34	100	
2026-061	080	ROCHE (CHE		053 055	053 055		055 - 3+	36	7	34	100	
2026-061	080	ROCHE (CHE		053 055	053 055		056 - 4+	36	2	34	0	
2026-061	089	AIMSTRIP		053 055	053 055		054 - 2+	163	145	162	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-061	089	AIMSTRIP		053 055	053 055		053 - 1+	163	5	162	100
2026-061	089	AIMSTRIP		053 055	053 055		055 - 3+	163	12	162	100
2026-061	089	AIMSTRIP		053 055	053 055		056 - 4+	163	1	162	0
2026-061	094	CLINITEK		053 055	053 055		054 - 2+	102	93	101	100
2026-061	094	CLINITEK		053 055	053 055		052 - TRACES	102	1	101	0
2026-061	094	CLINITEK		053 055	053 055		053 - 1+	102	1	101	100
2026-061	094	CLINITEK		053 055	053 055		055 - 3+	102	7	101	100
2026-061	102	ACON LAB		053 055	053 055		054 - 2+	110	93	109	100
2026-061	102	ACON LAB		053 055	053 055		052 - TRACES	110	1	109	0
2026-061	102	ACON LAB		053 055	053 055		053 - 1+	110	10	109	100
2026-061	102	ACON LAB		053 055	053 055		055 - 3+	110	6	109	100
2026-061	131	iCHEM VELO		053 055	053 055		054 - 2+	40	33	40	100
2026-061	131	iCHEM VELO		053 055	053 055		053 - 1+	40	2	40	100
2026-061	131	iCHEM VELO		053 055	053 055		055 - 3+	40	5	40	100
2026-061	140	MISSION A		053 055	053 055		054 - 2+	35	31	35	100
2026-061	140	MISSION A		053 055	053 055		053 - 1+	35	1	35	100
2026-061	140	MISSION A		053 055	053 055		055 - 3+	35	3	35	100
2026-061	145	CLINITEK		053 055	053 055		054 - 2+	46	42	46	100
2026-061	145	CLINITEK		053 055	053 055		053 - 1+	46	2	46	100
2026-061	145	CLINITEK		053 055	053 055		055 - 3+	46	2	46	100
2026-061	147	Mission120		053 055	053 055		054 - 2+	36	25	36	100
2026-061	147	Mission120		053 055	053 055		053 - 1+	36	11	36	100
2026-061	148	Mission500		053 055	053 055		054 - 2+	159	142	158	100
2026-061	148	Mission500		053 055	053 055		052 - TRACES	159	1	158	0
2026-061	148	Mission500		053 055	053 055		053 - 1+	159	11	158	100
2026-061	148	Mission500		053 055	053 055		055 - 3+	159	5	158	100
2026-061	151	Clari. Uro		053 055	053 055		054 - 2+	33	30	33	100
2026-061	151	Clari. Uro		053 055	053 055		053 - 1+	33	1	33	100
2026-061	151	Clari. Uro		053 055	053 055		055 - 3+	33	2	33	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
064 URIN-PROTEIN QUALI.													
2026-062	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	30	30	30	100		
2026-062	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	16	16	16	100		
2026-062	067	URISCAN		051 051	051 051		051 - NEGATIVE	54	54	54	100		
2026-062	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	50	49	49	100		
2026-062	072	URS-9-TECO		051 051	051 051		052 - TRACES	50	1	49	0		
2026-062	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	36	32	32	100		
2026-062	080	ROCHE (CHE		051 051	051 051		052 - TRACES	36	4	32	0		
2026-062	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	163	161	161	100		
2026-062	089	AIMSTRIP		051 051	051 051		052 - TRACES	163	2	161	0		
2026-062	094	CLINITEK		051 051	051 051		051 - NEGATIVE	102	102	102	100		
2026-062	102	ACON LAB		051 051	051 051		051 - NEGATIVE	110	110	110	100		
2026-062	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	40	40	40	100		
2026-062	140	MISSION A		051 051	051 051		051 - NEGATIVE	35	35	35	100		
2026-062	145	CLINITEK		051 051	051 051		051 - NEGATIVE	46	46	46	100		
2026-062	147	Mission120		051 051	051 051		051 - NEGATIVE	36	36	36	100		
2026-062	148	Mission500		051 051	051 051		051 - NEGATIVE	159	159	159	100		
2026-062	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	33	32	32	100		
2026-062	151	Clari. Uro		051 051	051 051		052 - TRACES	33	1	32	0		
2026-063	011	AMES NM10S		053 055	053 055		054 - 2+	30	19	30	100		
2026-063	011	AMES NM10S		053 055	053 055		053 - 1+	30	1	30	100		
2026-063	011	AMES NM10S		053 055	053 055		055 - 3+	30	10	30	100		
2026-063	013	BAYER CLI		053 055	053 055		054 - 2+	16	12	16	100		
2026-063	013	BAYER CLI		053 055	053 055		055 - 3+	16	4	16	100		
2026-063	067	URISCAN		053 055	053 055		054 - 2+	54	36	54	100		
2026-063	067	URISCAN		053 055	053 055		053 - 1+	54	15	54	100		
2026-063	067	URISCAN		053 055	053 055		055 - 3+	54	3	54	100		
2026-063	072	URS-9-TECO		053 055	053 055		054 - 2+	50	34	50	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	072	URS-9-TECO		053 055	053 055		055 - 3+	50	16	50	100	
2026-063	080	ROCHE (CHE		053 055	053 055		054 - 2+	36	26	34	100	
2026-063	080	ROCHE (CHE		053 055	053 055		053 - 1+	36	1	34	100	
2026-063	080	ROCHE (CHE		053 055	053 055		055 - 3+	36	7	34	100	
2026-063	080	ROCHE (CHE		053 055	053 055		056 - 4+	36	2	34	0	
2026-063	089	AIMSTRIP		053 055	053 055		054 - 2+	163	133	162	100	
2026-063	089	AIMSTRIP		053 055	053 055		053 - 1+	163	4	162	100	
2026-063	089	AIMSTRIP		053 055	053 055		055 - 3+	163	25	162	100	
2026-063	089	AIMSTRIP		053 055	053 055		056 - 4+	163	1	162	0	
2026-063	094	CLINITEK		053 055	053 055		054 - 2+	102	88	101	100	
2026-063	094	CLINITEK		053 055	053 055		052 - TRACES	102	1	101	0	
2026-063	094	CLINITEK		053 055	053 055		053 - 1+	102	1	101	100	
2026-063	094	CLINITEK		053 055	053 055		055 - 3+	102	12	101	100	
2026-063	102	ACON LAB		053 055	053 055		054 - 2+	110	90	109	100	
2026-063	102	ACON LAB		053 055	053 055		052 - TRACES	110	1	109	0	
2026-063	102	ACON LAB		053 055	053 055		053 - 1+	110	3	109	100	
2026-063	102	ACON LAB		053 055	053 055		055 - 3+	110	16	109	100	
2026-063	131	ICHEM VELO		054 056	053 055		054 - 2+	40	17	40	100	
2026-063	131	ICHEM VELO		054 056	053 055		055 - 3+	40	22	40	100	
2026-063	131	ICHEM VELO		054 056	053 055		056 - 4+	40	1	40	100	
2026-063	140	MISSION A		053 055	053 055		054 - 2+	35	30	35	100	
2026-063	140	MISSION A		053 055	053 055		055 - 3+	35	5	35	100	
2026-063	145	CLINITEK		053 055	053 055		054 - 2+	46	32	46	100	
2026-063	145	CLINITEK		053 055	053 055		055 - 3+	46	14	46	100	
2026-063	147	Mission120		053 055	053 055		054 - 2+	36	31	36	100	
2026-063	147	Mission120		053 055	053 055		053 - 1+	36	5	36	100	
2026-063	148	Mission500		053 055	053 055		054 - 2+	159	133	158	100	
2026-063	148	Mission500		053 055	053 055		052 - TRACES	159	1	158	0	
2026-063	148	Mission500		053 055	053 055		053 - 1+	159	6	158	100	
2026-063	148	Mission500		053 055	053 055		055 - 3+	159	19	158	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	151	Clari. Uro		053 055	053 055		054 - 2+	33	30	33	100	
2026-063	151	Clari. Uro		053 055	053 055		053 - 1+	33	1	33	100	
2026-063	151	Clari. Uro		053 055	053 055		055 - 3+	33	2	33	100	
064 URIN-PROTEIN QUALI.												
2026-064	011	AMES NM10S		053 055	054 056		054 - 2+	30	20	30	100	
2026-064	011	AMES NM10S		053 055	054 056		053 - 1+	30	1	30	100	
2026-064	011	AMES NM10S		053 055	054 056		055 - 3+	30	9	30	100	
2026-064	013	BAYER CLI		054 056	054 056		054 - 2+	16	8	16	100	
2026-064	013	BAYER CLI		054 056	054 056		055 - 3+	16	8	16	100	
2026-064	067	URISCAN		053 055	054 056		054 - 2+	54	40	54	100	
2026-064	067	URISCAN		053 055	054 056		053 - 1+	54	6	54	100	
2026-064	067	URISCAN		053 055	054 056		055 - 3+	54	8	54	100	
2026-064	072	URS-9-TECO		053 055	054 056		054 - 2+	50	25	50	100	
2026-064	072	URS-9-TECO		053 055	054 056		053 - 1+	50	1	50	100	
2026-064	072	URS-9-TECO		053 055	054 056		055 - 3+	50	24	50	100	
2026-064	080	ROCHE (CHE		053 055	054 056		054 - 2+	36	27	36	100	
2026-064	080	ROCHE (CHE		053 055	054 056		055 - 3+	36	7	36	100	
2026-064	080	ROCHE (CHE		053 055	054 056		056 - 4+	36	2	36	100	
2026-064	089	AIMSTRIP		053 055	054 056		054 - 2+	163	88	163	100	
2026-064	089	AIMSTRIP		053 055	054 056		053 - 1+	163	1	163	100	
2026-064	089	AIMSTRIP		053 055	054 056		055 - 3+	163	71	163	100	
2026-064	089	AIMSTRIP		053 055	054 056		056 - 4+	163	3	163	100	
2026-064	094	CLINITEK		053 055	054 056		054 - 2+	102	82	100	100	
2026-064	094	CLINITEK		053 055	054 056		051 - NEGATIVE	102	1	100	0	
2026-064	094	CLINITEK		053 055	054 056		052 - TRACES	102	1	100	0	
2026-064	094	CLINITEK		053 055	054 056		055 - 3+	102	18	100	100	
2026-064	102	ACON LAB		053 055	054 056		054 - 2+	110	66	110	100	
2026-064	102	ACON LAB		053 055	054 056		053 - 1+	110	3	110	100	
2026-064	102	ACON LAB		053 055	054 056		055 - 3+	110	41	110	100	
2026-064	131	iCHEM VELO		054 056	054 056		054 - 2+	40	11	40	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-064	131	iCHEM VELO		054 056	054 056		055 - 3+	40	28	40	100	
2026-064	131	iCHEM VELO		054 056	054 056		056 - 4+	40	1	40	100	
2026-064	140	MISSION A		053 055	054 056		054 - 2+	35	24	34	100	
2026-064	140	MISSION A		053 055	054 056		051 - NEGATIVE	35	1	34	0	
2026-064	140	MISSION A		053 055	054 056		055 - 3+	35	10	34	100	
2026-064	145	CLINITEK		054 056	054 056		054 - 2+	46	11	46	100	
2026-064	145	CLINITEK		054 056	054 056		055 - 3+	46	34	46	100	
2026-064	145	CLINITEK		054 056	054 056		056 - 4+	46	1	46	100	
2026-064	147	Mission120		053 055	054 056		054 - 2+	36	31	36	100	
2026-064	147	Mission120		053 055	054 056		053 - 1+	36	4	36	100	
2026-064	147	Mission120		053 055	054 056		055 - 3+	36	1	36	100	
2026-064	148	Mission500		053 055	054 056		054 - 2+	159	87	159	100	
2026-064	148	Mission500		053 055	054 056		053 - 1+	159	6	159	100	
2026-064	148	Mission500		053 055	054 056		055 - 3+	159	65	159	100	
2026-064	148	Mission500		053 055	054 056		056 - 4+	159	1	159	100	
2026-064	151	Clari. Uro		053 055	054 056		054 - 2+	33	26	33	100	
2026-064	151	Clari. Uro		053 055	054 056		055 - 3+	33	7	33	100	
064 URIN-PROTEIN QUALI.												
2026-065	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	30	30	30	100	
2026-065	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	16	16	16	100	
2026-065	067	URISCAN		051 051	051 051		051 - NEGATIVE	54	54	54	100	
2026-065	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	50	50	50	100	
2026-065	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	36	36	36	100	
2026-065	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	163	163	163	100	
2026-065	094	CLINITEK		051 051	051 051		054 - 2+	102	1	101	0	
2026-065	094	CLINITEK		051 051	051 051		051 - NEGATIVE	102	101	101	100	
2026-065	102	ACON LAB		051 051	051 051		054 - 2+	110	1	109	0	
2026-065	102	ACON LAB		051 051	051 051		051 - NEGATIVE	110	109	109	100	
2026-065	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	40	40	40	100	
2026-065	140	MISSION A		051 051	051 051		051 - NEGATIVE	35	35	35	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-065	145	CLINITEK		051 051	051 051		051 - NEGATIVE	46	46	46	100	
2026-065	147	Mission120		051 051	051 051		051 - NEGATIVE	36	36	36	100	
2026-065	148	Mission500		051 051	051 051		051 - NEGATIVE	159	159	159	100	
2026-065	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	33	33	33	100	
066 URINAL.-UROBILINOGEN												
2026-061	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	30	30	30	100	
2026-061	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	16	16	16	100	
2026-061	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	53	53	53	100	
2026-061	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	50	50	50	100	
2026-061	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2026-061	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	163	163	163	100	
2026-061	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100	
2026-061	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	109	109	109	100	
2026-061	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2026-061	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2026-061	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100	
2026-061	147	Mission120		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2026-061	148	Mission500		061 061	061 061		061 - NORMAL,NEG	160	160	160	100	
2026-061	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2026-062	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	30	30	30	100	
2026-062	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	16	16	16	100	
2026-062	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	53	53	53	100	
2026-062	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	50	49	49	100	
2026-062	072	URS-9-TECO		061 061	061 061		062 - 2	50	1	49	0	
2026-062	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2026-062	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	163	163	163	100	
2026-062	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100	
2026-062	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	109	109	109	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-062	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2026-062	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2026-062	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100	
2026-062	147	Mission120		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2026-062	148	Mission500		061 061	061 061		061 - NORMAL,NEG	160	160	160	100	
2026-062	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
066 URINAL.-UROBILINOGEN												
2026-063	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	30	30	30	100	
2026-063	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	16	16	16	100	
2026-063	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	53	53	53	100	
2026-063	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	50	50	50	100	
2026-063	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2026-063	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	163	163	163	100	
2026-063	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100	
2026-063	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	109	109	109	100	
2026-063	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2026-063	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2026-063	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100	
2026-063	147	Mission120		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2026-063	148	Mission500		061 061	061 061		061 - NORMAL,NEG	160	160	160	100	
2026-063	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2026-064	011	AMES NM10S		062 064	061 063		061 - NORMAL,NEG	30	3	30	100	
2026-064	011	AMES NM10S		062 064	061 063		062 - 2	30	12	30	100	
2026-064	011	AMES NM10S		062 064	061 063		063 - 4	30	15	30	100	
2026-064	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	16	4	16	100	
2026-064	013	BAYER CLI		061 063	061 063		062 - 2	16	7	16	100	
2026-064	013	BAYER CLI		061 063	061 063		063 - 4	16	5	16	100	
2026-064	067	URISCAN		062 064	061 063		061 - NORMAL,NEG	53	9	53	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-064	067	URISCAN		062 064	061 063		062 - 2	53	5	53	100	
2026-064	067	URISCAN		062 064	061 063		063 - 4	53	32	53	100	
2026-064	067	URISCAN		062 064	061 063		064 - 8	53	7	53	100	
2026-064	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	50	3	50	100	
2026-064	072	URS-9-TECO		061 063	061 063		062 - 2	50	36	50	100	
2026-064	072	URS-9-TECO		061 063	061 063		063 - 4	50	11	50	100	
2026-064	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	35	31	35	100	
2026-064	080	ROCHE (CHE		061 061	061 063		062 - 2	35	3	35	100	
2026-064	080	ROCHE (CHE		061 061	061 063		063 - 4	35	1	35	100	
2026-064	089	AIMSTRIP		061 061	061 063		061 - NORMAL,NEG	163	135	163	100	
2026-064	089	AIMSTRIP		061 061	061 063		062 - 2	163	20	163	100	
2026-064	089	AIMSTRIP		061 061	061 063		063 - 4	163	8	163	100	
2026-064	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	102	12	102	100	
2026-064	094	CLINITEK		062 064	061 063		062 - 2	102	26	102	100	
2026-064	094	CLINITEK		062 064	061 063		063 - 4	102	64	102	100	
2026-064	102	ACON LAB			061 063		061 - NORMAL,NEG	109	81	109	100	
2026-064	102	ACON LAB			061 063		062 - 2	109	21	109	100	
2026-064	102	ACON LAB			061 063		063 - 4	109	7	109	100	
2026-064	131	iCHEM VELO		062 064	061 063		062 - 2	42	1	42	100	
2026-064	131	iCHEM VELO		062 064	061 063		063 - 4	42	41	42	100	
2026-064	140	MISSION A		061 061	061 063		061 - NORMAL,NEG	34	29	34	100	
2026-064	140	MISSION A		061 061	061 063		062 - 2	34	4	34	100	
2026-064	140	MISSION A		061 061	061 063		063 - 4	34	1	34	100	
2026-064	145	CLINITEK		061 063	061 063		062 - 2	45	43	45	100	
2026-064	145	CLINITEK		061 063	061 063		063 - 4	45	2	45	100	
2026-064	147	Mission120		061 061	061 063		061 - NORMAL,NEG	36	36	36	100	
2026-064	148	Mission500		061 061	061 063		061 - NORMAL,NEG	160	156	160	100	
2026-064	148	Mission500		061 061	061 063		062 - 2	160	3	160	100	
2026-064	148	Mission500		061 061	061 063		063 - 4	160	1	160	100	
2026-064	151	Clari. Uro			061 063		061 - NORMAL,NEG	33	25	33	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-064	151	Clari. Uro			061	063	062 - 2	33	7	33	100	
2026-064	151	Clari. Uro			061	063	063 - 4	33	1	33	100	
066 URINAL.-UROBILINOGEN												
2026-065	011	AMES NM10S		061	061	061	061	061 - NORMAL,NEG	30	30	30	100
2026-065	013	BAYER CLI		061	061	061	061	061 - NORMAL,NEG	16	16	16	100
2026-065	067	URISCAN		061	061	061	061	061 - NORMAL,NEG	53	52	52	100
2026-065	067	URISCAN		061	061	061	061	062 - 2	53	1	52	0
2026-065	072	URS-9-TECO		061	061	061	061	061 - NORMAL,NEG	50	50	50	100
2026-065	080	ROCHE (CHE		061	061	061	061	061 - NORMAL,NEG	35	35	35	100
2026-065	089	AIMSTRIP		061	061	061	061	061 - NORMAL,NEG	163	163	163	100
2026-065	094	CLINITEK		061	061	061	061	061 - NORMAL,NEG	102	100	100	100
2026-065	094	CLINITEK		061	061	061	061	062 - 2	102	1	100	0
2026-065	094	CLINITEK		061	061	061	061	063 - 4	102	1	100	0
2026-065	102	ACON LAB		061	061	061	061	061 - NORMAL,NEG	109	109	109	100
2026-065	131	iCHEM VELO		061	061	061	061	061 - NORMAL,NEG	42	42	42	100
2026-065	140	MISSION A		061	061	061	061	061 - NORMAL,NEG	34	34	34	100
2026-065	145	CLINITEK		061	061	061	061	061 - NORMAL,NEG	45	45	45	100
2026-065	147	Mission120		061	061	061	061	061 - NORMAL,NEG	36	35	35	100
2026-065	147	Mission120		061	061	061	061	062 - 2	36	1	35	0
2026-065	148	Mission500		061	061	061	061	061 - NORMAL,NEG	160	160	160	100
2026-065	151	Clari. Uro		061	061	061	061	061 - NORMAL,NEG	33	33	33	100
184 URINALYSIS LEUKOCYTE												
2026-061	011	AMES NM10S		001	001	001	001	001 - Negative	31	31	31	100
2026-061	013	BAYER CLI		001	001	001	001	001 - Negative	16	16	16	100
2026-061	067	URISCAN		001	001	001	001	001 - Negative	53	53	53	100
2026-061	072	URS-9-TECO		001	001	001	001	001 - Negative	48	48	48	100
2026-061	080	ROCHE (CHE		001	001	001	001	001 - Negative	33	33	33	100
2026-061	089	AIMSTRIP		001	001	001	001	001 - Negative	160	159	159	100
2026-061	089	AIMSTRIP		001	001	001	001	003 - Small	160	1	159	0

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-061	094 CLINITEK			001 001	001 001		001 - Negative	102	102	102	100	
2026-061	102 ACON LAB			001 001	001 001		001 - Negative	102	102	102	100	
2026-061	131 iCHEM VELO			001 001	001 001		001 - Negative	43	43	43	100	
2026-061	140 MISSION A			001 001	001 001		001 - Negative	39	39	39	100	
2026-061	145 CLINITEK			001 001	001 001		001 - Negative	45	45	45	100	
2026-061	147 Mission120			001 001	001 001		001 - Negative	35	35	35	100	
2026-061	148 Mission500			001 001	001 001		001 - Negative	159	159	159	100	
2026-061	151 Clari. Uro			001 001	001 001		001 - Negative	33	33	33	100	
184 URINALYSIS LEUKOCYTE												
2026-062	011 AMES NM10S			001 001	001 001		001 - Negative	31	31	31	100	
2026-062	013 BAYER CLI			001 001	001 001		001 - Negative	16	16	16	100	
2026-062	067 URISCAN			001 001	001 001		001 - Negative	53	53	53	100	
2026-062	072 URS-9-TECO			001 001	001 001		001 - Negative	48	48	48	100	
2026-062	080 ROCHE (CHE			001 001	001 001		001 - Negative	33	33	33	100	
2026-062	089 AIMSTRIP			001 001	001 001		001 - Negative	160	160	160	100	
2026-062	094 CLINITEK			001 001	001 001		001 - Negative	102	102	102	100	
2026-062	102 ACON LAB			001 001	001 001		001 - Negative	102	102	102	100	
2026-062	131 iCHEM VELO			001 001	001 001		001 - Negative	43	43	43	100	
2026-062	140 MISSION A			001 001	001 001		001 - Negative	39	39	39	100	
2026-062	145 CLINITEK			001 001	001 001		001 - Negative	45	45	45	100	
2026-062	147 Mission120			001 001	001 001		001 - Negative	35	35	35	100	
2026-062	148 Mission500			001 001	001 001		001 - Negative	159	159	159	100	
2026-062	151 Clari. Uro			001 001	001 001		001 - Negative	33	33	33	100	
2026-063	011 AMES NM10S			001 001	001 001		001 - Negative	31	31	31	100	
2026-063	013 BAYER CLI			001 001	001 001		001 - Negative	16	16	16	100	
2026-063	067 URISCAN			001 001	001 001		001 - Negative	53	53	53	100	
2026-063	072 URS-9-TECO			001 001	001 001		001 - Negative	48	48	48	100	
2026-063	080 ROCHE (CHE			001 001	001 001		001 - Negative	33	33	33	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-063	089	AIMSTRIP		001 001	001 001		001 - Negative	160	159	159	100	
2026-063	089	AIMSTRIP		001 001	001 001		002 - Traces	160	1	159	0	
2026-063	094	CLINITEK		001 001	001 001		001 - Negative	102	102	102	100	
2026-063	102	ACON LAB		001 001	001 001		001 - Negative	102	102	102	100	
2026-063	131	iCHEM VELO		001 001	001 001		001 - Negative	43	43	43	100	
2026-063	140	MISSION A		001 001	001 001		001 - Negative	39	39	39	100	
2026-063	145	CLINITEK		001 001	001 001		001 - Negative	45	45	45	100	
2026-063	147	Mission120		001 001	001 001		001 - Negative	35	35	35	100	
2026-063	148	Mission500		001 001	001 001		001 - Negative	159	159	159	100	
2026-063	151	Clari. Uro		001 001	001 001		001 - Negative	33	33	33	100	
184 URINALYSIS LEUKOCYTE												
2026-064	011	AMES NM10S		001 001	001 001		001 - Negative	31	31	31	100	
2026-064	013	BAYER CLI		001 001	001 001		001 - Negative	16	16	16	100	
2026-064	067	URISCAN		001 001	001 001		001 - Negative	53	53	53	100	
2026-064	072	URS-9-TECO		001 001	001 001		001 - Negative	48	48	48	100	
2026-064	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	33	33	100	
2026-064	089	AIMSTRIP		001 001	001 001		001 - Negative	160	159	159	100	
2026-064	089	AIMSTRIP		001 001	001 001		002 - Traces	160	1	159	0	
2026-064	094	CLINITEK		001 001	001 001		001 - Negative	102	101	101	100	
2026-064	094	CLINITEK		001 001	001 001		003 - Small	102	1	101	0	
2026-064	102	ACON LAB		001 001	001 001		001 - Negative	102	102	102	100	
2026-064	131	iCHEM VELO		001 001	001 001		001 - Negative	43	43	43	100	
2026-064	140	MISSION A		001 001	001 001		001 - Negative	39	38	38	100	
2026-064	140	MISSION A		001 001	001 001		004 - Moderate	39	1	38	0	
2026-064	145	CLINITEK		001 001	001 001		001 - Negative	45	45	45	100	
2026-064	147	Mission120		001 001	001 001		001 - Negative	35	35	35	100	
2026-064	148	Mission500		001 001	001 001		001 - Negative	159	159	159	100	
2026-064	151	Clari. Uro		001 001	001 001		001 - Negative	33	33	33	100	

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
184 URINALYSIS LEUKOCYTE													
2026-065	011 AMES NM10S			002 004	003 005		003 - Small	31	26	31	100		
2026-065	011 AMES NM10S			002 004	003 005		004 - Moderate	31	5	31	100		
2026-065	013 BAYER CLI			002 004	003 005		003 - Small	16	11	16	100		
2026-065	013 BAYER CLI			002 004	003 005		004 - Moderate	16	4	16	100		
2026-065	013 BAYER CLI			002 004	003 005		005 - Large	16	1	16	100		
2026-065	067 URISCAN			003 005	003 005		003 - Small	53	9	53	100		
2026-065	067 URISCAN			003 005	003 005		004 - Moderate	53	29	53	100		
2026-065	067 URISCAN			003 005	003 005		005 - Large	53	15	53	100		
2026-065	072 URS-9-TECO			002 004	003 005		002 - Traces	48	1	48	100		
2026-065	072 URS-9-TECO			002 004	003 005		003 - Small	48	29	48	100		
2026-065	072 URS-9-TECO			002 004	003 005		004 - Moderate	48	17	48	100		
2026-065	072 URS-9-TECO			002 004	003 005		005 - Large	48	1	48	100		
2026-065	080 ROCHE (CHE			004 005	003 005		004 - Moderate	33	1	33	100		
2026-065	080 ROCHE (CHE			004 005	003 005		005 - Large	33	32	33	100		
2026-065	089 AIMSTRIP			002 004	003 005		001 - Negative	160	1	159	0		
2026-065	089 AIMSTRIP			002 004	003 005		002 - Traces	160	7	159	100		
2026-065	089 AIMSTRIP			002 004	003 005		003 - Small	160	96	159	100		
2026-065	089 AIMSTRIP			002 004	003 005		004 - Moderate	160	50	159	100		
2026-065	089 AIMSTRIP			002 004	003 005		005 - Large	160	6	159	100		
2026-065	094 CLINITEK			002 004	003 005		001 - Negative	102	1	101	0		
2026-065	094 CLINITEK			002 004	003 005		003 - Small	102	85	101	100		
2026-065	094 CLINITEK			002 004	003 005		004 - Moderate	102	14	101	100		
2026-065	094 CLINITEK			002 004	003 005		005 - Large	102	2	101	100		
2026-065	102 ACON LAB			003 005	003 005		002 - Traces	102	1	101	0		
2026-065	102 ACON LAB			003 005	003 005		003 - Small	102	44	101	100		
2026-065	102 ACON LAB			003 005	003 005		004 - Moderate	102	50	101	100		
2026-065	102 ACON LAB			003 005	003 005		005 - Large	102	7	101	100		
2026-065	131 iCHEM VELO			004 005	003 005		004 - Moderate	43	2	43	100		
2026-065	131 iCHEM VELO			004 005	003 005		005 - Large	43	41	43	100		

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-065	140 MISSION A			003 005	003 005		002 - Traces	39	1	38	0
2026-065	140 MISSION A			003 005	003 005		003 - Small	39	10	38	100
2026-065	140 MISSION A			003 005	003 005		004 - Moderate	39	25	38	100
2026-065	140 MISSION A			003 005	003 005		005 - Large	39	3	38	100
2026-065	145 CLINITEK			003 005	003 005		004 - Moderate	45	45	45	100
2026-065	147 Mission120			002 004	003 005		002 - Traces	35	4	35	100
2026-065	147 Mission120			002 004	003 005		003 - Small	35	19	35	100
2026-065	147 Mission120			002 004	003 005		004 - Moderate	35	12	35	100
2026-065	148 Mission500			003 005	003 005		001 - Negative	159	1	153	0
2026-065	148 Mission500			003 005	003 005		002 - Traces	159	5	153	0
2026-065	148 Mission500			003 005	003 005		003 - Small	159	38	153	100
2026-065	148 Mission500			003 005	003 005		004 - Moderate	159	108	153	100
2026-065	148 Mission500			003 005	003 005		005 - Large	159	7	153	100
2026-065	151 Clari. Uro			003 005	003 005		002 - Traces	33	2	31	0
2026-065	151 Clari. Uro			003 005	003 005		003 - Small	33	9	31	100
2026-065	151 Clari. Uro			003 005	003 005		004 - Moderate	33	18	31	100
2026-065	151 Clari. Uro			003 005	003 005		005 - Large	33	4	31	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
063 URI-PREGNANCY TEST												
2026-061	091	AIM STEP		001	001	001	001	001 - NEGATIVE	29	29	29	100
2026-061	101	HCG Alere		001	001	001	001	001 - NEGATIVE	24	24	24	100
2026-062	091	AIM STEP		001	001	001	001	001 - NEGATIVE	29	29	29	100
2026-062	101	HCG Alere		001	001	001	001	001 - NEGATIVE	24	24	24	100
2026-063	091	AIM STEP		002	002	002	002	002 - POSITIVE	29	29	29	100
2026-063	101	HCG Alere		002	002	002	002	002 - POSITIVE	24	24	24	100
2026-064	091	AIM STEP		002	002	002	002	002 - POSITIVE	29	29	29	100
2026-064	101	HCG Alere		002	002	002	002	002 - POSITIVE	24	24	24	100
2026-065	091	AIM STEP		001	001	001	001	001 - NEGATIVE	29	29	29	100
2026-065	101	HCG Alere		001	001	001	001	001 - NEGATIVE	24	24	24	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2026-071					006	006	002 - FATTY CAST	921	1	915	0
2026-071					006	006	004 - HYALINE C.	921	3	915	0
2026-071					006	006	006 - WAXY CAST	921	915	915	100
2026-071					006	006	031 - FIBERS	921	2	915	0
2026-072					028	028	028 - TRIPLE PH.	921	921	921	100
2026-073					040	040	039 - E. vermic.	921	2	919	0
2026-073					040	040	040 - S. haemat.	921	919	919	100
2026-074					017	017	017 - CYSTINE C.	921	920	920	100
2026-074					017	017	042 - WBC in clu	921	1	920	0
2026-075					042	042	005 - RED CELL C	921	3	889	0
2026-075					042	042	007 - WHITE CELL	921	7	889	0
2026-075					042	042	008 - ERYTHROCYT	921	10	889	0
2026-075					042	042	009 - LEUKOCYTE	921	12	889	0
2026-075					042	042	042 - WBC in clu	921	889	889	100

Participant Summary

MONTH 2 OF YEAR 2026

SPE: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
154 FECAL OCCULT BLOOD												
2026-081	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	334	334	334	100
2026-081	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	760	759	759	100
2026-081	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	760	1	759	0
2026-082	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	334	1	333	0
2026-082	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	334	333	333	100
2026-082	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	760	1	759	0
2026-082	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	760	759	759	100
2026-083	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	334	334	334	100
2026-083	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	760	760	760	100
2026-084	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	334	334	334	100
2026-084	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	760	759	759	100
2026-084	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	760	1	759	0
2026-085	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	334	334	334	100
2026-085	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	760	1	759	0
2026-085	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	760	759	759	100

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. LABS	PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
068 CARCINOE. ANTIG. CEA		CLIA TEST ID #: 352		EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}							
2026-031	29	VITROS		11		0.300	0.000	0.00	0	1.300	
2026-031	38	ROCHE E		21		0.524	0.123	23.50	0	1.500	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-031	44	BECK.COUL.		17	0.388	0.048	12.49	0	1.400	
2026-031	50	ARC		12	1.117	0.584	52.32	0.100	2.100	
2026-031	58	APELLICA		10	0.650	0.703	108.19	0	1.700	
068	CARCINOE. ANTIG. CEA		CLIA TEST ID #: 352		EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}					
2026-032	29	VITROS		11	24.109	0.822	3.41	20.500	27.700	
2026-032	38	ROCHE E		21	20.205	0.707	3.50	17.200	23.200	
2026-032	44	BECK.COUL.		17	25.194	1.414	5.61	21.400	29.000	
2026-032	50	ARC		12	23.708	1.005	4.24	20.200	27.300	
2026-032	58	APELLICA		10	20.510	1.412	6.88	17.400	23.600	
2026-033	29	VITROS		11	4.745	0.462	9.73	3.700	5.700	
2026-033	38	ROCHE E		21	4.557	0.201	4.42	3.600	5.600	
2026-033	44	BECK.COUL.		17	5.129	0.232	4.52	4.100	6.100	
2026-033	50	ARC		12	5.000	0.280	5.60	4.000	6.000	
2026-033	58	APELLICA		10	4.710	0.301	6.40	3.700	5.700	
2026-034	29	VITROS		11	32.318	0.933	2.89	27.500	37.200	
2026-034	38	ROCHE E		21	26.505	1.312	4.95	22.500	30.500	
2026-034	44	BECK.COUL.		17	34.041	1.953	5.74	28.900	39.100	
2026-034	50	ARC		12	31.567	2.060	6.52	26.800	36.300	
2026-034	58	APELLICA		10	26.130	1.600	6.12	22.200	30.000	
2026-035	29	VITROS		11	9.800	0.409	4.17	8.300	11.300	
2026-035	38	ROCHE E		21	8.695	0.554	6.37	7.400	10.000	
2026-035	44	BECK.COUL.		17	10.159	0.587	5.78	8.600	11.700	
2026-035	50	ARC		12	10.008	0.629	6.29	8.500	11.500	
2026-035	58	APELLICA		10	9.040	0.550	6.08	7.700	10.400	
069	PROS. SPEC-ANTIG-PSA		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}					
2026-031	29	VITROS		49	0.100	0.000	0.00	0	0.300	
2026-031	38	ROCHE E		53	0.000	0.000	0.00	0	0.200	

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-031	44	BECK.COUL.		44	0.020	0.040	197.20	0	0.200
2026-031	50	ARC		22	0.014	0.034	251.66	0	0.200
2026-031	57	S. EXL 200		45	0.062	0.048	77.92	0	0.300
2026-031	58	ATELLICA		28	0.057	0.049	86.60	0	0.300
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	20	% OR 0.20	{GREATER}			
2026-032	29	VITROS		49	16.308	0.667	4.09	13.000	19.600
2026-032	38	ROCHE E		53	22.430	1.025	4.57	17.900	26.900
2026-032	44	BECK.COUL.		44	25.595	1.578	6.17	20.500	30.700
2026-032	50	ARC		22	16.338	0.967	5.92	13.100	19.600
2026-032	57	S. EXL 200		45	18.847	1.019	5.41	15.100	22.600
2026-032	58	ATELLICA		28	20.464	1.292	6.31	16.400	24.600
2026-033	29	VITROS		49	3.558	0.164	4.62	2.800	4.300
2026-033	38	ROCHE E		53	4.577	0.240	5.24	3.700	5.500
2026-033	44	BECK.COUL.		44	5.295	0.262	4.95	4.200	6.400
2026-033	50	ARC		22	3.233	0.215	6.64	2.600	3.900
2026-033	57	S. EXL 200		45	3.634	0.214	5.89	2.900	4.400
2026-033	58	ATELLICA		28	4.282	0.224	5.22	3.400	5.100
2026-034	29	VITROS		49	21.392	1.067	4.99	17.100	25.700
2026-034	38	ROCHE E		53	29.452	1.281	4.35	23.600	35.300
2026-034	44	BECK.COUL.		44	33.359	1.983	5.94	26.700	40.000
2026-034	50	ARC		22	21.132	1.395	6.60	16.900	25.400
2026-034	57	S. EXL 200		45	24.918	1.110	4.45	19.900	29.900
2026-034	58	ATELLICA		28	26.439	1.791	6.77	21.200	31.700
2026-035	29	VITROS		49	6.831	0.286	4.18	5.500	8.200
2026-035	38	ROCHE E		53	9.275	0.435	4.69	7.400	11.100
2026-035	44	BECK.COUL.		44	10.752	0.642	5.97	8.600	12.900
2026-035	50	ARC		22	6.623	0.494	7.47	5.300	7.900

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-035	57	S. EXL 200		45	7.518	0.412	5.48	6.000	9.000	
2026-035	58	APELLICA		28	8.504	0.368	4.32	6.800	10.200	
071 VITAMIN B 12			CLIA TEST ID #: 600		EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}					
2026-031	29	VITROS		31	217.387	7.250	3.33	163.000	272.000	
2026-031	38	ROCHE E		39	198.333	35.713	18.01	149.000	248.000	
2026-031	44	BECK.COUL.		26	148.000	10.355	7.00	111.000	185.000	
2026-031	50	ARC		22	184.500	17.668	9.58	138.000	231.000	
2026-031	57	S. EXL 200		18	214.556	15.489	7.22	161.000	268.000	
2026-031	58	APELLICA		24	108.125	16.654	15.40	78.000	138.000	
2026-032	29	VITROS		31	730.161	35.410	4.85	548.000	913.000	
2026-032	38	ROCHE E		39	816.872	56.204	6.88	613.000	1021.000	
2026-032	44	BECK.COUL.		26	582.360	29.413	5.05	437.000	728.000	
2026-032	50	ARC		22	685.045	41.206	6.02	514.000	856.000	
2026-032	57	S. EXL 200		18	752.778	36.951	4.91	565.000	941.000	
2026-032	58	APELLICA		24	616.083	68.601	11.14	462.000	770.000	
2026-033	29	VITROS		31	304.161	9.419	3.10	228.000	380.000	
2026-033	38	ROCHE E		39	307.205	40.098	13.05	230.000	384.000	
2026-033	44	BECK.COUL.		26	236.440	12.541	5.30	177.000	296.000	
2026-033	50	ARC		22	282.818	18.879	6.68	212.000	354.000	
2026-033	57	S. EXL 200		18	318.059	15.418	4.85	239.000	398.000	
2026-033	58	APELLICA		24	217.083	25.255	11.63	163.000	271.000	
2026-034	29	VITROS		31	750.516	42.084	5.61	563.000	938.000	
2026-034	38	ROCHE E		39	1029.231	92.967	9.03	772.000	1287.000	
2026-034	44	BECK.COUL.		26	711.520	52.251	7.34	534.000	889.000	
2026-034	50	ARC		22	826.455	51.192	6.19	620.000	1033.000	
2026-034	57	S. EXL 200		18	923.889	37.541	4.06	693.000	1155.000	
2026-034	58	APELLICA		24	655.958	119.140	18.16	492.000	820.000	

Participant Summary

MONTH 2 OF YEAR 2026

ANALYTE			NO. PART		TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
071 VITAMIN B 12			CLIA TEST ID #: 600		EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}				
2026-035	29	VITROS		31	417.323	14.554	3.49	313.000	522.000
2026-035	38	ROCHE E		39	437.744	35.951	8.21	328.000	547.000
2026-035	44	BECK.COUL.		26	330.923	19.265	5.82	248.000	414.000
2026-035	50	ARC		22	393.727	25.915	6.58	295.000	492.000
2026-035	57	S. EXL 200		18	431.111	22.811	5.29	323.000	539.000
2026-035	58	ATELLICA		24	339.375	23.315	6.87	255.000	424.000

ANALYTE			NO. PART		TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
146 GLYCOHEMOGLOBIN			CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %				
2026-041	12	COBAS/INT.		23	5.767	0.047	0.82	5.300	6.200
2026-041	12	COBAS/INT.		23	5.061	0.413	8.15	4.700	5.500
2026-041	14	IMMUNOTUR.		14	5.086	0.164	3.23	4.700	5.500
2026-041	22	VITROS		63	4.595	0.136	2.96	4.200	5.000
2026-041	31	IMMUNOTURB		57	5.033	0.125	2.48	4.600	5.400
2026-041	31	IMMUNOTURB		57	4.845	0.244	5.04	4.500	5.200
2026-041	40	SIEMENS DI		59	5.767	0.047	0.82	5.300	6.200
2026-041	40	SIEMENS DI		59	4.800	0.155	3.24	4.400	5.200
2026-041	46	ARCHITECT		16	4.844	0.257	5.31	4.500	5.200
2026-041	46	ARCHITECT		16	5.033	0.125	2.48	4.600	5.400
2026-041	48	ATELLICA		28	4.764	0.093	1.96	4.400	5.100
2026-041	50	CS400DIRUI		11	4.918	0.237	4.81	4.500	5.300
2026-041	50	CS400DIRUI		11	6.625	0.277	4.19	6.100	7.200
2026-042	12	COBAS/INT.		23	6.178	0.313	5.07	5.700	6.700
2026-042	12	COBAS/INT.		23	6.200	0.216	3.48	5.700	6.700
2026-042	14	IMMUNOTUR.		14	6.185	0.146	2.36	5.700	6.700

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 95 GLYCOHEMOGLOBINE			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-042	22	VITROS		63	5.825	0.120	2.05	5.400	6.300
2026-042	31	IMMUNOTURB		57	5.963	0.170	2.84	5.500	6.400
2026-042	31	IMMUNOTURB		57	6.133	0.094	1.54	5.600	6.600
2026-042	40	SIEMENS DI		59	6.017	0.198	3.28	5.500	6.500
2026-042	40	SIEMENS DI		59	6.200	0.216	3.48	5.700	6.700
2026-042	46	ARCHITECT		16	6.133	0.094	1.54	5.600	6.600
2026-042	46	ARCHITECT		16	5.787	0.196	3.39	5.300	6.200
2026-042	48	ATELLICA		28	5.681	0.094	1.66	5.200	6.100
2026-042	50	CS400DIRUI		11	7.050	0.269	3.82	6.500	7.600
2026-042	50	CS400DIRUI		11	6.091	0.334	5.49	5.600	6.600
146	GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %				
2026-043	12	COBAS/INT.		23	5.900	0.141	2.40	5.400	6.400
2026-043	12	COBAS/INT.		23	5.057	0.403	7.97	4.700	5.500
2026-043	14	IMMUNOTUR.		14	5.071	0.133	2.63	4.700	5.500
2026-043	22	VITROS		63	4.571	0.120	2.62	4.200	4.900
2026-043	31	IMMUNOTURB		57	4.967	0.125	2.51	4.600	5.400
2026-043	31	IMMUNOTURB		57	4.871	0.218	4.47	4.500	5.300
2026-043	40	SIEMENS DI		59	5.900	0.141	2.40	5.400	6.400
2026-043	40	SIEMENS DI		59	4.846	0.249	5.13	4.500	5.200
2026-043	46	ARCHITECT		16	4.794	0.148	3.08	4.400	5.200
2026-043	46	ARCHITECT		16	4.967	0.125	2.51	4.600	5.400
2026-043	48	ATELLICA		28	4.764	0.104	2.19	4.400	5.100
2026-043	50	CS400DIRUI		11	4.864	0.267	5.49	4.500	5.300
2026-043	50	CS400DIRUI		11	6.625	0.238	3.60	6.100	7.200
2026-044	12	COBAS/INT.		23	8.423	0.188	2.23	7.700	9.100
2026-044	12	COBAS/INT.		23	8.833	0.386	4.37	8.100	9.500
2026-044	14	IMMUNOTUR.		14	8.557	0.256	2.99	7.900	9.200
2026-044	22	VITROS		63	8.150	0.187	2.30	7.500	8.800
2026-044	31	IMMUNOTURB		57	8.341	0.177	2.12	7.700	9.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE				
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-044	31	IMMUNOTURB		57	8.533	0.170	1.99	7.900	9.200
2026-044	40	SIEMENS DI		59	8.471	0.193	2.28	7.800	9.100
2026-044	40	SIEMENS DI		59	8.833	0.386	4.37	8.100	9.500
2026-044	46	ARCHITECT		16	8.533	0.170	1.99	7.900	9.200
2026-044	46	ARCHITECT		16	8.193	0.274	3.35	7.500	8.800
2026-044	48	ATELLICA		28	7.954	0.127	1.59	7.300	8.600
2026-044	50	CS400DIRUI		11	9.325	0.277	2.97	8.600	10.100
2026-044	50	CS400DIRUI		11	8.600	0.484	5.63	7.900	9.300
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %					
2026-045	12	COBAS/INT.		23	6.467	0.125	1.93	5.900	7.000
2026-045	12	COBAS/INT.		23	6.291	0.315	5.00	5.800	6.800
2026-045	14	IMMUNOTUR.		14	6.143	0.244	3.97	5.700	6.600
2026-045	22	VITROS		63	5.815	0.140	2.41	5.300	6.300
2026-045	31	IMMUNOTURB		57	6.100	0.141	2.32	5.600	6.600
2026-045	31	IMMUNOTURB		57	5.911	0.155	2.63	5.400	6.400
2026-045	40	SIEMENS DI		59	6.467	0.125	1.93	5.900	7.000
2026-045	40	SIEMENS DI		59	6.028	0.209	3.47	5.500	6.500
2026-045	46	ARCHITECT		16	6.100	0.141	2.32	5.600	6.600
2026-045	46	ARCHITECT		16	5.773	0.205	3.55	5.300	6.200
2026-045	48	ATELLICA		28	5.644	0.087	1.55	5.200	6.100
2026-045	50	CS400DIRUI		11	7.000	0.200	2.86	6.400	7.600
2026-045	50	CS400DIRUI		11	6.100	0.305	4.99	5.600	6.600

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D				
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
178 Vitamin D		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-261	3	VITROS		45	87.227	6.392	7.33	70.000	105.000
2026-261	5	ROCHE E		41	46.000	4.257	9.25	37.000	55.000

Participant Summary

MONTH 2 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 99 Vitamin D

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-261	5	ROCHE E		41	41.707	6.787	16.27	33.000	50.000
2026-261	9	BECK.COUL.		40	62.075	3.460	5.57	50.000	74.000
2026-261	11	ARC		19	47.632	2.322	4.87	38.000	57.000
2026-261	25	S. DIME		26	50.808	3.903	7.68	41.000	61.000
2026-261	27	APELLICA		25	95.440	4.767	4.99	76.000	115.000
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-262	3	VITROS		45	111.318	7.131	6.41	89.000	134.000
2026-262	5	ROCHE E		41	67.805	11.402	16.82	54.000	81.000
2026-262	5	ROCHE E		41	69.857	6.770	9.69	56.000	84.000
2026-262	9	BECK.COUL.		40	79.282	4.332	5.46	63.000	95.000
2026-262	11	ARC		19	66.579	2.278	3.42	53.000	80.000
2026-262	25	S. DIME		26	67.115	3.490	5.20	54.000	81.000
2026-262	27	APELLICA		25	116.440	4.060	3.49	93.000	140.000
2026-263	3	VITROS		45	54.477	4.979	9.14	44.000	65.000
2026-263	5	ROCHE E		41	26.000	1.841	7.08	21.000	31.000
2026-263	5	ROCHE E		41	20.415	4.066	19.92	16.000	24.000
2026-263	9	BECK.COUL.		40	40.775	2.444	5.99	33.000	49.000
2026-263	11	ARC		19	28.053	0.825	2.94	22.000	34.000
2026-263	25	S. DIME		26	31.692	2.700	8.52	25.000	38.000
2026-263	27	APELLICA		25	65.840	2.148	3.26	53.000	79.000
2026-264	3	VITROS		45	14.600	2.164	14.82	12.000	18.000
2026-264	5	ROCHE E		41	6.000	0.000	0.00	5.000	7.000
2026-264	5	ROCHE E		41	7.000	2.214	31.62	6.000	8.000
2026-264	9	BECK.COUL.		40	12.308	1.399	11.37	10.000	15.000
2026-264	11	ARC		19	8.053	0.510	6.34	6.000	10.000
2026-264	25	S. DIME		26	10.962	1.055	9.63	9.000	13.000
2026-264	27	APELLICA		25	20.720	2.030	9.80	17.000	25.000

Participant Summary

MONTH 2 OF YEAR 2026

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-265	3	VITROS		45	125.159	1.705	1.36	100.000	150.000	
2026-265	5	ROCHE E		41	97.714	10.753	11.00	78.000	117.000	
2026-265	5	ROCHE E		41	92.075	15.525	16.86	74.000	110.000	
2026-265	9	BECK.COUL.		40	94.282	4.685	4.97	75.000	113.000	
2026-265	11	ARC		19	87.632	4.521	5.16	70.000	105.000	
2026-265	25	S. DIME		26	80.000	3.555	4.44	64.000	96.000	
2026-265	27	ATELLICA		25	128.680	5.112	3.97	103.000	154.000	